

PHYSICIAN-FOCUSED PAYMENT MODEL
TECHNICAL ADVISORY COMMITTEE (PTAC)

PUBLIC MEETING

The Great Hall
The Hubert H. Humphrey Federal Building
200 Independence Avenue, SW
Washington, D.C. 20201

Monday, December 18, 2017
9:00 a.m.

COMMITTEE MEMBERS PRESENT:

JEFFREY W. BAILET, MD, Chair
ROBERT BERENSON, MD
PAUL N. CASALE, MD, MPH
TIM FERRIS, MD, MPH
RHONDA M. MEDOWS, MD
HAROLD D. MILLER
ELIZABETH MITCHELL, Vice Chair
LEN M. NICHOLS, PhD
KAVITA PATEL, MD, MSHS
BRUCE STEINWALD, MBA
GRACE TERRELL, MD, MMM

STAFF PRESENT:

Tim Dube, Office of the Assistant Secretary for Planning
and Evaluation (ASPE)
Ann Page, Designated Federal Officer (DFO), ASPE
Sarah Selenich, ASPE
Mary Ellen Stahlman, ASPE

CONTRACTOR STAFF:

Adele Shartzter, PhD, Urban Institute

| AGENDA | PAGE |
|---|------------------------|
| Opening Remarks by Chair Bailet..... | 6 |
| Renal Physicians Association (RPA): Incident ESRD (End-Stage Renal Disease) Clinical Episode Payment Model | |
| PRT (Preliminary Review Team): | |
| Paul N. Casale, MD, MPH (Lead); | |
| Jeffrey W. Bailet, MD; Harold D. Miller | |
| Staff Lead: Adele Shartzter, PhD | |
| Committee Member Disclosures..... | 11 |
| PRT Report to the Full PTAC - Paul N. Casale..... | 14 |
| Clarifying Questions from PTAC to PRT..... | 24 |
| Submitter's Statement, Questions and Answers, and Discussion with PTAC..... | 46 |
| - Jeff Giullian, MD | - Dale Singer |
| - Robert Kenney, MD | - Terry Ketchersid, MD |
| - Michael Shapiro, MD | |
| Comments from the Public..... | 93 |
| Committee Deliberation..... | 96 |
| Voting | 96 |
| - Criterion 1..... | 98 |
| - Criterion 2..... | 99 |
| - Criterion 3..... | 108 |
| - Criterion 4..... | 109 |
| - Criterion 5..... | 110 |
| - Criterion 6..... | 110 |
| - Criterion 7..... | 111 |
| - Criterion 8..... | 112 |
| - Criterion 9..... | 112 |
| - Criterion 10..... | 113 |
| - Final Vote..... | 115 |
| Instructions on Report to the Secretary..... | 115 |

**New York City Department of Health and Mental Hygiene
(NYC DOHMH): Multi-Provider Bundled Episode-of-Care Payment
Model for Treatment of Chronic Hepatitis C Virus (HCV)
Using Care Coordination by Employed Physicians in Hospital
Outpatient Clinics**

PRT: Robert Berenson, MD (Lead);
Jeffrey W. Bailet, MD; Grace Terrell, MD, MMM
Staff Lead: Sarah Selenich

| | |
|--|--------------------------|
| Committee Member Disclosures..... | 141 |
| PRT Report to the Full PTAC - Robert Berenson..... | 143 |
| Clarifying Questions from PTAC to PRT..... | 156 |
| Submitter's Statement, Questions and Answers, and Discussion with PTAC..... | 162 |
| - Czarina Navos Behrends, PhD - Paul Meissner | |
| - Lauren Benyola | - Ponni Perumalswami, MD |
| - Marie Bresnahan | - Bruce Schackman, MD |
| - Kyle Fluegge, PhD | - Shuchin Shukla, MD |
| - Rashi Kumar | - Jeffrey Weiss, PhD |
| - Alain Litwin, MD | - Ann Winters, MD |
| Comments from the Public..... | 219 |
| Committee Deliberation..... | 225 |
| Voting | 226 |
| - Criterion 1..... | 230 |
| - Criterion 2..... | 231 |
| - Criterion 3..... | 231 |
| - Criterion 4..... | 232 |
| - Criterion 5..... | 233 |
| - Criterion 6..... | 233 |
| - Criterion 7..... | 234 |
| - Criterion 8..... | 235 |
| - Criterion 9..... | 235 |
| - Criterion 10..... | 236 |
| - Final Vote..... | 238 |
| Instructions on Report to the Secretary..... | 239 |

Zhou Yang, PhD, MPH: Medicare 3-Year Value-Based Payment Plan (Medicare 3VBPP)

PRT: Bruce Steinwald, MBA (Lead);
 Robert Berenson, MD; Elizabeth Mitchell
 Staff Lead: Ann Page

| | |
|---|-----|
| Committee Member Disclosures..... | 265 |
| PRT Report to the Full PTAC - Bruce Steinwald..... | 267 |
| Clarifying Questions from PTAC to PRT..... | 272 |
| Submitter's Statement, Questions and Answers, and Discussion with PTAC..... | 282 |
| -Zhou Yang, PhD, MPH | |
| Comments from the Public..... | 299 |
| Committee Deliberation..... | 300 |
| Voting | 300 |
| - Criterion 1..... | 301 |
| - Criterion 2..... | 302 |
| - Criterion 3..... | 303 |
| - Criterion 4..... | 303 |
| - Criterion 5..... | 304 |
| - Criterion 6..... | 304 |
| - Criterion 7..... | 305 |
| - Criterion 8..... | 305 |
| - Criterion 9..... | 306 |
| - Criterion 10..... | 307 |
| - Final Vote..... | 315 |
| Instructions on Report to the Secretary..... | 316 |

Mercy Accountable Care Organization: Annual Wellness Visit Billing at Rural Health Clinics

PRT: Robert Berenson, MD (Lead);
Tim Ferris, MD; Len M. Nichols, PhD
Staff Lead: Tim Dube

Committee Member Disclosures.....321

PRT Report to the Full PTAC - Robert Berenson.....323

Clarifying Questions from PTAC to PRT.....330

Submitter’s Statement, Questions and Answers, and Discussion with PTAC.....342
- Anne Wright - Sandra Christensen

Comments from the Public.....352

Committee Deliberation.....353

Voting 353

- Criterion 1.....354
- Criterion 2.....354
- Criterion 3.....355
- Criterion 4.....356
- Criterion 5.....356
- Criterion 6.....357
- Criterion 7.....358
- Criterion 8.....358
- Criterion 9.....359
- Criterion 10.....359

- Final Vote.....360

Instructions on Report to the Secretary.....361

Discussions on Atypical Proposals.....368

Adjourn.....387

P R O C E E D I N G S

[9:04 a.m.]

*** Opening Remarks**

CHAIR BAILET: All right. Good morning. Good morning, everyone. We're going to go ahead and get started. We're the Physician-Focused Payment Technical Advisory Committee, or PTAC. Good morning. Welcome to -- welcome to our -- this is our third public session. We're pleased to have all you here. In addition to members that are in the room with us, there are some watching on the live stream. Also, there'll be some folks on the phone as well.

This meeting allows us to deliberate and vote on the physician-focused payment models submitted by members of the public. We'd like to thank all of you for your interest in today's meeting. In particular, we'd like to thank the stakeholders who have submitted models, especially those who are here today. Your hard work and dedication to payment reform is truly appreciated.

PTAC has been very active since our last public meeting in September. Since that meeting, we have submitted recommendations and comments on two physician-focused payment model proposals to the Secretary of Health and Human Services that were voted on at the September meeting.

1 In addition, we've been very busy reviewing and
2 evaluating physician-focused payment model proposals from
3 the public. I'm pleased to report that interest in
4 submitting PFPMs to PTAC continues since we first began
5 accepting proposals for review on December 1st of 2016. We
6 have received 20 full proposals and an additional 13
7 letters of intent to submit proposals.

8 These proposals represent a wide variety of
9 specialties and practice sizes, and they propose a range of
10 payment model types. For example, over a dozen different
11 specialties and subspecialties are represented in the
12 letters of intent that we've received. There is interest
13 in physician-focused payment models by both small and
14 large-group practices. Bundled payments and care
15 management proposals comprise the majority of the proposals
16 to-date, but we've also received proposals or letters of
17 intent that relate to capitated payment and other payment
18 models.

19 We are pleased that we have so much interest from
20 clinical stakeholders in proposing physician-focused
21 payment models, and we're fully engaged to ensure proposals
22 are reviewed carefully and with the needs of both
23 clinicians and patients in mind.

24 We are already looking ahead to the agenda for
25 our next public meeting, which will be held here in the

1 Great Hall of the Humphrey Building, March 26th and 27th.
2 One simple reminder: To the extent that questions may
3 arise as we consider your proposal, please reach out to
4 staff through the PTAC.gov mailbox. The staff will work
5 with me as Chair and with Elizabeth, the Vice Chair, to
6 answer your questions.

7 We have established this process in the interest
8 of consistency in responding to submitters and members of
9 the public and appreciate everyone cooperating with us.

10 Today, we will be deliberating on four proposals
11 and deliberate on three proposals tomorrow. To remind the
12 audience, the order of activities for each proposal is as
13 follows: First, PTAC members will make disclosures of
14 potential conflicts of interest and announcements of any
15 Committee members not voting on a particular proposal.
16 Second, discussions of each proposal would begin with
17 presentation from the Preliminary Review Team, or PRTs.

18 Following the PRT's presentation and some initial
19 questions from PTAC members, the Committee looks forward to
20 hearing comments from the proposal submitters and the
21 public. The Committee will then deliberate on the
22 proposal.

23 As deliberations conclude, I will ask the
24 Committee whether they are ready to vote on the proposal.
25 If the Committee is ready to vote, each Committee member

1 will vote electronically on whether the proposal meets each
2 of the Secretary's 10 criteria.

3 Those of you who have read all the PRT reports
4 ahead know that members of the Committee have used the term
5 "not applicable" to refer to the elements of proposals that
6 they believe the criteria are not applicable to.

7 We will discuss this more in the context of
8 individual proposals, and we look forward to input from the
9 public as this -- on this particular issue as we finalize
10 our policy.

11 The last vote will be on an overall
12 recommendation to the Secretary of Health and Human
13 Services, and finally, I will ask PTAC members to provide
14 any specific guidance to ASPE staff on key comments they
15 would like to include in the report to the Secretary.

16 A few reminders as we begin discussions on the
17 first proposal: The PRT reports are reports from three
18 PTAC members to the full PTAC and do not represent the
19 consensus or position of the PTAC. The PRT reports are not
20 binding. The full PTAC may reach different conclusions
21 from that contained in the PRT report.

22 Finally, the PRT report is not a final report to
23 the Secretary of Health and Human Services. PTAC will
24 write a new report that reflects the deliberations and
25 decisions of the full PTAC, which will then be sent to the

1 Secretary.

2 It is our job to provide the best possible
3 recommendation to the Secretary, and I have every
4 expectation that our discussions over the next few days
5 will accomplish this goal.

6 I would like to take the opportunity to thank my
7 colleagues, all of whom give countless hours to the careful
8 and expert review of the proposals before them.

9 Thank you again for your work, and thank you to
10 the public for participating in today's meeting in person,
11 via live stream or by teleconference.

12 So, before we get started, I'd like to turn to my
13 Vice Chair, Elizabeth Mitchell, for any comments she'd like
14 to make.

15 VICE CHAIR MITCHELL: Thank you, Jeff.

16 And I would just like to add my thanks to the
17 Committee members who have, as you have said, have really
18 contributed countless hours to this process, and to the
19 submitters for bringing such good ideas forward. I think
20 we are achieving our aim, as set out in MACRA to create a
21 transparent and open process for consideration of new ideas
22 to expand the Medicare payment portfolio, and I just want
23 to thank you all for your commitment.

24 CHAIR BAILET: Thank you, Elizabeth.

25 The first proposal we will discuss today was

1 submitted by Renal Physicians Association, or RPA, and it's
2 entitled "Incident ESRD" -- or end-stage renal disease --
3 "Clinical Episode Payment Model."

4 PTAC members, as we start the process, let's
5 start by introducing ourselves and, at the same time, read
6 your disclosure statements on this proposal.

7 **Renal Physicians Association (RPA): Incident ESRD**
8 **Clinical Episode Payment Model**

9 * **Committee Member Disclosures**

10 DR. BAILET: So I'll start with myself. I'm Dr.
11 Jeffrey Bailet. I am currently the Executive Vice
12 President of Health Care Quality and Affordability with
13 Blue Shield of California. On the first proposal, I have
14 nothing to disclose.

15 We can go ahead and start with Tim.

16 DR. FERRIS: Tim Ferris. I'm the CEO (of the
17 Mass General Physicians Organization, and I have nothing to
18 disclose.

19 DR. TERRELL: Grace Terrell, CEO of Envision
20 Genomics, and I have nothing to disclose.

21 MR. MILLER: Harold Miller. I'm the CEO of the
22 Center for Healthcare Quality and Payment Reform.

23 I gave a presentation on alternative payment
24 models to the Renal Physicians Association's annual meeting
25 in March of 2016, and I was compensated for my time and

1 travel. During that presentation, I described potential
2 approaches to APMS for patients with chronic kidney
3 disease. While there, I met with a group of RPA leaders to
4 answer questions about APMS, and I provided comments on a
5 very preliminary concept paper they had developed about
6 bundled payments for chronic kidney disease. But I have
7 had no further involvement with RPA or its members in the
8 past 12 months, and I have not had any involvement in the
9 preparation of the PFPM described in the proposal. The
10 proposed payment model would have no special or distinct
11 effect on me.

12 DR. CASALE: Paul Casale, cardiologist and
13 Executive Director of New York Quality Care, the ACO of New
14 York-Presbyterian, Weill Cornell, and Columbia. I have no
15 disclosures.

16 MR. STEINWALD: I'm Bruce Steinwald. I have a
17 little consulting practice here in Washington, D.C., and
18 I'm doing some work on payment policy with the Brookings
19 Institution. And I have nothing to disclose on this
20 proposal.

21 VICE CHAIR MITCHELL: Elizabeth Mitchell,
22 President and CEO of the Network for Regional Healthcare
23 Improvement, and I have nothing to disclose.

24 DR. NICHOLS: Len Nichols. I direct the Center
25 for Health Policy Research and Ethics at George Mason

1 University, and I have nothing to disclose.

2 DR. PATEL: Kavita Patel, an internist at Johns
3 Hopkins and Fellow at the Brookings Institution, and I have
4 nothing to disclose.

5 DR. BERENSON: I'm Bob Berenson. I'm an Institute
6 Fellow at the Urban Institute, and I have nothing to
7 disclose.

8 DR. MEDOWS: Rhonda Medows, Executive Vice
9 President, Population Health, Providence St. Joseph Health.
10 I have nothing to disclose.

11 CHAIR BAILET: Could we go ahead and ask the
12 staff to introduce themselves. Marry Ellen?

13 MS. STAHLMAN: I'm Mary Ellen Stahlman, and I'm
14 the ASPE staff lead for PTAC.

15 MS. PAGE: I'm Ann Page. I'm the Designated
16 Federal Officer for the PTAC Committee, which is a
17 committee governed by the provisions of the Federal
18 Advisory Committee Act, FACA.

19 DR. SHARTZER: I'm Adele Shartzer. I'm a
20 contractor. I work for the Urban Institute, and I'm
21 helping staff this particular committee.

22 * **PRT Report to the Full PTAC**

23 CHAIR BAILET: Great. Thanks, everyone.

24 I'd like to now turn the microphone over to Dr.
25 Paul Casale who led the Preliminary Review Team for the

1 first proposal. Paul?

2 DR. CASALE: Thanks, Jeff.

3 I'll look for the first slide.

4 [Pause.]

5 DR. CASALE: Thank you. So, yeah, the title of
6 this proposal is "Incident ESRD Clinical Episode Payment
7 Model," submitted by Renal Physicians Association, and I'll
8 likely refer to it as the "RPA proposal" because it seems
9 easier to say.

10 So, which way do I point this? Okay.

11 So, in my presentation, I'll briefly review the
12 compositional role of the PRT, then give an overview of the
13 proposal, summary of our PRT review, and then evaluation
14 using the criteria, and finally key issues identified.

15 Jeff has already gone over this in terms of PRT.
16 I'll just -- as a reminder, a PRT report is not binding on
17 the PTAC, and PTAC may reach a different conclusion from
18 that contained in the PRT report.

19 Where am I supposed to point this at?

20 CHAIR BAILET: Just testing you, Paul.

21 DR. CASALE: Okay.

22 CHAIR BAILET: Okay.

23 DR. CASALE: Yeah, yeah.

24 Okay. So model overview. The model focuses on
25 optimal transition to dialysis. Some modalities, as an

1 example, initiating dialysis with catheters, are associated
2 with higher costs, higher rates of infection, and
3 hospitalizations. Advanced preparation is required for
4 less costly modalities.

5 So the eligible population for this proposal are
6 patients with incident ESRD, who are enrolled in Medicare
7 when they begin dialysis. The episode length is six
8 months, beginning the first day of the month during which
9 dialysis begins, unless it begins after the 16th of the
10 month.

11 And the major components are a shared savings /
12 loss based on total cost of care during the episode, and
13 also it depends on performance on quality metrics. And
14 then a second component is a transplant bonus of \$3,000 if
15 that occurs prior to beginning dialysis or \$1,500 during
16 the episode.

17 At the end of the presentation, there is a slide
18 that provides much more detail around the specifics. I
19 know everyone's read the proposal, so I'm just leaving it
20 at the back of the proposal for reference rather than going
21 through the specific details around all of the payment.
22 I'm sure we'll have discussion around that.

23 Okay. So summarizing the PRT criteria, you can
24 see here, and then we'll walk through each one of these
25 individually.

1 So, Criterion 1 for Scope. The PRT conclusion
2 was "proposal meets the criterion". On the strengths, this
3 APM is the only one that currently focuses on high-cost
4 ESRD patients.

5 The Comprehensive ERCD Care, or CEC model, has
6 limited participation of approximately 10 percent of
7 nephrologists. So this model expands access to APMs to
8 more nephrologists and their patients. And one of the ways
9 it expands it is that this model does not include the
10 requirement for minimum number of cases or patients or
11 other geographic considerations that make participation in
12 the CEC model difficult for many nephrologists.

13 One of the concerns we discussed in the PRT was
14 the potential issue of random variation and spending for
15 savings and loss calculations, particularly for small
16 nephrology practices, given the fact that ESRD patients
17 tend to be very high cost.

18 I went too fast. Okay.

19 Criterion 2 on Quality and Cost. The PRT
20 conclusion was the proposal meets the criterion. The
21 strengths that we identified was that the model addresses
22 the high annual spending for incident ESRD patients,
23 including potentially preventable hospitalizations related
24 in part to suboptimal transition to dialysis, and the model
25 makes shared savings payment contingent on a number of

1 important quality measures.

2 The concerns, as outlined and discussed by PRT,
3 the biggest opportunities for improvement need to occur
4 prior to dialysis, but the episode begins at dialysis
5 initiation. So the PRT is concerned about the ability of
6 nephrologists to influence upstream care, given treatment
7 patterns.

8 The minimum quality score for shared savings is
9 30, which is achievable merely by reporting performance.
10 The PRT would like to see greater emphasis on patient
11 experiences in the quality score threshold. And finally,
12 the difficulty we identified in evaluating the impact of
13 transplant bonus on quality and cost.

14 For Criterion 3, Payment Methodology, the PRT
15 conclusion was that the proposal meets the criterion,
16 except for the transplant bonus. So, the strength was at
17 the model's design to direct higher payments to
18 nephrologists who achieve better results for patients in
19 the first six months of dialysis. Again, this is a time of
20 particularly high cost and poor outcomes.

21 The concern is that the methodology does not
22 include up-front payments to providers to support enhanced
23 education and care management. The shared savings payments
24 are based on risk-adjusted spending and regional
25 benchmarks, but again, small numbers could impact the

1 effectiveness of the risk adjustment.

2 Again, weighting of the quality measures, we feel
3 should place more emphasis on patient experience.

4 And then the kidney transplant bonus is an area
5 of major concern, as it is unlikely to change the net
6 number of kidney transplants due to the organ supply
7 constraints, and factors determining transplant are largely
8 out of a nephrologist control. Encouraging transplant
9 referral and education could more accurately reflect
10 nephrologist actions.

11 For Criterion 4, Value over Volume, the PRT
12 conclusion was that the proposal meets the criterion. The
13 strength identified was the model provides incentives to
14 reduce the total cost of care for incident dialysis
15 patients in part by reducing the rate of hospitalizations
16 and other avoidable complications of treatment.

17 The concern that by beginning the episode with
18 the procedure, this model could create an incentive to
19 start dialysis earlier in the disease process when patients
20 are healthier and less likely to have complications.

21 For Criterion 5, Flexibility, the PRT conclusion,
22 "proposal meets the criterion". The strength that the --
23 we identified the model provides greater flexibility than
24 fee-for-service Medicare or the CEC model in the types of
25 activities physicians could undertake to deliver high-

1 quality health care, and providers could then use the
2 shared savings payments to support a range of activities to
3 improve quality.

4 The concern that the model requires providers to
5 make up-front investments that they hope to recoup during
6 reconciliation, this could discourage practices,
7 particularly small practices from making expensive but
8 valuable investments.

9 the Ability to be Evaluated, the PRT conclusion,
10 "proposal meets the criteria". Under strengths, the PRT
11 believed it is feasible to assess changes in spending and
12 quality associated with model implementation. The goals of
13 the model, the quality measures, and potential impact on
14 health care costs are clear and can be evaluated.

15 The concerns, again, for assessment of quality
16 outcomes, there may be challenges in reporting some of the
17 quality measures through the EHR, particularly the patient
18 experience measures, if a nephrologist does not participate
19 in the RPA-sponsored Kidney Quality Improvement Registry.

20 Under Criterion 7, Integration and Care
21 Coordination, PRT conclusion: "proposal does not meet the
22 criteria". The strengths identified: the model would
23 indirectly encourage the nephrologist to establish better
24 mechanisms for communication with other providers in the
25 community regarding patients with CKD who are likely to

1 need dialysis in the future, and the model would also
2 implicitly encourage nephrologists to improve care
3 coordination with the patient's other physicians. The
4 concern, however, is that the proposal does not provide
5 clarity about how providers would achieve better
6 coordination, both prior to and during dialysis.

7 There's no indication as to whether or how
8 nephrologists would involve other physicians in the APM
9 Entity or share savings and losses with other providers.

10 Under Criterion 8, Patient Choice, PRT conclusion
11 was that the proposal meets the criterion. The strengths
12 identified was this proposal has the potential to expand
13 the range of treatment options available to patients with
14 incident ESRD by encouraging early education and
15 preparation for the transition to dialysis.

16 The proposal also could encourage providers to
17 identify patients unlikely to benefit from dialysis and
18 educate patients about the alternative of conservative
19 management of their CKD. The concern is that the model may
20 incentivize providers to start dialysis earlier in the
21 disease process when patients are healthier, and the
22 transplant bonus may encourage patient choice by providing
23 a pathway to overcome existing barriers, but the large size
24 of bonus may influence the role of patient preferences.

25 Under Patient Safety, the PRT concluded "proposal

1 meets the criterion". The strength identified was this
2 proposal has a clear focus on avoiding hospitalizations,
3 reducing infection rates, et cetera, for patients during
4 the first six months of dialysis.

5 And for Criterion 10, Health Information
6 Technology, PRT conclusion was "proposal meets the
7 criterion". The strengths: All providers would be
8 required to use CEHRT. Oh, yeah. Nephrologists and other
9 participating providers would be encouraged to coordinate
10 care prior to and during dialysis with the aid of health
11 information technology.

12 The proposal notes that the RPA qualified
13 clinical data registry would be available to model
14 participants and would facilitate the collection of patient
15 and disease data.

16 The concern was this proposal does not provide
17 specific information about how to encourage use of health
18 information technology specifically.

19 So, key issues identified by the PRT: The PRT
20 supports the proposal's goal of improving the transition to
21 dialysis for patients with incident ESRD. The PRT's major
22 concerns are: One, the upstream activities. The model has
23 potential to improve quality and reduce costs, but it
24 relies on the assumption that the same nephrologists or
25 nephrology practice is involved in the care of the patient

1 for an extended time prior to and then after dialysis
2 initiation.

3 In terms of upfront investments, the model's
4 payment methodology requires upfront investments from
5 providers for patient education, care management, and other
6 services that could be returned to providers during
7 reconciliation. However, small providers are particularly
8 vulnerable to random variation that could put that
9 investment at risk.

10 And the third concern relates to the transplant
11 bonus. The PRT supports efforts to increase
12 transplantation, but paying bonuses in this model is
13 problematic and an unnecessary component of the model.

14 So, with that, I'll stop and ask my fellow PRT
15 members if they have additional comments before opening it
16 up. So, well, Harold and then Jeff.

17 MR. MILLER: I have none.

18 DR. CASALE: None? Okay.

19 * **Clarifying Questions from PTAC to PRT**

20 CHAIR BAILET: Thanks. I have no specific
21 comments to make, Paul, but I think if there are clarifying
22 questions, this would be a good time. Bob?

23 DR. BERENSON: Yeah, I just want to talk a little
24 bit about the eligibility criteria here. As I understand
25 it, it's people who are already on Medicare, not

1 populations who will become eligible by virtue of having
2 ESRD. Isn't that a relatively small percentage of a renal
3 physician's dialysis population? And isn't it a pretty
4 unique population? I guess -- so, one, do I have that
5 correct, that it's a minority of dialysis patients? And
6 I'll ask them, too, but did you explore that at all?

7 DR. CASALE: Yeah. It's our understanding that
8 it's patients who are on Medicare who would be --

9 DR. BERENSON: So that's -- I mean, most people
10 who -- my understanding is that -- and there's some data
11 here which I don't understand -- is that most ESRD patients
12 are below 65 and become eligible because they start
13 dialysis. They are not already on Medicare. So we are
14 dealing with a subpopulation of patients who are in a renal
15 physician's practice here, and so, one, I think that
16 exacerbates the problem of small numbers. But two is would
17 we expect behavior change for just a relatively small
18 percentage of a physician's practice, dialysis practice, is
19 my question.

20 MR. MILLER: It's not as small as you're
21 representing it to be, and I think we should ask them that.
22 So anybody who would be -- have chronic kidney disease when
23 they become eligible for Medicare and go on Medicare and
24 who then progress to end-stage renal disease would be
25 included in this.

1 The population you're talking about would be
2 people who were commercially insured or -- commercially
3 insured who would then reach end-stage renal disease. And
4 then there's a 20-month period when they don't become
5 eligible for Medicare, anyway. So that's -- that
6 population, the commercially insured becoming -- going on
7 dialysis wouldn't be --

8 DR. BERENSON: Or the Medicaid insured or the
9 uninsured.

10 MR. MILLER: Correct. But anybody who is -- goes
11 on Medicare and has chronic kidney disease when they go on
12 Medicare or develops it afterwards, presumably, and then
13 progresses to end-stage renal disease would be included in
14 this population, and that's -- I'm not sure that we ever
15 tabulated that specifically. My recollection is that
16 that's, I don't know, a third-to-a-half of the people. But
17 we can ask them that.

18 DR. BERENSON: Okay. All right. Thanks.

19 CHAIR BAILET: Tim?

20 DR. FERRIS: So I have a question for the whole
21 PRT that this proposal raises, but it's come up in other
22 proposals, and the reason why I'm pointing it out is
23 because we appear to be inconsistent in our recommendations
24 about this, and so probably we're learning as we go.

25 But the concern raised on Criterion 3, the

1 methodology, does not include upfront payments. We've
2 actually stated the opposite concern in the past as well,
3 which is if the payment is up front, then you -- and that's
4 at risk, then you have a possibility for the practical
5 problems associated with clawbacks and the associated
6 practical problems. So both upfront payments and after-
7 the-fact payments present challenges. We've stated it here
8 as a concern, but I would say that I'm not also -- I'm not
9 sure that we have come to some -- and I'm not sure, maybe
10 the economists in the group can help us out here. But I
11 don't know that there's a preferred way. It may be that
12 both ways have positives and negatives and that the context
13 might be important.

14 CHAIR BAILET: Right. Len, do you want to
15 comment on that?

16 DR. NICHOLS: Well, just as the forenamed
17 economist in the room, I would say both God and devil live
18 in the details, and so it really does depend. You can do
19 it smartly either way, and I would say our task is to
20 decide, A, if what they proposed meets the standards we
21 worry about; and, B, if there are modifications we would
22 like to suggest, and I think that'll come out.

23 But to me, the big thing about the PRT's
24 conclusion here was that they were afraid the investment
25 upstream wouldn't take place without some kind of money

1 because they'd have to do that on spec, in essence, and
2 that's different. You could have a partial upfront and
3 then an ex post. That would solve your nuance problem.
4 Don't worry. There's a solution.

5 CHAIR BAILET: It'll work itself out. Paul.

6 DR. CASALE: I think in our PRT discussion, you
7 know, one of the strengths of this -- because we were
8 comparing it a bit to the CEC model, and one of the
9 strengths was this would involve, you know, the smaller
10 groups --

11 CHAIR BAILET: Right.

12 DR. CASALE: -- in areas where there is no CEC
13 model available to them. And so I think part of our
14 thinking around that was as you involve these smaller
15 practices, potentially more rural, et cetera, the need for
16 some upfront investment is going to be important.

17 MR. MILLER: Can I just add to Tim's point?
18 Because I think that is a general issue going on. There's
19 also a difference between whether the upfront payment is an
20 incentive payment that's being given somehow then to be
21 taken back if the practice doesn't achieve something,
22 versus a payment that's designed to cover a cost. And I
23 think on one of the other proposals, the issue was it's an
24 incentive payment; it's not intended to cover a cost, and
25 then it's being taken back if the practice doesn't achieve

1 it. The issue here was the concern was if the practice
2 needs to incur new costs and doesn't have any upfront way
3 to pay for that and is dependent on getting a shared
4 savings payment, which it doesn't know whether or when it
5 will get, that that could be biased against very small
6 practices that don't have those resources. So that was
7 really -- that was the distinction.

8 CHAIR BAILET: Bruce.

9 MR. STEINWALD: It's my understanding that ESRD
10 patients and Medicare beneficiaries are major consumers of
11 Part B drugs, particularly Epogen for the relief of anemia
12 related to kidney failure. And I didn't -- here's the
13 standard disclaimer: I didn't see it in the materials I
14 read, but the disclaimer is could have been there and I
15 missed it, and that could apply to almost any of the
16 proposals, so I'll just say -- so I won't repeat that
17 disclaimer. But was there some discussion either in the
18 proposal or your discussions with the proposer or amongst
19 yourselves about how this model would affect the
20 consumption of Part B drugs? And is that one of the
21 targeted areas of potential savings under the model?

22 DR. CASALE: It's interesting. I don't think we
23 had that discussion in the PRT that I can recall, in
24 particular whether it would be impacted.

25 MR. MILLER: The drugs you're referring to,

1 Bruce, are bundled into the dialysis payment now. So if
2 patients --

3 MR. STEINWALD: Not Epogen -- I don't think so --
4 or iron and some of the -- some of the drugs are, but
5 others are not.

6 CHAIR BAILET: Well, the submitters are going to
7 clarify that for us. I'm seeing a lot of heads nodding
8 over there. So we'll get clarification on that point.

9 Kavita?

10 DR. PATEL: All right. I have a -- it's not
11 really for -- actually, it is for the PRT, but it might be
12 for staff, too. I'm just struggling. I'm kind of building
13 off of Bob's analytic question, and in Table 1A on page --
14 I don't know what -- there's -- it looks like if I'm
15 reading this correctly that there are a total of 51,240
16 patients who got the Medicare benefit and had some Medicare
17 benefit that are kind of potentially in this denominator
18 for this payment model. Am I -- and then of that, 31,000,
19 so a little over half, got it because of age. And it looks
20 like only 700 were in because of end-stage renal disease?
21 So, I'm just trying to understand the, like, actual
22 population of people, kind of just building on Bob's
23 question of if this really is like people who are kind of
24 imminently going to be on dialysis and would not have
25 already had been on Medicare potentially or -- I'm just

1 trying to ask what the denominator is.

2 And then the second question, somewhere in the
3 conversation -- one of the criticisms that you pointed out,
4 Paul, was this inability to kind of think about going up --
5 the coordination and going upstream. And in the back-and-
6 forth with the clinical expert from Penn, they talked about
7 that need. And then in response, RPA I thought provided a
8 thoughtful kind of assessment of, yes, we agree but,
9 unfortunately, by the time they come to us, it's so
10 heterogeneous we can't really get to the upstream. I'm
11 just curious if you all could put a little more color onto
12 that potential to go more upstream into like the Stage 3
13 and 4 CKD, and I think you went into some of that.

14 DR. CASALE: Yeah, I'll take the second one
15 first, so we can think through the numbers again. We had a
16 lot of discussion around that, and with our expert from
17 Penn and with the submitters, because I think it may -- you
18 know, it depends a little if you're in an academic medical
19 center versus in the community, I would say, a bit, where
20 our -- the experience of our expert at Penn was, well, you
21 know, they check in with me once a year, they're sort of
22 managed -- you know, they have CKD that's advanced. They
23 check in with me once a year, but they're really managed in
24 their local community. And then they may then get started
25 on dialysis. They may -- Penn may start their dialysis,

1 but then ultimately they're going to be cared for locally
2 because they're not going to be commuting back and forth
3 for their dialysis. And so we did have concerns around
4 that. So who's going to be responsible for that upfront
5 education in terms of even for transplant evaluation and
6 then, you know, preparation, putting the graft in, et
7 cetera, and all of that?

8 And so I think there is a bit of difference,
9 depending on the experience at the academic versus the
10 community, although I think we recognize that one of the
11 concerns is that a lot of these patients, you know, in the
12 current system aren't really -- may not be seen any
13 nephrologist until they start dialysis, and we talked about
14 that. So they're trying to get upstream on that, and so
15 that's going to require more care coordination, et cetera.

16 CHAIR BAILET: Yeah, and part of the -- a lot of
17 the expense in the first six months is chewed up for people
18 who go to dialysis because they have a catheter in place,
19 so the infection rates, et cetera. Ideally, either they're
20 going to get a transplant before they need dialysis, or
21 they can get a shunt, which would be the ideal way, for
22 peritoneal dialysis. And the challenge is that if it's a
23 vascular shunt that needs to be placed, those have to
24 mature, and there, you know, we talked with our expert and
25 the nephrology submitters, and that takes months for that

1 to mature. So it's a timing issue, and we also talked
2 about, well, where's the marker? Because, again, we're
3 trying -- ideally, the more care that can be delivered up
4 front prior to dialysis instead of having people crash into
5 dialysis, that's really going to get at the cost, the
6 hospitalizations and some of the complications and
7 mortality that they talked about. There's a significant
8 mortality increase if you go into dialysis on a catheter.

9 The challenge is there's no specific marker.
10 They talked about glomerular filtration rate and some of
11 the other labs that get you into the different stages, but
12 there was -- it's -- still there's not a consistent belief.
13 There was some flexibility on interpreting when is the
14 appropriate time. So there's a lot of moving parts, I
15 guess is what I'm trying to say. We pressed hard on
16 couldn't we just put a -- you know, if your glomerular
17 filtration rate is X or your kidney function is Y, we're
18 going to put a graft in at that time. That gives us 18
19 months of upstream, and then we can start to impact some of
20 the complications.

21 The other point is that the statistics show that
22 28 percent of end-stage renal patients have not seen a
23 nephrologist prior to starting dialysis, and another 43
24 percent see a nephrologist less than six months. So you're
25 talking about 71 percent of the patients who end up on

1 dialysis really had almost -- you know, had limited or no
2 nephrology care, and that's where that upstream input would
3 be necessary. So hopefully the submitters, when we get
4 them up here, we can talk about that as well.

5 Elizabeth, you had a -- or Paul?

6 MALE PARTICIPANT: [Off microphone.]

7 DR. PATEL: [Off microphone.] Maybe somebody
8 could clarify the numbers.

9 MR. MILLER: Sure. I wasn't sure exactly what
10 your question was. Table 1A was our effort to try to
11 determine how long people had been on Medicare who were --
12 people who were on Medicare when they started dialysis, the
13 moment that they started dialysis, how long had they been
14 on Medicare? And the answer is a long time, more than a
15 year. It wasn't that they just suddenly became eligible
16 for Medicare and then suddenly started on dialysis.

17 There are a lot of people who are on Medicare
18 getting dialysis that didn't start dialysis on Medicare
19 because they were still covered by a commercial insurance
20 or whatever. In fact, it's one of the odd things about
21 this structure, is that in a sense Medicare is getting them
22 after somebody else has been responsible for start -- it's
23 not the small -- a very small proportion, but if you look
24 at all the people who are on ESRD, Medicare is, if you
25 will, taking care of them after somebody else was

1 responsible for paying for the start. So this is focused
2 on the people that under Medicare, at least, there is the
3 potential to be able to do something when they start.

4 You could potentially then extend this to other
5 payers. You could say some commercial payer could have the
6 exact same model because they would say we're paying for
7 these patients for the first 20 months, and that's a time
8 when based on all this data suggests that there is a very
9 significant opportunity to be able to reduce costs, et
10 cetera. So it would certainly be attractive to them also,
11 but we're only doing Medicare right here.

12 So this particular area of disease has really
13 fascinating margins between, you know, when commercial
14 insurance, et cetera, and so also anybody here who would be
15 -- who would be uninsured and who would be starting home
16 dialysis would be starting under Medicare initially, but
17 that's a fairly small population.

18 DR. SHARTZER: Kavita, if you flip back to Table
19 C3, it shows the health insurance coverage status of
20 incident ESRD patients, and it looks like 60, about 60
21 percent have Medicare when they're incident. Sorry. I
22 know there are a lot of tables.

23 DR. CASALE: Okay. All right. Very good.
24 Elizabeth?

25 VICE CHAIR MITCHELL: Thank you. My question is

1 around the quality metrics, and this might be better for
2 the submitters, but particularly around the patient
3 centeredness and the PROMIS metric and the referral to
4 transplant, were there any concerns about sort of
5 collection of the information, particularly if it's across
6 providers, and any thought about how -- what is an optimal
7 outcome given the various scenarios for treatment? And,
8 also, what interaction you might have had about having a
9 threshold beyond just reporting to actual performance?

10 DR. CASALE: I think a lot of our discussion
11 focused on the weighting of it, the concern that it wasn't
12 -- there were a lot of measures, and the experience ones we
13 felt should be weighted higher.

14 In terms of the collection, I think we identified
15 the one around their -- around their registry and if you're
16 not participating, particularly if you're trying to reach
17 out to, you know, smaller groups and rural, et cetera, that
18 may not -- may or may not be part of the registry.

19 I don't recall we had much -- you know, in terms
20 of the outcome versus the reporting, I'm not sure we
21 discussed that extensively. I think a lot of the emphasis
22 was around the weighting of experience versus all the
23 process measures. That would be important to weigh those
24 higher in terms of qualifying for the shared savings.

25 CHAIR BAILET: Harold.

1 MR. MILLER: I think the issue with this
2 population, this model, is that patients who are on
3 dialysis are known to have problems in terms of
4 complications and hospitalizations, et cetera. And so, in
5 a sense, the whole thrust of this is about reducing that
6 and thereby improving it. So, in a sense, the quality
7 improvement is really fundamentally focused around that
8 idea, of helping patients during that initial period of
9 dialysis to not have complications and end up in the
10 hospital, to be able to get a fistula rather than a
11 catheter, not have -- be subject to infections, et cetera.

12 So, in a sense, there's sort of -- this is really
13 -- the payment model is fundamentally directed at a
14 particular quality initiative. It is not saying we're
15 going to somehow pay you more and we hope that you are
16 doing it in the right way, or that you're spending less and
17 we hope you're -- because if they're on dialysis, I mean,
18 roughly about almost half of the cost of the -- during that
19 period of time, is the dialysis itself, and most of the
20 rest ends up being these avoidable hospitalizations.

21 So that's kind of why we thought it was important
22 to make sure that the patient experience, et cetera, was
23 being weighed appropriately, but it wasn't that somehow you
24 were being rewarded for a mysterious quality improvement.
25 That, fundamentally, if you're going to save money it's

1 probably because you've achieved the quality improvement
2 that this is about.

3 DR. CASALE: Although I would add, you know, in
4 terms of the experience part, not, you know, certainly not
5 going to the hospital and not being in the ER, that's all
6 very good. But even our expert at Penn, you know, when
7 they come in with their CKD, and he mentions dialysis, I
8 mean, that's a big -- you know, that people don't want to
9 hear that. And so the experience that people have around
10 the conversations and the education and the -- as they move
11 from CKD to dialysis, is important, and to be able to
12 measure and understand what that experience is. And I
13 think that's part of what you're, I think, trying to get
14 at, in terms of how are patients -- and again, we
15 highlighted that a little bit in terms of is there
16 -- could there potentially be -- an unintended consequence
17 of people moving to dialysis sooner than not, based on this
18 model.

19 So I think the registry is helpful in terms of
20 the reporting but not everyone necessarily will have access
21 to that, potentially, and how would you measure it.

22 CHAIR BAILET: Grace?

23 DR. TERRELL: It's interesting to me that a lot
24 of our conversation here is not around the "doesn't meet
25 criteria" one that -- Criteria 7 -- about integration and

1 care coordination. And so this is something that may be a
2 comment now, it may be something that our presenters want
3 to clarify. But I think it's a broader issue as it relates
4 to how you all may have analyzed that.

5 And this has to do with some known facts about
6 quality of care at this point in somebody's journey into
7 end-stage renal disease, specifically one thing that I
8 believe is well-known, you sort of alluded to it, Jeff, is
9 vascular access and how that's performed in the community
10 makes a great deal of difference. So if you've got a shunt
11 placed by a vascular surgeon who does hundreds of these,
12 then your outcome is better than somebody who does it
13 occasionally.

14 So that, to me, looks like an opportunity to have
15 talked in great detail about the care coordination and
16 integration, but the response that they had back was, well,
17 we wanted to make it so it would be relevant and sort of at
18 the local level as it relates to there may be small rural
19 communities or whatever where this -- you know, where
20 innovation or care coordination would have a different tone
21 or color than it would with somebody else.

22 So this is a big issue with respect to the U.S.,
23 and what constitutes a standard of care and what
24 constitutes a standard of quality, as it relates to people
25 coming to us, wanting to think and talk about care

1 coordination and integration, because it's not equal
2 everywhere in the U.S. But we do know that there are some
3 very different outcomes that occur as the result of some
4 communities having access to things.

5 I'm an internist at Wake Forest Baptist Health,
6 and one of the debates that has happened there, and I
7 believe been resolved, is they have many, many good
8 vascular surgeons, they all like to do these shunts,
9 they're going to have one guy do it, because he does the
10 best and the access is -- you know, the outcomes are
11 better.

12 That's a true, you know, quality outcome in a
13 place that happens to have a lot of resources. That's not
14 going to work so well in a rural area if there's one
15 vascular surgeon within 200 miles or something. But yet
16 the payment is supposed to be the same across the country.

17 So their response to this was actually not a bad
18 one, which is we need to give it some flexibility across
19 the country for rural communities, small communities as
20 well as large ones, but that's kind of a big deal with
21 respect to anybody's individual outcomes.

22 So I would like to hear how far the Committee
23 actually pushed on this issue of integration and care
24 coordination and then when the nephrologists have a chance
25 to speak, I would really like to get their thought process

1 in a little more detail about why they left it so vague.
2 Because the PRT said "didn't meet criteria," but this is an
3 issue that actually, I think, is a much bigger one, not
4 only for this proposal but for many, and it just has to do
5 with how are we going to evaluate things when we know that
6 some types of behaviors and some situations are going to be
7 better than others.

8 DR. CASALE: Yeah. I think we had a fair amount
9 of discussion around this issue of care coordination and
10 integration. We talked a bit about, you know, the vascular
11 access, but I think it was even more around what I
12 mentioned before, around patients with CKD who sort of have
13 this every-six-months or yearly visit with a nephrologist
14 somewhere, and then - but then they're sort of managed
15 locally. And it's not until they then go on dialysis and
16 then who is actually managing their care, and who is making
17 the decisions about when they're going to put the graft in,
18 et cetera, when there may be sort of the expert
19 nephrologists who they have little contact with, and how
20 are you going to specifically do that coordination with
21 either the local internist, in particular?

22 But, you know, I think what you've said about
23 vascular surgeons applies, to you know, many others, right,
24 where certainly volume of procedures and outcomes certainly
25 have a significant relationship. So I think -- and, Jeff,

1 you want to add to that -- but I think we had a fair amount
2 of discussion around the concerns around integration and
3 care coordination.

4 CHAIR BAILET: I think the other point, Grace,
5 was that in many instances patients with chronic kidney
6 disease will see -- they'll travel a distance to see the
7 nephrologist on these check-in appointments that Paul's
8 alluding to. But when they get their dialysis, which is on
9 a serial basis, they tend to get that closer to home. So
10 that was another challenge.

11 So, in some centers and situations, the
12 nephrologist that's treating them for the end-stage renal
13 disease is also the nephrologist that was supporting them,
14 but not always the case.

15 So, again, there -- one of the reasons that it
16 "didn't meet" was it was underdeveloped relative to talking
17 about the -- how this model is actually going to drive that
18 integration. So it's not necessarily it wasn't there or
19 isn't happening. It's just this model specifically didn't
20 address it with the granular detail that we felt sufficient
21 for it to meet the criteria. Does that -- is that a -- I'm
22 just looking at my colleagues. Harold?

23 MR. MILLER: I would just add, for me this comes
24 down to the issue we were talking about with Tim before,
25 was -- is there -- Is the payment model designed in such a

1 way that it would actually support what you think people
2 would want to do? We don't -- it's not necessarily that
3 they have to be specified that, but there's actually lots
4 of care coordination issues here. There's, "How do you
5 reach out to the PCP, for people who are headed in this
6 direction?" "How do you talk to the vascular surgeon?" "How
7 do you deal with other specialists when the patient may
8 have comorbidities that need to be managed to keep them out
9 of the hospital, because it's a total cost?" So, they
10 could be being hospitalized not just for complications of
11 their dialysis but for, you know, access but for other
12 kinds of conditions that they have.

13 So, the issue was, in theory, the nephrologist is
14 going to have to be managing all those things, and it's
15 just a shared savings model. So the question was, well,
16 "Is that really going to enable all that to happen?" And
17 we said -- it wasn't that we wanted to specify it, but we
18 didn't see it articulated as to how one would imagine that
19 working well and whether it would work well under this
20 particular payment model.

21 CHAIR BAILET: Thank you, Harold. Bob, we're
22 going to get to you and then we'll invite the proposers to
23 come to the table.

24 DR. BERENSON: And this, again, I will be asking
25 the docs, but I just wanted to know if the PRTs had any

1 insight into this. The proposal had a lot of information
2 about very high mortality rates early on. There was a
3 discussion about both going upstream to predict and prepare
4 for dialysis and also crashing into dialysis. I'm just
5 wondering if there's two populations here, one that are
6 going into the hospital and the ICU for some other reason
7 and get acute renal failure, dialysis has started, and many
8 of them don't survive.

9 So the technical question is, "does the episode
10 start with outpatient dialysis for survivors of the
11 hospital or for any dialysis?" So that's my concern, is
12 that we may have two populations, and I'm just wondering
13 who this payment model applies to, if you know what I'm
14 asking.

15 DR. CASALE: Yeah, and Harold was just whispering
16 to me. That reminded me that acute kidney injury, I
17 believe, was excluded. So it would not apply to that
18 scenario that you just suggested.

19 DR. BERENSON: Does it start with an outpatient
20 dialysis or any dialysis? It doesn't -- it's not
21 specified.

22 DR. CASALE: Yeah, I think it kind of --

23 CHAIR BAILET: It's -- I think it's inpatient or
24 outpatient, but not acute.

25 MR. MILLER: No, I think it's outpatient. It's

1 only -- it's outpatient. But the issue is they can't --
2 they're not starting it because of an acute injury that
3 occurred in the hospital. They have to be starting -- they
4 may have started in the hospital but, I mean, first
5 dialysis, but it has to be because of chronic kidney
6 disease, not because of something that happened during a
7 hospitalization.

8 DR. BERENSON: So the question I will be about to
9 ask is whether that high mortality rate and presumably, in
10 the discussions you had with them, high cost in the first
11 couple of months applies to that population that's not the
12 acute kidney injury, and that's what I'm interested in.

13 CHAIR BAILET: Okay. Thank you, Bob.

14 * **Submitter's Statement, Questions and Answers, and**
15 **Discussion with PTAC**

16 CHAIR BAILET: So we're going to go ahead and
17 invite the submitters to come on up. I think you've got to
18 flip your tent table there, flip them over. We have 10
19 minutes, and then the Committee will engage in questions.
20 Appreciate it. And thank you all for coming out. We
21 appreciate that.

22 So if you could introduce yourselves and --

23 DR. GIULLIAN: Great. I'll start. My name is
24 Jeff Giullian. I'm a nephrologist from Denver.

25 MS. SINGER: I'm Dale Singer. I'm RPA's

1 Executive Director.

2 DR. KENNEY: I'm Robert Kenney. I'm a
3 nephrologist from Baton Rouge, Louisiana.

4 DR. KETCHERSID: Terry Ketchersid, a nephrologist
5 from Southern Virginia.

6 DR. SHAPIRO: Michael Shapiro, a nephrologist,
7 San Diego area and President of the RPA.

8 CHAIR BAILET: Thank you.

9 DR. GIULLIAN: Thank you all very much for
10 allowing us to come. As I mentioned, my name is Jeff
11 Giullian. I'm a nephrologist from Denver, and certainly on
12 behalf of my colleagues here we want to thank this
13 Committee for inviting the Renal Physicians Association to
14 discuss the physician-focused payment model for patients in
15 the incident period of end-stage renal disease.

16 As you guys have already come to conclude, end-
17 stage renal disease affects nearly half a million patients
18 and accounts for seven percent of all Medicare spending,
19 and each year over 120,000 new patients start dialysis, of
20 which approximately 50 percent, by our estimate, are
21 Medicare-eligible patients. And this account -- this time
22 frame of incident dialysis accounts for a disproportionate
23 share of those overall costs.

24 And since 1973, really, this group, the RPA, has
25 represented nephrologists in the pursuit and delivery of

1 quality renal health care and has been the leading advocacy
2 organization for the renal community. And in this
3 endeavor, the RPA represents the voice of practicing
4 nephrologists in the United States, and we remain quite
5 committed to public policy which supports patient-centered
6 quality outcomes, clinical safety, and responsible resource
7 utilization.

8 So, this morning we look forward to reviewing our
9 clinical episode payment care model with you and answering
10 the questions, many of which have already come up this
11 morning, and we're looking forward to discussing those with
12 you.

13 I want to start, though, by saying that
14 throughout the design of this model, we have really
15 maintained intentional focus on five key tenets, and I just
16 want to share those with you so that we kind of level set.

17 The first key tenet is physician flexibility,
18 which we just discussed, and we wanted to use that to
19 better ensure care coordination, which I will go into in
20 more detail, along with patient education and shared
21 decision-making.

22 The second was to incentivize optimal transition
23 to end-stage kidney disease and ultimately into the
24 prevalent dialysis time period for distinct patient
25 populations, and that includes, as we mentioned previously,

1 those that had prior nephrology care and those that had
2 limited or no prior nephrology care.

3 The third tenet was to reduce the very high spike
4 in cost associated with the care of these populations.

5 The fourth was to increase patient-shared
6 decision-making regarding options for renal replacement
7 therapy, and very specifically for alternatives, including
8 conservative medical management and renal transplant.

9 And the final tenet was to reduce and even
10 eliminate unintended consequences that might undermine the
11 clinical and cost-savings benefits of any new payment
12 model.

13 So as we discuss this payment model, I want to
14 kind of remind the members of this Committee of really the
15 magnitude of this issue. Based on published data and in
16 spite of clear medical benefits, nearly 80 percent of
17 patients begin dialysis suboptimally, which might include
18 initiation with a central venous catheter in place, without
19 shared decision-making, and/or without the benefit of
20 essential care coordination. And this places undue
21 clinical and financial costs, both on the system and also
22 on patients in those first few months of dialysis, and
23 often leads to longer-term health-related issues.

24 And as noted by your committee's own analysis,
25 the cost of dialysis in the first few months is quite

1 expensive, and may even reach \$90,000, with the direct
2 nephrologist's billing account only for a very, very small
3 amount of that total. Hospitalization rates, readmission
4 rates during this time period tend to be very, very high,
5 and that's related, in great extent to, as I mentioned,
6 that suboptimal transition, inadequate patient-shared
7 decision-making, and limited care coordination.

8 And so as we constructed this alternative payment
9 model, we identified several opportunities within the
10 current reimbursement environment which may contribute to
11 the high costs and unsatisfactory clinical outcomes, which
12 I just described. And some of these include non-dialysis
13 options for patients whose quality and longevity of life
14 might not well be -- might not be well served by receiving
15 dialysis; enhancing alignment on reimbursement across the
16 entire continuum of care, and enhanced payment structure
17 aimed at reducing hospitalizations; provision of greater
18 patient choice, and understanding of home dialysis options,
19 which we think may mitigate some of those issues you
20 discussed with regard to vascular access; waivers to allow
21 mechanisms that will improve care coordination, patient
22 transportation, and other obstacles across -- to improve
23 health care access; and ultimately greater advocacy for,
24 and access to, renal transplantation.

25 The RPA believes that a novel payment model,

1 which includes costs for patients across this care
2 continuum, will positively impact the patient experience,
3 care coordination, clinical outcomes, and resource
4 utilization during this time period, and ultimately that
5 benefit will impact the prevalent dialysis time frame as
6 well.

7 And so with these points in mind, the RPA based
8 this proposal on a shared savings model, with requirements
9 to achieve well-vetted, evidence-based clinical metrics and
10 patient-centered outcomes. And these metrics, which we've
11 begun talking about already this morning, were chosen to
12 represent really tangible results to impact those clinical
13 outcomes and reduce complications, decrease
14 hospitalizations, and overall improve the quality of life
15 that we provide to our patients.

16 So, in short, this CEP model will alter and
17 refocus physician incentives to break down barriers that
18 might exist for this vulnerable patient population,
19 ultimately increasing care quality while reducing those
20 expenditures.

21 So according to the findings of the PRT, as we've
22 discussed this morning, the RPA has met or nearly met 9 out
23 of the 10 Secretary's criteria for an alternative payment
24 model, and so I want to discuss some of those quite
25 quickly.

1 Regarding the payment methodology criterion, the
2 PRT has mentioned this morning, and with its notes back to
3 us, that they had some concerns regarding payment of the
4 preemptive and early renal transplant, and while the RPA
5 remains committed to renal transplant as the gold-standard
6 treatment for appropriate patients, we do understand the
7 PRT's critique of this portion of our payment model, and as
8 such we realize the need possibly to remove this reward
9 payment for preemptive and early renal transplant.

10 And then moving on to the criterion number 7,
11 integration and care coordination, we look forward to
12 discussing more this morning several techniques that we've
13 identified that would incentivize nephrologists to serve as
14 the principal care coordinator for this very vulnerable
15 patient population and allow the necessary flexibility to
16 address local clinical variables. We fully anticipate that
17 a model that aligns incentives to keep patients healthy,
18 involve them in care choice, and keep them out of the
19 hospital will appropriately incentivize this care
20 coordination and integration, both somewhat upstream but
21 also during these first six months of care during dialysis.
22 And this is true for care coordination with other
23 specialists and also with health care organizations.

24 So specifically, the RPA anticipates that
25 practices will implement any number of process improvements

1 to achieve greater care coordination. These might include
2 items such as systematic referral of all appropriate CKD
3 Stage 4 patients to kidney education, which is available
4 throughout communities in the United States; formal
5 coordination with vascular surgeons and interventionists
6 ahead of time or in the early period during dialysis;
7 expedited office visits for ill ESRD patients, so that they
8 don't have to rely on the emergency room for care; and
9 enhanced evaluation of post-hospitalization are all
10 possible under this CEP model and do not require drastic
11 infrastructure investments up front. We also look forward
12 this morning to addressing all points raised by the PRT
13 regarding the Secretary's criteria.

14 As we've noted in our previous comments to the
15 PTAC, the RPA evaluated several potential clinical payment
16 models before refining our current episode of care model,
17 which begins upon completion of CMS Form 2728. So acute
18 kidney injury patients, even AKI patients, acute kidney
19 injury patients who receive outpatient dialysis, would not
20 be included in this model because Form 2728 indicates the
21 diagnosis of end-stage renal disease.

22 This model represents the RPA's effort to
23 maximally impact cost, patient experience, shared decision-
24 making, and high-quality clinical outcomes for nearly every
25 subpopulation of patient transitioning onto dialysis, those

1 with prior nephrology care, those with limited nephrology
2 care, and those that we call crashers that had no prior
3 nephrology care.

4 And additionally, while not explicitly directing
5 the management of upstream CKD care and patient education,
6 we strongly anticipate that this type of care model will
7 positively impact both upstream and downstream care.

8 Regarding our proposal to initiate shared savings
9 payment at a threshold of 30 quality points, the RPA
10 believes that this was a starting point, which represents
11 care that meets or exceeds current standards. We have
12 proposed some metrics based upon well-vetted clinical
13 outcomes and others based upon patient experience and
14 functional status, which while evidence-based, remain to be
15 fully normalized to this patient population, which
16 ultimately is why we recommended a reporting metric for the
17 first year so that we could ultimately normalize.

18 We also note that some of the clinical outcomes
19 we believe will have patient experience benefits, such as
20 the clinical outcome of home dialysis, which provides
21 patients that otherwise wouldn't be offered this modality
22 an opportunity to dialyze at home rather than dialyzing in
23 a center. And we believe that this amalgamation of outcomes
24 represents really the greatest opportunity to provide new
25 ESRD patients better care, fewer hospitalizations, and

1 superior quality of life.

2 And finally, the RPA wishes to recognize that
3 there are other renal-focused alternative payment models
4 that either have been proposed or are already in existence.
5 There is likely not a single one-size-fits-all model for
6 the heterogeneous states of early CKD, late CKD, incident
7 end-stage renal disease, and prevalent end-stage renal
8 disease, and this clinical episode payment model was
9 designed to complement other efforts where appropriate but
10 also stand alone by serving all practice sizes,
11 geographies, and patient populations.

12 So, again, on behalf of my colleagues within the
13 Renal Physicians Association, I wish to convey my gratitude
14 for the opportunity to work with this Committee to refine
15 this proposal. The RPA is highly committed to providing
16 physicians the best possible opportunities to deliver
17 world-class care and service to our kidney patients.

18 We are also committed to engaging with and
19 equipping physicians with tools and resources needed to
20 deliver optimal care that our patients and really our
21 communities deserve.

22 Thank you all very much.

23 CHAIR BAILET: Questions for the submitters?

24 Tim.

25 DR. FERRIS: So, first of all, let me thank you

1 all for an incredible amount of work that you put into this
2 and for what is clearly an incredibly diligent effort to
3 meet those five criteria, which I would say are sort of a
4 model for how a physician association should approach the
5 development of an alternative payment model.

6 My comment is not so much about the specifics of
7 your proposal. It is more of an out-of-the-box, so this
8 may be a little bit of a curveball.

9 But I'd like to hear you think out loud -- and
10 you may have already considered this -- about the
11 triggering event, and several -- if I were to summarize
12 several comments from both the PRT and the members of the
13 PTAC, that there is a lot of opportunity -- and I see this
14 in my own patients and the patients we care for at Partners
15 and Mass General -- just upstream of dialysis.

16 I don't want to get into a -- like, where there's
17 more opportunity, because there's lots of opportunity on
18 both sides of the dialysis divide. But I wondered, you
19 know, in an ideal world if there was a trigger that was
20 more upstream that you could use in a practical sense,
21 would that be of use?

22 And then more specifically on that point --
23 because in my system, we do use a trigger more upstream to
24 set in place a whole bunch of processes that we start, and
25 it's GFR, as actually as Jeff said. So we know the GFR of

1 every single patient we treat who's ever had, you know, a
2 creatinine done.

3 But I live in a world where we have a system with
4 an electronic medical record that [unintelligible] catches
5 that on every nephrology patient and every primary care
6 patient and every pulmonary, right? We have it for
7 everyone treated in the system, and I thought -- you know,
8 two triggers came to mind as potential options, and I
9 wondered if you considered them.

10 The first is, you know, one of the, you know
11 physicians like to complain about is ICD-10. But actually,
12 ICD-10 does have specific codes for GFR that one could use
13 if it was a billed event as a trigger. So ICD-10 is one
14 potential option.

15 The other one, which is -- and I want to applaud
16 you in your approach to the use of registries. I'm a big
17 fan of the use of registries, but if every patient we treat
18 is in a registry, then obviously a registry event, which is
19 an auditable event, when a patient's GFR reaches a
20 particular threshold, then one might want to then trigger
21 all these interventions, care coordination, shared
22 decision-making.

23 So an auditable registry event, where a GFR
24 passed a certain threshold, or just an ICD-9 billed code
25 struck me as two potential options for broadening the lens

1 a little bit and including all that opportunity upstream.

2 Sorry for such a long question.

3 DR. GIULLIAN: No, it's a very valuable question,
4 and I assure you we talked all about that because we would
5 say the same thing. In an ideal world, starting a payment
6 model at specifically, I think, a GFR of either 20 or maybe
7 25 would be optimal. Now, as you're well aware, the ICD-
8 10, they don't make a distinction at 20. They make a
9 distinction at 30 and at 15.

10 So when we first thought about ICD-10, we felt
11 that 30 was really too early for something that was really
12 going to focus on end-stage renal disease. Most patients
13 still with chronic kidney disease Stage 4 and a glomerular
14 filtration rate of 25 or 28 or 29 ultimately will never
15 progress to dialysis.

16 The next step that's formally recognized is a GFR
17 of 15, and ultimately, that's really where patients in many
18 cases are beginning dialysis or are right on the cusp and
19 maybe too late for doing the formal education that's
20 necessary for having a robust discussion about clinical
21 options other than starting dialysis. And so that left us
22 really with 20.

23 Where we fell on that, though, was a couple of
24 things. As we've noted, about a third of patients would
25 then never have been entered into this, and that makes what

1 may be considered small numbers even smaller and really
2 leaves out one of the most vulnerable patient populations
3 where we can impact both care and cost.

4 But also 20, at that level of GFR, is actually
5 highly variable with the current creatinine measures that
6 we've got, and even as we look towards some newer
7 biomeasures, it's still not perfect.

8 So somebody can have a GFR of 22, and we could
9 add 40 milligrams of Lasix, and all of a sudden, they have
10 a GFR of 19. Their kidney function hasn't really changed,
11 but they've now become part of this model. And then you
12 stop the Lasix because their edema is gone. Now their GFR
13 is 22. So that left us with a little bit of a concern that
14 maybe this wasn't the right approach, and it's not true
15 just obviously for diuretics. It's true for ACE inhibitors
16 and ARBs and certain antibiotics and those types of things.

17 And so when we looked at it, we really looked at
18 CMS Form 2728 not as the beginning of a procedure, but
19 rather the beginning of a diagnosis, a true time frame when
20 you know there's no going back. That this is a point in
21 time when a patient is uremic sufficiently and the
22 physician does not believe that there's any chance of
23 reasonable renal recovery.

24 And so while, yes, in a perfect world, we would
25 have a model that both works upstream and downstream and in

1 the middle, we unfortunately couldn't figure out how to put
2 that square peg into a round hole.

3 DR. KETCHERSID: Yeah. I would build on that,
4 Tim, just to say that in my day job, we've recognized that
5 outside of large vertically integrated health care systems,
6 primary care providers don't frequently use the CKD ICD-10
7 codes. So the patients are coming in, and they are being
8 seen for hypertension or diabetes. And, oh, by the way,
9 the creatinine clearance or eGFRs, it's frequently ignored,
10 so it creates another challenge. But we're with you in the
11 ideal world.

12 CHAIR BAILET: So, we have Bob, Grace, and Bruce.

13 DR. BERENSON: [unintelligible] just a couple
14 other questions. First, a general question, the mortality
15 data, then, that you presented in various tables, and the
16 \$90,000, that excludes acute renal failure patients. So
17 could you give me a sense of -- the mortality rates were
18 remarkably high in the first two months. What do people
19 actually die of? Could you give me a sense of that?

20 DR. GIULLIAN: So this is, again, a heterogeneous
21 group, but one of the things that occurs often, although I
22 don't have a specific number, is that patients that are
23 really fundamentally not suitable for long-term dialysis
24 have a terminal illness, end-stage liver disease, an
25 oncology issue, terminal heart failure, oftentimes get

1 started on dialysis as sort of a last-ditch effort.

2 There is now, I would say, relatively robust data
3 that suggests that those patients do not do well on
4 dialysis in terms of increased longevity of life or
5 increased quality of life, and yet the default currently
6 is, well, start them on dialysis.

7 We think that a model like this would further
8 incentivize, albeit not directly, physicians to really have
9 those coordination-type meetings with patients, with
10 family, with the primary caregiver, and oftentimes with
11 either palliative care or some team of physicians such as
12 that. So that's part of the reason that mortality is so
13 high.

14 The second reason mortality is high in this
15 patient population is both cardiac events and infection
16 events, and that goes along with starting dialysis non-
17 optimally. When we place a dialysis catheter into a
18 patient, it not only increases inflammation, which
19 increases the likelihood of a cardiac event, but it's
20 obviously a conduit for bacteria. The tip of that catheter
21 sits right in the right atrium or right next to the right
22 atrium, so when it gets infected, it's really the worst
23 possible place to have an infection.

24 So we do believe that this type of model would
25 positively affect mortality, both again by allowing for

1 different options for those patients that might not benefit
2 from dialysis and better options for those patients that
3 will benefit from dialysis.

4 DR. BERENSON: So that's very interesting. Let
5 me follow up, then. So the first population, you mentioned
6 somebody -- those who come in with a severe, maybe life-
7 ending disease started on dialysis, they would be in the
8 program because a 2728 will be created for them?

9 DR. GIULLIAN: If they start dialysis, then, yes,
10 they would be in the program.

11 And our assumption is that this is really an
12 indirect incentive for physicians to have those meaningful
13 and quality conversations with patients and families to
14 say, you know, dialysis is an option, but it's not a good
15 option for you. It's an option that ultimately is going to
16 leave you no better off from a longevity standpoint and
17 potentially worse off from a quality-of-life standpoint,
18 thereby those patients never start dialysis if that's
19 appropriate and part of their shared decision-making. That
20 then benefits the APM as a whole because those high-
21 utilizer patients ultimately don't start.

22 DR. BERENSON: And then the final question, for
23 this population, for what you're proposing, which are
24 people who are already on Medicare, what is the purpose of
25 the 2728? It's not for eligibility into ESRD, or is it,

1 even though they've already been on Medicare? So what's --
2 yeah, that's the question.

3 DR. GIULLIAN: Do you want to answer this, Terry?
4 Or go ahead, Robert.

5 DR. KENNEY: The purpose of the Form 2728 is to
6 notify CMS of enrollment in the ESRD program. It is
7 required of all patients starting dialysis with end-stage
8 renal disease, whether or not they have Medicaid or
9 uninsured.

10 It also sets Medicare eligibility if other
11 requirements are met as well.

12 DR. BERENSON: Does ESRD provide additional
13 benefits beyond just Medicare? If somebody is already on
14 Medicare, do they get anything additional by then being
15 eligible for ESRD?

16 DR. KENNEY: No, they do not, but they become
17 enrolled in all the programs and monitor the ESRD program.

18 DR. BERENSON: I see. Okay.

19 DR. SHAPIRO: And just to add, this is a
20 physician's, the nephrologist's attestation that in their
21 best judgment, this patient has reached end-stage renal
22 disease sign. It's important and is taken very seriously.

23 CHAIR BAILET: Grace?

24 DR. TERRELL: I recently saw an end-stage renal
25 patient of mine that I hadn't seen in seven years because

1 she's been managed by a nephrologist who's done an
2 exceptionally good job, but apparently, I guess she was
3 under some sort of managed Medicare, thought that she
4 needed a Medicare wellness visit, so they sent her back to
5 me.

6 It speaks to an issue of who owns the patient and
7 what I believe is a really essential issue with patients
8 who have complex disease, particularly this population, in
9 that I feel that this population needs to be owned by the
10 nephrologists. They do a better job.

11 In my previous roles, we were working with the
12 concept of a nephrology medical home for patients who have
13 particular aspects of a chronic progressive illness that's
14 end-stage renal disease.

15 So when I was looking at this model of care, this
16 payment model, I was trying to put it around a care model,
17 which is an issue that we've talked about previously in
18 other proposals here, and I would like to hear your
19 thoughts on that because I believe that in the flexibility
20 that you all put in the proposal, it may be there, but it
21 wasn't explicitly talked about.

22 Who actually owns a patient for everything,
23 whether it's a Medicare wellness visit or whatever, is
24 really crucial, particularly when they're going through a
25 transitional time like this.

1 DR. GIULLIAN: Yeah, you're absolutely right. We
2 had on this Committee a robust discussion around that.

3 The RPA actually put out a white paper two or
4 three years ago that addressed this particular issue
5 because there's some heterogeneity in the way different
6 communities utilize the primary care physician in this.

7 I was fortunate in my community that my primary
8 care physicians stayed very involved in the care of their
9 ESRD patients, and in other places, when the patient became
10 ESRD, the nephrologist became ultimately the primary giver,
11 care coordinator.

12 So, in our white paper, we actually, I would say,
13 coined a term, which we called the -- I'm going to find it
14 here -- it's the "principal care provider," lowercase PCP,
15 as compared to the Primary Care Physician or Primary Care
16 Provider, uppercase PCP. And this designation in that
17 white paper was very purposeful in sort of allowing
18 nephrologists to understand kind of what their role is,
19 again, based on the flexibility needed in their particular
20 system or in their particular geography.

21 And so we agree that in most cases, I think the
22 term Terry has used is "the nephrologist becomes the
23 quarterback". We're not always the best primary care
24 physicians and oftentimes need the primary care physicians
25 for true help in things that are a little bit outside of

1 our wheelhouse, and yet when it comes to making sure that
2 the patient goes and sees their cardiologist and that we
3 have an understanding of what needs to happen volume
4 status-wise or when the patient sees the endocrinologist
5 and we have a better understanding of what needs to happen
6 from a diabetes management standpoint, we are the ones that
7 are sort of quarterbacking it. So lowercase pcp is the way
8 we envision the role of the nephrologist within this model.

9 DR. KETCHERSID: Just to build on that though,
10 Grace, it brings up a point that you raised earlier, and
11 that's -- it's really fundamentally one of the reasons why
12 we were not overt about specific care coordination
13 activities. It's to prevent that level of flexibility, and
14 to some degree, it builds on exactly what Jeff described.
15 We know that across the country in certain communities, not
16 only are the primary care providers still involved, they
17 fully intend to be involved. And we had no interest in
18 disrupting that, and then in other circumstances, that's
19 not the case.

20 The other impetus behind that was we were a
21 little bit concerned that if we put overt mandated
22 requirements that the first people to jump ship and not
23 participate would be the small-practice nephrologist and
24 those in rural communities. That was not because we missed
25 that criteria. We were overt in that attention.

1 CHAIR BAILET: Bruce?

2 MR. STEINWALD: Thank you.

3 You may have heard earlier I asked the PRT a
4 question about the consumption of Part -- separately
5 billable -- Part B drugs. I'd like to broaden my question
6 for you a little bit.

7 You also said -- and I think it's widely believed
8 -- that the current payment system discourages patients
9 from selecting alternatives to in-center hemodialysis. So,
10 could you say a little bit more about how you think your
11 model would encourage those alternatives, to what extent
12 they would encourage them, and then maybe build your
13 response about Part B drugs into that answer?

14 DR. GIULLIAN: Yeah, absolutely.

15 I'm going to start with the second part of your
16 question because it's now fresh on my mind.

17 The way dialysis providers, not physicians, but
18 the large dialysis and small and medium dialysis
19 organizations are paid is now what's called a "bundle." So
20 they get a, in essence, a capitated rate per dialysis
21 session, and that includes the vast majority of those
22 medicines, those Part B medicines. Epo is in there. Iron
23 is in there. Those types of things.

24 MR. STEINWALD: Just to clarify. So, they are in
25 the bundle now? When did that happen?

1 MALE PARTICIPANT: 2011

2 DR. GIULLIAN: 2011, if you didn't hear.

3 And so we don't necessarily believe that by
4 changing anything within this model, there would be a
5 differential impact. If anything, it would be a
6 differential beneficial impact to shareholders in dialysis
7 organizations, which, while great, is not what we mean to
8 achieve by this at all. So that was the second part.

9 The first part of your question -- or maybe I
10 have them backwards is -- is how is this really
11 meaningfully going to have an impact on the choice of home
12 dialysis. Home dialysis is considered one of the things
13 that would be an optimal transition to dialysis. CMS has
14 stated that they anticipate that between 20 and 25 percent
15 of all patients would be eligible and should be on home
16 dialysis, and yet in the United States, I think we're at
17 9.6 percent right now. So we've got a large gap to close.

18 The physician organizations -- I believe I speak
19 for all of them -- would say that we're all on board with
20 this, and finding ways to appropriately incentivize for
21 home dialysis is meaningful.

22 So for crasher patients, for example, I would say
23 the vast majority of patients right now start in-center
24 dialysis with a dialysis catheter in place because it is
25 the path of least resistance. It's easy, and

1 interventional radiologists or interventional nephrologists
2 or vascular surgeons can very quickly place a tunneled
3 catheter in a patient on their third day of being in the
4 hospital, and they can then go out to in-center.

5 The problem is, when that happens, they typically
6 stay on in-center forever, so well past the first six
7 months, well past the first year, inevitably, and maybe
8 they get a fistula or maybe they keep that catheter for a
9 prolonged period of time.

10 With this in place and home dialysis being one of
11 the metrics that is a quality metric, we believe that
12 there's actually an impetus now for even crasher patients
13 to get emergency hemodialysis in the hospital but actually
14 leave the hospital with a peritoneal dialysis catheter.

15 In the past 24 months, there's been significant,
16 significant improvements by dialysis providers in providing
17 what's called "urgent start peritoneal dialysis," and this
18 would be an impetus for those patients to then leave the
19 hospital with a peritoneal dialysis catheter and urgently
20 start home PD.

21 There's also now an impetus, I would say, not
22 just for the upstream education for home modalities, but
23 also for education once patients start dialysis on home
24 modalities. And quite frankly, there's just no incentive
25 for that at this point.

1 DR. SHAPIRO: Well said.

2 CHAIR BAILET: Len?

3 DR. NICHOLS: So thanks. I appreciate Tim's
4 really good question, and I appreciate your answer about
5 this ideal triggering event. But I want to return to it
6 just for a minute. Do you see a pathway whereby the
7 discovery of an improvement on a trigger event could be
8 part of a research program that went along with
9 implementation of this model? Have you all thought about
10 that?

11 DR. GIULLIAN: We have, and while I can't discuss
12 specifics because we have a nondisclosure agreement, we've
13 actually recently evaluated technology that would be better
14 at determining actual glomerular filtration rate compared
15 to estimated glomerular filtration rate. So I could
16 personally envision, without making any promises on
17 technology, that there could come a time in the future,
18 maybe the near future, where we really have a gold standard
19 where we know what somebody's kidney function truly is, not
20 because they're on an ACE inhibitor, not because they're on
21 a diuretic, but what their actually filter rate -- their
22 actual filter rate is. And I would love to come back to
23 this Committee at that point and say, "Woo-hoo, we've got
24 it, let's move upstream."

25 DR. NICHOLS: Or perchance CMS.

1 Go ahead, Terry.

2 DR. KETCHERSID: Yeah, Len, I'll add to that. A
3 couple of us up here have enough gray hairs that, back when
4 we were in training, there was this thing called "one over
5 creatinine," right?

6 [Laughter.]

7 DR. KETCHERSID: And there was this idea that you
8 could predict -- right? -- when things were going to start.
9 And I -- I'm not trying to be a pessimist here. I welcome
10 the idea of being able to get ahead of that and to be able
11 to predict, because one of the challenges -- and we debated
12 this as well, right? -- is let's say you did decide you
13 were going to start with today's GFR trigger of 20. Then
14 you could begin to wonder how many AV fistulas would be put
15 in that would never be used, right? Because they have a
16 GFR of 20 and I'm sure they're going to start --

17 DR. NICHOLS: Oh, yeah.

18 DR. KETCHERSID: -- in six months or 12 months.
19 So it's a -- we really, really, really would like an ideal
20 circumstance so that we could include the entire continuum
21 of care.

22 DR. NICHOLS: We appreciate your restraint in
23 reaching the simple solution. So, I was also intrigued at
24 how your proposal allowed choice to different physician
25 groups, sort of Track 1, Track 2, whatever. So what do you

1 think about this idea that Tim elicited from me earlier
2 about splitting the shared savings bonus into a kind of a
3 PMPM, particularly for those small rural practices so they
4 could have resources up front to do their investment in the
5 upstream stuff? And then on the other end, you would lower
6 their percentage of the savings or shared savings. Did you
7 all think about that?

8 DR. SHAPIRO: I think we did look at what's the
9 best model to capture the most patients, and one of the
10 concerns -- and it's been -- I think it's been identified
11 and discussed here already -- is that quite a large number,
12 a third to 40 percent or so, of the patients are not
13 engaged in the system in some way upstream. And so we
14 reach them first or they reach us first when they're at
15 that starting point at the 2728 Form of starting dialysis.
16 And we thought that, well, given all the other things we
17 talked about here with identification, use of the GFR, when
18 to plug them into a payment model, we would capture
19 everybody. The patients who are already being cared for
20 with late-stage CKD who their physician thinks are likely
21 to progress are going to -- those patients and those
22 physicians will see the benefit if the patient reaches ESRD
23 and enrolls in the model. But it also gives -- that six-
24 month time frame gives the physicians an opportunity to be
25 able to do something good on behalf of that patient with

1 incentives to be able to do that, too, in a shared savings
2 model where they wouldn't have had that patient if we moved
3 upstream with a PMPM type of payment, exclusively, at
4 least, anyway. How to best -- is there a way to be able to
5 coordinate that?

6 DR. NICHOLS: Or blend it, that's all --

7 DR. SHAPIRO: Well, I guess just one more
8 comment, and I'll let my colleagues opine here as well,
9 that I think the resource requirements for a practice are
10 fairly small to be able to provide education to the
11 patient. Most nephrologists, if you ask them, "Do you run
12 a CKD clinic? Are you running an education program?"
13 they'll say, "Yes, of course we do." We've discussed that.
14 But they can't always show the good results, and in today's
15 health care economy for the practices, they need to show
16 commercial insurers, they need to show perhaps ACOs in
17 their environment, IPAs, why should we choose you to be our
18 specialist? In that area, we have practices across town
19 that do -- that look at their results. They're showing
20 really good results. The impetus now in this triple-aim
21 era is for the physicians to be able to say, "No, I had
22 really good results; I get more patients with fistulas. I
23 get -- "Well, what's the benefit to those nephrologists for
24 expending or putting more money into their practice
25 infrastructure? Well, one of them is to be the provider of

1 choice and get some contract. Another here in this
2 particular case would be, "You know what? If I do a really
3 good job of this, when my patients do go on dialysis,
4 they're going to be less costly and I'll get to share in
5 that, in those savings as well."

6 DR. KETCHERSID: Len, I would add I don't recall
7 overtly thinking about the split that you discussed, but I
8 do think a couple of things did come up, one of which was
9 would there be opportunity, much like the -- I hope it's
10 okay to say "quality payment program" in this room. But
11 that program offers to small practices. Is there an
12 opportunity for us in some fashion to provide relief?
13 Because we were concerned about small practices and rural
14 practices.

15 But the last thing I'll mention is the experience
16 that a number of us have had with the ESCO program, is the
17 remarkable attraction that the Advanced APM bonus has for
18 nephrologists that are participating in that program. And
19 so with the opportunity to join this model and take the
20 two-sided risk approach, certainly those benefits would
21 extend. Now, granted, you're still weighting right? -- But
22 that five percent bonus is fairly significant for a
23 nephrologist. And even if this model were to come to
24 fruition after the extinction of that bonus, the
25 differential in the fee schedule increase that the A-APM

1 provides is - that's --

2 DR. NICHOLS: That's a good point. Thank you
3 very much.

4 Okay. So the last thing I'm impressed with is
5 your geographic diversity here. We've got southern
6 Virginia, we've got Baton Rouge, San Diego. Have you all
7 thought about offering the option to lump small practices
8 together in kind of a virtual group? I hope it's okay to
9 say that in this room, too. So tell me about -- because
10 that's -- obviously, diminishing the risk those guys will
11 bear is a major concern.

12 DR. KETCHERSID: Yeah, absolutely. It's not
13 overtly stated in the model, but we're hoping that the
14 virtual group component of the MIPS program this year will
15 gain some traction because the actuarial precision piece
16 for the small practices we're certainly concerned about,
17 and we think that by -- at a local region, probably,
18 because we want the baselines to be local, assimilating
19 those groups in a way that recognizes that if Michael's a
20 small doc, I'm a small doc, and I'm asleep at the wheel but
21 he's performing well, I don't take the whole ship down, if
22 we could figure out how to solve that particular issue.

23 DR. GIULLIAN: And we actually did say that in
24 the model. I can't find it right offhand, but it is three
25 whole words, so it's not much. Don't blame you at all for

1 overlooking it, but we did make that mention somewhere in
2 here.

3 DR. SHAPIRO: And to differentiate it from the
4 CEC model as well with the two contiguous CBSA (Core-based
5 Statistical Area) limitation for that model.

6 CHAIR BAILET: Thank you. Kavita?

7 DR. PATEL: I have a brief question. You brought
8 up a number of the kind of issues with the CEC model. If
9 we were just to kind of speak openly, having -- if CMMI
10 were to lift those constraints, would that model still kind
11 of be a potential for more nephrologists to do what you're
12 describing?

13 DR. KETCHERSID: Yes and no. So if the
14 constraints were lifted, the challenge still exists to
15 reach that kind of an actuarial credible number, and so you
16 would need to at least invoke the virtual component.

17 The other challenge is, when we've looked inside
18 our -- this is personally speaking -- our ESCO experience,
19 of the beneficiaries that are assigned to the model, less
20 than five percent are in their first 120 days of dialysis.
21 So there's not a significant focus today because the bulk
22 of those patients are prevalent dialysis patients.

23 DR. GIULLIAN: And I would add one other key
24 difference, which is within the ESCO model, physicians must
25 -- excuse me, patients must stay within a given dialysis

1 provider that is the provider/owner of that ESCO APM. Our
2 model is substantially different in that patients would
3 have choice as to who their provider is and could go to a
4 different provider, assuming that's what's better for them
5 for any number of reasons and remain within the model.

6 CHAIR BAILET: Bob.

7 DR. BERENSON: Yeah, I want to get back to my
8 question related to insurance status. If I understand the
9 table that Adele pointed us to, it looks like about half of
10 patients are already on Medicare that are in -- does that
11 seem right to you? And that there's a substantial number
12 who are on Medicaid. What happens -- does a Medicaid
13 patient after the three and a half months or three-plus
14 months to become eligible for ESRD, does ESRD Medicare
15 become primary for those patients?

16 DR. GIULLIAN: I'm not sure I'm the perfect
17 person to answer, so I'll open it up to the committee. But
18 I do want to make sure that we explain there is a slight
19 difference. So for patients that go on to in-center
20 dialysis, they have a 90-day waiting period before they
21 become eligible for Medicare. For patients that choose
22 home dialysis, Medicare becomes available, assuming they
23 don't have another insurance on Day One.

24 DR. BERENSON: Did you want to say something?

25 DR. KENNEY: If a patient has Medicare

1 eligibility and say they had previously Medicaid, Medicare
2 in almost all circumstances will be primary to the
3 Medicaid.

4 DR. BERENSON: So that's what I was hoping you
5 were going to say. I like the model, and it seems like it
6 would affect 50 percent of the patient population on
7 average. Is there any way to expand the model, probably
8 not to commercial insurance, but, I mean, I'd like it so --
9 I mean, so my basic question is: I assume 50 percent of
10 your practice is enough to change your behavior and that
11 there would be some spillover or -- and is there any way to
12 expand the model to other payers such as Medicaid?

13 DR. KENNEY: Not in its current proposed form,
14 clearly. Now, whether or not -- because Medicaid is not
15 just a federal program. It's a 50-state program. So I
16 think that would be a little bit daunting right now.

17 We did try to include as many Medicare patients
18 as we could. However, there are problems. For one thing,
19 say a patient who is under 65 and is not disabled so,
20 therefore, does not have Medicare, starts dialysis, whether
21 it's home or in-center, they get Medicare eligibility, but
22 there is a coordination period of 30 months at which point
23 Medicare is secondary to whatever else they have. So how
24 do we fit those people in this model?

25 So it just became the simplest thing to do was to

1 have -- to include patients who have Medicare as their
2 primary payer Day One of the enrollment.

3 DR. SHAPIRO: And regarding your question about
4 expansion to other payers, that speaks to me very clearly,
5 because I think that practices are looking for
6 opportunities for a competitive differential advantage with
7 -- especially in the commercial sector, where they have --
8 where they can become the provider of choice in that area.
9 And this is a model where they'd say, you know what? Wow,
10 this applies to my Medicare patients as well. If I need
11 any infrastructure to be able to go into a commercial payer
12 as well and say, look, look what we're doing, you know, we
13 can do an APM type of model here and get paid a little bit
14 differently, differentially. In our experience with that
15 in my practice, we were able to reach commercial payers.
16 They were quite interested in something like that.

17 DR. KETCHERSID: Bob, the only thing I'll add is
18 we do anticipate a halo effect that you describe. To
19 Robert's point, this was the simplest starting point, but
20 we don't anticipate nephrologists treating different payer
21 patients substantially different when they bill these
22 things. We're seeing that in the ESCO program today.

23 DR. BERENSON: And the average renal physician
24 treats the variety of patients? They don't sort themselves
25 out?

1 DR. GIULLIAN: I can speak for my own group when
2 I was in practice. We were at about 50 percent Medicare
3 patients in general, just all comers, CKD, et cetera. And
4 so really there was a spillover effect. We didn't look at
5 a patient and say, gosh, you're United Health, you're Blue
6 Cross, you're Medicare. It was just whatever was sort of
7 mandated was the standard of care for all patients, and so
8 I anticipate a spillover effect for all patients.

9 CHAIR BAILET: All right. Thank you. Harold?

10 MR. MILLER: Two questions. Do you see the
11 shared savings model and the transplant bonus as completely
12 separable concepts? In other words, do you see that the
13 nephrologists would be equally attracted to the shared
14 savings model if the transplant bonus wasn't there, that
15 they would be equivalently successful without it there?
16 And, conversely, since you thought that the transplant
17 bonus was a good idea, do you think that it would be a good
18 idea if there was no shared savings model and simply have
19 that? So talk about how you see them as -- are they two
20 separable concepts or are they interlinked in some fashion?

21 DR. GIULLIAN: Yeah, let me back up just a little
22 bit and say that, you know, the transplant bonus was
23 completely novel and different than anything that's within
24 the realm of fee-for-service or anything else. It was
25 truly, I think, an opportunity for us to say a couple of

1 things:

2 Number one, to say that transplant is the gold
3 standard, both for quality of life but also for overall
4 cost of care for patients.

5 Secondly, we wanted to make sure, as I mentioned
6 in one of our tenets, that we were doing absolutely nothing
7 that might be viewed as having unintended consequences.
8 And so by somehow establishing a financial incentive for
9 dialysis, which ultimately this APM does, we wanted to make
10 sure that that in no way changed a physician's goal first
11 and foremost of getting patients transplanted, either
12 before they start dialysis or as soon as possible.

13 I don't know if this Committee knows, but
14 patients can actually be listed for a renal transplant when
15 that glomerular filtration rate hits 20. So, they actually
16 can get on the list well ahead of time, and yet the vast
17 majority of patients aren't referred to a transplant center
18 in CKD Stage 4. The vast majority of patients aren't
19 referred until they're well on to dialysis, and we still
20 run into, unfortunately, discrepancies in which types of
21 patients get referred.

22 So our primary goal in all of this was to make
23 sure that we were advocating for the gold standard and to
24 make sure that we weren't leading to any unintended
25 consequences.

1 That being said, we understood when we put this
2 in there that this was completely novel, something that I
3 don't think there is precedent for, for actually paying
4 somebody a reward for something occurring, especially as it
5 occurs a little bit outside of their control. As the
6 nephrologists, we have control to refer the patient. We
7 also have some control in terms of how much care
8 coordination we do: Making sure that patients gets their
9 cardiac evaluation, making sure that the primary care
10 records make it over to the transplant center, and things
11 like that. So there is some role of the general
12 nephrologist, but it is also somewhat outside of our
13 control.

14 So to answer your question, I do think they're
15 separate. They weren't designed in tandem. In fact, the
16 transplant bonus is the one part of this model that is
17 upstream, in essence, that's outside of the ESRD time
18 frame. And so while we certainly wanted to go down that
19 road and are still interested in exploring options with
20 this Committee, we do understand that they're different,
21 and we do understand the PRT's concern with it.

22 MR. MILLER: Thanks. The second question is:
23 Assuming that this model you proposed were actually
24 approved and implemented, is there -- who else do you wish
25 was also in a different payment model to help the

1 nephrologist be successful in this? Primary care
2 physicians? Transplant surgeons? Vascular surgeons?
3 Hospitals? Cardiologists? Who else do you wish would be
4 -- or, I mean, the other way to ask that question was: Who
5 do you think might be rowing against you that you would
6 like to have them changed?

7 DR. GIULLIAN: I don't know that anybody's rowing
8 against us necessarily. I think the easy answer to your
9 question is: All of the above. We are proponents of APMs,
10 and so we're proponents of that being really the model of
11 payment going forward as it works for other specialists.

12 We've also had conversations with other
13 specialists in determining, hey, how can we think about, in
14 the future as we get this under our belt, an APM that
15 includes other specialists for things like placement of a
16 vascular access or something like that?

17 I think what we have found, as we've discussed
18 with other societies, is the bigger something gets and the
19 more complex it gets, the harder it is to get off the
20 ground. And that doesn't mean that these guys are
21 simpletons -- I am -- but I think that the goal would be
22 let's really prove that we can accomplish something, and
23 let's take that and snowball that into more -- larger APMs
24 that include hospitals, that include primary care
25 physicians, that include vascular surgeons, et cetera. But

1 right now we're really focused on what we can control,
2 which is the treatment given by the nephrologist.

3 DR. KETCHERSID: Harold, if I might add to that
4 -- and this is information that has kind of recently become
5 available. It's out in the public domain, and I hate to
6 keep relying on the CEC model. But it's interesting. If
7 you look at the experience that the three large -- in CMS'
8 eyes, large dialysis organizations have had in the first
9 year of the CEC model, and you go out and you see who the
10 participants are, there's one of those organizations that
11 enlisted primary care providers and vascular surgeons as
12 participants. There's another organization that partnered
13 with a health care system. And then there's another
14 organization that just worked with nephrologists. And the
15 upshot was that the shared savings that was generated for
16 Medicare was almost identical in all three.

17 And so I think the jury's still out. You know,
18 we'd love to have everybody in the boat rowing in the same
19 direction, but in terms of picking today, I think that's a
20 heavy lift.

21 CHAIR BAILET: Elizabeth.

22 VICE CHAIR MITCHELL: Thank you. I wasn't going
23 to ask anything, but you piqued my interest when you said
24 so few patients are actually getting -- are having the
25 conversations about transplants early enough. And this

1 might be related to Harold's question, actually. Sort of
2 who -- will this payment model address that problem? Will
3 you get at some of the more upstream issues -- smoking
4 cessation or any of the sort of population health
5 interventions that could actually help patients earlier on?
6 And if so, how?

7 DR. GIULLIAN: They're looking at me, so I'll
8 take this.

9 Not specifically. So while all of that is
10 important, some of that remains still outside of the domain
11 of the nephrologist. For right or for wrong, some of the
12 population health discussions that you just had -- smoking
13 cessation, et cetera -- tends still to be on the side of
14 the primary care physician, even into late CKD. And I may
15 be speaking only on behalf of my own practice, but that's
16 often what it was, because we in our clinic visits spent
17 the majority of our time talking about cardiac risk factors
18 other than smoking but specifically with regard to volume
19 status, CHF stuff, things such as diabetes control and
20 ultimately trying to prepare, when appropriate, the patient
21 for dialysis.

22 So, I think that the issue for us is we wanted to
23 make sure that there was nothing in this model that
24 deterred a physician from referring out, for referring for
25 renal transplant, et cetera, but we didn't build this model

1 specifically to deal with the population health items that
2 you just mentioned like smoking cessation.

3 I don't know if I answered your question clearly.
4 So if you have further, I'll be more than happy to dig in
5 deeper.

6 DR. SHAPIRO: But, again, I think the
7 responsibility, the shared savings responsibility and
8 opportunity in a two-sided model, I think encourages the
9 physicians to attempt to manage or influence the outcome of
10 the patients as early on as they have that opportunity and
11 through their course of progression towards the SRD and to
12 ESRD if, indeed, that's what happens, in which I think will
13 have, as you were referring to it, the halo effect, the
14 halo effect on the overall care of the patient.

15 We see that now again in commercial contracts
16 when our incentive is to educate more, our incentive is to
17 perhaps make sure that they optimally start preemptive
18 transplant, home dialysis, et cetera. Those patient
19 populations tend to -- or those practices tend to stimulate
20 that type of conversation and education and reinforcement
21 with those patients.

22 DR. GIULLIAN: And I should also mention that
23 outside of the preemptive bonus or the bonus for preemptive
24 transplant, one of the quality metrics remains referral to
25 a renal transplant center.

1 VICE CHAIR MITCHELL: That was actually my
2 related question. Will any of these quality metrics
3 actually get at this? So earlier education or engagement,
4 I mean will that -- do you think that could be reflected in
5 either the PROMIS score or the patient-centeredness score?

6 DR. GIULLIAN: Yeah, I do think so, potentially.
7 So upstream education will impact a number of the quality
8 scores -- quality metrics. So upstream education, we know
9 has an impact on the choice of home dialysis, we know has
10 an impact on both Day Zero catheter rates but also Day 90
11 catheter rates, and while maybe not directly impacting the
12 PROMIS score specifically, we believe that by giving
13 patients the shared decision-making, the modality choice,
14 that ultimately that will have the downstream impact on
15 patient centeredness.

16 DR. KENNEY: And if I may add to just what
17 Michael was saying a second ago about the importance of
18 addressing these things such as smoking cessation, remember
19 population health metrics are still, for the most part,
20 carried out one patient at a time. And anything we can do
21 to improve comorbidities will translate into this reduced
22 -- hopefully reduced mortality information this patient
23 doesn't tell us in that early dialysis period, because as
24 Jeff pointed out, the two biggest areas for cause of death,
25 cardiovascular with all its attendant comorbidities and

1 infections.

2 CHAIR BAILET: Thank you.

3 Paul, you may have the final word here.

4 DR. CASALE: I just wanted to add, my institution
5 is the Rogosin Institute, which as you know is an ESCO, and
6 the CEC is the smaller one as compared to -- and having
7 seen their thinking and their work, there is clearly a halo
8 effect, and that's on the prevalent. I mean, they are
9 thinking upstream, but they've already seen that their
10 transplant peritoneal dialysis rate has gone up. Their
11 peritoneal dialysis rate has gone up. So it's sort of
12 natural, though not implicit, and even in that model, which
13 again is not on the incident, but on prevalent, that
14 there's a lot of work being done to move upstream.

15 CHAIR BAILET: Yeah.

16 DR. CASALE: So I think there's a lot of
17 opportunity.

18 CHAIR BAILET: Thank you, Paul.

19 So I'd like to thank our submitters for traveling
20 here today and the valuable conversation that we just had.

21 We are now -- if I could -- we're going to move
22 to the public's comment portion, and then the next phase
23 would be deliberation.

24 But I'd like to again thank the submitters, and
25 if you guys could take your seats, we have one public

1 comment. And that is David White from the American Society
2 of Nephrology. If you could come to the microphone. Is he
3 here? Yes, he is. Awesome. Yes, please. Thank you.

4 * **Comments from the Public**

5 MR. WHITE: Hello.

6 Sorry. I have to change glasses.

7 Hi. My name is David White. I am a policy
8 specialist at the American Society of Nephrology here in
9 Washington. On behalf of ASN, I want to thank you for
10 being here and for the work that you're doing on the PTAC,
11 and we want to thank you for the opportunity to be able to
12 speak about the Renal Physicians Association's incident
13 ESRD clinical episode payment model, which we call the CEC.

14 ASN is a little like RPA. It's also comprised of
15 nephrologists, and they are nephrologists, scientists,
16 nurses, and other health professionals dedicated to
17 treating and trying to improve the lives of people with
18 kidney diseases.

19 ASN commends RPA for bringing forth this
20 proposal. It is an extremely important proposal, and we
21 believe that it should be recommended for testing to the
22 Secretary. And we do so because we believe that it will
23 encourage coordinated care.

24 There's a great deal that needs to be done in
25 terms of improving coordinated care with ESRD populations,

1 and there are many different approaches that need to be
2 tested and to see what will work. And I think this is
3 definitely a very promising one and could make a big
4 difference in the lives and the costs for those beginning
5 ESRD, beginning dialysis.

6 RPA and ASN both recognize the severity of the
7 burden of ESRD on the American public and the entire
8 Medicare system, which has become enormous. Patients with
9 kidney failure among the sickest and most complex in the
10 Medicare system and are resulting in a disproportionately
11 high utilization of Medicare resources and also a very
12 heavy toll on the quality of life for these people as well.

13 RPA-proposed CEC focuses on one of the most
14 precarious periods for patients. That transition to
15 dialysis and that first six-month period, it is a very
16 important period to focus on and to test.

17 They also correctly highlight that the cost of
18 the first six months of ESRD care are disproportionately
19 higher than annualized cost, and that improvements in
20 incident dialysis in the first six months could yield major
21 improvements in patient care and reduction in cost.

22 In addition to cost, I have to always underline
23 that this is an exceptionally risky period for these
24 patients. You've seen the mortality rates, and it is
25 something that if it were happening in some other form --

1 so, for example, that number of car crashes a year or that
2 number of other incidents -- there would be a major outcry
3 in this country about trying to get a hold of this.

4 The proposed model builds a clear,
5 straightforward care approach based on a well-defined
6 episode that is ready for testing now. And it does that by
7 streamlining ESRD patient care oversight by nephrologists.
8 It does it by alleviating the need for new administrative
9 infrastructures that's ready to go, in allowing flexibility
10 for implementation by various practice sizes and geographic
11 locations, which we've addressed a great deal this morning,
12 and I would also say by undertaking innovative steps to
13 increase patient access to transplantation, which is, as
14 we've heard this morning, the gold standard.

15 ASN thanks members of the PTAC for this
16 opportunity to comment on the RPA model and endorses the
17 model for testing.

18 Thank you.

19 CHAIR BAILET: Thank you.

20 I'm going to -- we have a phone line. I want to
21 make sure if there's someone on the phone that wants to
22 make a public comment, now would be a good time.

23 UNIDENTIFIED SPEAKER: I don't want to comment.
24 I'm just here on the phone is all.

25 * **Committee Deliberation**

This document is 508 Compliant according to the U.S. Department of
Health & Human Services Section 508 Accessibility guidelines.

1 CHAIR BAILET: Alrighty. Nothing. Very good.

2 So, we are going to -- I'm asking my colleagues.

3 We have the time for general deliberation, if there is
4 additional discussion or move to deliberation and voting.

5 So I look to my teammates here for any general comments.

6 If not, we'll go to Criterion 1.

7 I'm feeling it.

8 All right. So we're going to make a transition here. So
9 we're going to mark through criterion -- we have our
10 electronic devices ready to go. Yes.

11 UNIDENTIFIED SPEAKER: [Speaking off microphone.]

12 * **Voting**

13 CHAIR BAILET: Yes. So I think that that is
14 actually -- we need to revisit that.

15 UNIDENTIFIED SPEAKER: Can we do Criterion 3,
16 maybe payment?

17 CHAIR BAILET: Okay. So the question is are we
18 going -- we're voting on the proposal as it's written
19 because the submitters made -- at least expressed a
20 willingness to address the transplant challenge that was
21 brought forward in the PRT report but also discussed here
22 today. So perhaps we could get to that particular question
23 when we get to the Criterion 3 under the payment model.

24 So why don't we go ahead and -- are we ready to
25 go ahead and start with -- I don't see it up here. Are we

1 ready to --

2 MS. STAHLMAN: Remember to watch and make sure
3 that the light clicks on your voting technology and that
4 you see that your vote's been cast.

5 CHAIR BAILET: All right. Just to level set
6 here, as we walk through the criteria, 1 and 2 means it
7 does not meet; 3 to 4 meets; and 5 to 6 meets and deserves
8 priority consideration.

9 For Criterion 1, they either directly address an
10 issue in payment policy that broadens and expands the CMS
11 alternative payment model portfolio or includes alternative
12 payment model entities whose opportunities to participate
13 in APMs have been limited. And this is one of the high-
14 priority criteria that the PTAC believes is important.

15 So, we're going to go ahead and vote.

16 [Electronic voting.]

17 CHAIR BAILET: There you go. And, Ann, please?

18 MS. PAGE: Sure.

19 * **Criterion 1**

20 On Criterion 1, one member voted 6, meets and
21 deserves priority consideration; three members voted 5,
22 meets and deserves priority consideration; five members
23 voted 4, meets; two members voted 3, meets; and zero
24 members voted does not meet. They voted -- zero members
25 voted 1 or 2 or not applicable. So according to the

1 Committee's decision rules, we need six votes as a simple
2 majority, and that roles down to meets, so the majority of
3 Committee members voted that this meets Criterion 1.

4 CHAIR BAILET: Thank you, Ann.

5 And remind me. There's going to be one more. It
6 looks like there is one more vote than actual Committee
7 members, and that's just for technical support; is that
8 right?

9 MS. PAGE: That's right. In case we need another
10 member.

11 CHAIR BAILET: Okay. All right. Very good.

12 All right. So, we're going to move on to
13 Criterion 2, Quality and Cost, which is also a high-
14 priority criterion, anticipated to improve health care
15 quality at no additional cost, maintain quality while
16 decreasing costs, or both improve health care quality and
17 decrease cost.

18 So, we're going to go ahead and vote.

19 [Electronic voting.]

20 CHAIR BAILET: Ann?

21 * **Criterion 2**

22 MS. PAGE: One member voted 6, meets and deserves
23 priority consideration; two members voted 5, meets and
24 deserves priority consideration; four members voted 4,
25 meets; four members voted 3, meets; and zero members voted

1 1 or 2 or not applicable. So the majority of members find
2 that this proposal meets Criterion 2, Quality and Cost.

3 CHAIR BAILET: Thank you, Ann.

4 We'll move on to Criterion 3.

5 So I think before we vote, this is important that
6 we revisit the question on what are we specifically voting
7 on here today. The question really is: are we voting on
8 the proposal as it's written, or are we incorporating
9 information that was brought forward during the dialogue?
10 And I would open it up to the Committee. I think we have
11 different points of view, but I think it would be good to
12 get clarity before we vote so we can be on the record.

13 So Tim and then Harold and then Len.

14 DR. FERRIS: I would move that we vote to -- let
15 me see if I can word this correctly -- vote to not include
16 the -- what am I trying to say here? -- the bonus in our
17 deliberation at this point.

18 UNIDENTIFIED SPEAKER: [Speaking off microphone.]

19 CHAIR BAILET: So, no, I think what I heard Tim
20 say is amend. Amend. Yeah. Remove it. Vote on it as if
21 it's not incorporated in the proposal. Is that correct?

22 DR. FERRIS: Correct.

23 CHAIR BAILET: Okay.

24 DR. FERRIS: Based on what I heard from the --
25 I'm making that motion based on what I heard from the team

1 that submitted the application.

2 CHAIR BAILET: So that -- okay. Thanks, Tim.

3 Harold.

4 MR. MILLER: I would second that.

5 I guess the way I would characterize it would be
6 that we would anticipate making our recommendation that the
7 transplant bonus should not be included, so jumping ahead
8 to that, that that would be included as sort of a
9 qualitative recommendation, and that we would vote now on
10 the criterion with the assumption that that's what we will
11 be saying. That's the way I would characterize it because
12 we have to -- we have to say here what we're voting on. So
13 I think the issue -- what Tim was suggesting is, that we
14 would be saying what we're voting on is a modified model
15 that has that out with the anticipation that we would be
16 saying -- we recommend, if we decide to recommend it, that
17 we recommend it without that in it. That's all.

18 I mean, so it's not that -- we're saying that
19 that's what will be in our statement about the model, and
20 that we're voting with the anticipation that that's coming.

21 Anyway, I'm seconding the motion.

22 CHAIR BAILET: All right. Very good.

23 So we have Len, Grace, and Bob at this point.

24 Len?

25 DR. NICHOLS: I'm good.

1 CHAIR BAILET: You're good?

2 Grace?

3 DR. TERRELL: The population that ends up on
4 dialysis is one of the most vulnerable populations there is
5 out there, and I'm a little concerned that if we don't have
6 something about the transplant bonus in some way in our
7 proposal that you're not going to see across the board, the
8 thought put into how we would actually get that part of
9 this important aspect of the entire proposal in there.

10 So just omitting it by taking it out -- I heard
11 some things from the presenters that I thought was very
12 important, which is there's a halo effect upstream. There
13 is an impact in behaviors to have some motivation to do
14 this, and there needs to be some thought in some way about
15 not just us taking the original proposal, just because we
16 can split this out and agree to one, not have something in
17 there. So this could be an imperfect proposal in terms of
18 that, but I do think that there needs to be some aspect of
19 the transplant component that we address because I think
20 that's actually pretty crucial.

21 CHAIR BAILET: So I'm going to just make a
22 comment to your comment, Grace, because the PRT did have a
23 discussion around modifying instead of the actual
24 transplant, but modifying the education or the referral for
25 a formal transplant. Am I getting that right, Paul? We

1 had that discussion whereby it would still be bookmarked.
2 It would still be part of the model, but it wouldn't
3 specifically be the actual bonus for transplant. It was
4 more the education, because I agree with you it's really
5 important that that work gets done where it's appropriate.
6 So I think that that's -- Harold -- I mean, Paul, you were
7 leading the PRT.

8 DR. CASALE: Yeah. No, no. I agree with that.
9 Our intent wasn't to ignore that part necessarily, but I
10 think as the submitter said, it can -- it was a separate --
11 to Harold's question, how integrated is it into their
12 model, and we had obviously sufficient -- we had a lot of
13 concerns about paying a bonus for that in particular, and
14 we already know the standard of care, which they have
15 commented on is early transplant before dialysis. We know
16 that that is optimal care, and we would expect that that
17 would continue, regardless of any particular incentive
18 around that in this model, and on top of that, the
19 limitation of organ availability, which is really one of
20 the critical issues.

21 CHAIR BAILET: Right.

22 So I've got Bob, Len, and then Harold.

23 DR. BERENSON: Yeah. I'm going to support, in
24 this case, sort of removing the transplant part of the
25 payment proposal from the original, because I don't see it

1 as intrinsic or essential to the payment model. At the
2 same time, I am worried about the potential or the
3 precedent that people come and say, okay, we'll just take
4 that out and we'll go forward.

5 So there's sort of a judgment -- I don't know any
6 other way to say this -- a judgment call as to whether the
7 proposal -- the proposed payment model is sort of basic to
8 the proposal, in which case we shouldn't be negotiating it
9 out at this meeting, or whether, as in this case, I would
10 agree that that wasn't really core to this proposal.

11 And so I'm comfortable with, in this case,
12 pulling it out, but I'm worried that we don't set this up
13 so that each time we're sort of negotiating at this
14 meeting, if that makes sense.

15 CHAIR BAILET: It does make sense, Bob, and I
16 agree with you, and I think I'm seeing a lot of heads nod
17 around the Committee. I think we all see that as a
18 potential concern. But thank you for that, and we have Len
19 next.

20 DR. NICHOLS: So I'm a little less worried about
21 the negotiation because economists like negotiation, but I
22 honestly believe, Bob, we're not quite required to reach
23 the level of Solomon here. It's not that hard to see
24 something that's truly integral and something that's truly
25 modular, and we hope the line is always bright.

1 But I want to come back to Grace and say I
2 believe we can express our desire for the transplant option
3 to be encouraged in the letter to the Secretary and still
4 keep it out, because we don't have a payment model we're
5 happy with about that. But Lord knows it needs to go on,
6 and I think it could be facilitated, and I have some
7 negotiable ideas. But I think it's something the Secretary
8 should work out with professionals.

9 CHAIR BAILET: All right, Len, thank you.
10 Harold.

11 MR. MILLER: Just quickly I would agree with
12 Grace's point and Len's point. I think that we have, on a
13 number of models, argued that we're recommending it but we
14 think that the quality measures need to be tweaked in some
15 fashion, and we're already saying that about this one.

16 There is a transplant referral measure that they
17 already had included. They didn't boost its significance,
18 I think, because they had this other -- they were
19 anticipating this other component. But I think that that,
20 to me, would be something that we would, if we recommended
21 it, that we would say that we thought that needed to be
22 strengthened as part of that.

23 CHAIR BAILET: So that's -- so, exactly. So
24 thank you for everyone's input.

25 So I want to clarify, we are voting on Criteria 3

1 as if the transplant bonus was not included, and I guess I
2 just want to revisit the concern that we expressed here,
3 which is this -- we want to avoid these, you know, last-
4 minute modifications, and in some cases major modifications
5 to the proposal at the time of deliberation. That's not
6 our intent. But in this circumstance we are going to do
7 that.

8 So that's the motion. It's been confirmed by the
9 Committee. So at this point --

10 DR. CASALE: Sorry, Jeff, I was just going to
11 answer that.

12 CHAIR BAILET: Yeah.

13 DR. CASALE: I mean, it is a bit last-minute, but
14 on the other hand the PRT sort of thought about that --

15 CHAIR BAILET: Right.

16 DR. CASALE: -- and sort of separated it in the
17 report. So there was -- so it's a little different than
18 sort of just -- I mean, I know we're changing --

19 CHAIR BAILET: Right, and that's an --

20 DR. CASALE: -- but we did think through that.

21 CHAIR BAILET: -- that's an excellent -- yeah,
22 that's an excellent point. Harold?

23 MR. MILLER: I just want to amend this. I think
24 that we should be providing some further guidance to future
25 applicants, that if they think that there are multiple

1 types of changes in payment that would be helpful but are
2 separable, that they should say that when they apply, so
3 that we know that, so that we're not kind of making these
4 judgments, to Bob's concern. Because I do think that there
5 will be cases in which people come and identify multiple
6 aspects of payment that need to be fixed, and rather than
7 us getting two completely separate proposals that are
8 disconnected, it would be better to look at them together
9 but to know that -- whether or not the applicant thinks
10 that they are integral or not.

11 CHAIR BAILET: Elizabeth and then Bob.

12 VICE CHAIR MITCHELL: Thank you. I am prepared
13 to vote on the proposal as amended, minus the transplant
14 payment, but I want to make sure that we get to Grace's
15 point about identifying ways to incentivize early
16 appropriate transplants. So can that be covered in the
17 comments?

18 CHAIR BAILET: That was -- yeah, it can.

19 VICE CHAIR MITCHELL: Okay.

20 CHAIR BAILET: Again, I thought that was the
21 intent.

22 DR. BERENSON: I'll pass.

23 CHAIR BAILET: All right. We are ready to vote.
24 So payment methodology, pay the APM Entity with a payment
25 methodology designed to achieve the goals of the PFPM

1 criteria, addresses in detail through this methodology how
2 Medicare and other payers, if applicable, pay APM Entities
3 and how the payment methodology differs from current
4 payment methodologies, and why the physician-focused
5 payment model cannot be tested under current payment
6 methodologies.

7 This is a high priority. We are ready to vote.
8 Please vote.

9 [Electronic voting.]

10 CHAIR BAILET: Ann.

11 * **Criterion 3**

12 MS. PAGE: Zero members have voted 5 or 6, meets
13 and deserves priority consideration; nine members voted 4,
14 meets the criterion; and two members voted 3, meets the
15 criterion; zero members voted 2 or 1 or not applicable. So
16 the majority finds that this proposal meets Criterion 3,
17 Payment Methodology.

18 CHAIR BAILET: Thank you, Ann. We're going to
19 move on to Criterion 4, Volume over Value -- Value over
20 Volume. I was -- now, wait, that was purposeful. I was
21 just testing to see if my colleagues were awake. Very
22 good, so Value over Volume. I think this is my last public
23 meeting.

24 [Laughter.]

25 CHAIR BAILET: They're going to pull me off here.

1 So provide incentives to practitioners to deliver
2 high-quality health care. Boy, I'm going to have a hard
3 time living that one down.

4 We are ready to vote, please.

5 [Electronic voting.]

6 CHAIR BAILET: Ann.

7 * **Criterion 4**

8 MS. PAGE: Zero members voted 6, meets and
9 deserves priority consideration; three members voted 5,
10 meets and deserves priority consideration; eight members
11 voted 4, meets; and zero members voted 3 or 2 or 1 or not
12 applicable. The majority of the Committee finds that this
13 meets Criterion 4, Value over Volume.

14 CHAIR BAILET: Thank you, Ann. We're going to
15 move to Criterion number 5, Flexibility. Provide the
16 flexibility needed for practitioners to deliver high-
17 quality health care.

18 Please vote.

19 [Electronic voting.]

20 CHAIR BAILET: Go ahead, Ann.

21 * **Criterion 5**

22 MS. PAGE: Zero members voted 6, meets and
23 deserves priority consideration; two members voted 5, meets
24 and deserves priority consideration; seven members voted 4,
25 meets; two members 3, meets; and zero members voted 2 or 1

1 or not applicable. The majority finds that this proposal
2 meets Criterion 5, Flexibility.

3 CHAIR BAILET: Thank you, Ann. We're going to
4 move to Criterion 6, Ability to Be Evaluated. Have
5 evaluable goals for quality of care costs and any other
6 goals of the PFPM.

7 Please vote.

8 [Electronic voting.]

9 CHAIR BAILET: Ann.

10 * **Criterion 6**

11 MS. PAGE: Zero members voted 5 or 6, meets and
12 deserves priority consideration; nine members voted 4,
13 meets; two members voted 3, meets; and zero members voted 2
14 or 1 or not applicable. And the majority finds that this
15 proposal meets Criterion 6, Ability to Be Evaluated.

16 CHAIR BAILET: Thank you, Ann. We're going to
17 move to number 7, Integration and Care Coordination.
18 Encourage greater integration and care coordination among
19 practitioners and across settings where multiple
20 practitioners or settings are relevant to delivering care
21 to populations treated under the PFPM.

22 Please vote.

23 [Electronic voting.]

24 CHAIR BAILET: Ann.

25 * **Criterion 7**

1 MS. PAGE: Zero members voted 6, meets and
2 deserves priority consideration; one member voted 5, meets
3 and deserves priority consideration; two members voted 4,
4 meets; seven members voted 3, meets; one member voted 2,
5 does not meet; and zero members voted 1, does not meet; and
6 zero members voted asterisk, not applicable. The majority
7 finds that this proposal meets Criterion 7.

8 CHAIR BAILET: Thank you, Ann. We're moving to
9 8, Patient Choice, which encourages greater attention to
10 the health of the population served while also supporting
11 the unique needs and preferences of individual patients.

12 Please vote.

13 [Electronic voting.]

14 CHAIR BAILET: Ann.

15 * **Criterion 8**

16 MS. PAGE: Zero members voted 6, meets and
17 deserves priority consideration; one member voted 5, meets
18 and deserves priority consideration; eight members voted 4,
19 meets; two members voted 3, meets; and zero members voted 2
20 or 1 or not applicable. The majority finds that this
21 proposal meets Criterion 8, Patient Choice.

22 CHAIR BAILET: Thank you, Ann. We're moving to
23 Criterion 9, Patient Safety. Aim to maintain or improve
24 standards of patient safety.

25 Please vote.

1 [Electronic voting.]

2 CHAIR BAILET: Ann.

3 * **Criterion 9**

4 MS. PAGE: One member voted 6, meets and deserves
5 priority consideration; one member voted 5, meets and
6 deserves priority consideration; five members voted 4,
7 meets; four members voted 3, meets; and zero members voted
8 2 or 1 or not applicable. The majority finds that this
9 proposal meets Criterion 9.

10 CHAIR BAILET: Thank you, Ann. And number 10,
11 Health Information Technology. Encourages the use of
12 health information technology to inform care.

13 Please vote.

14 [Electronic voting.]

15 * **Criterion 10**

16 MS. PAGE: Zero members voted 5 or 6, meets and
17 deserves priority consideration; three members voted 4,
18 meets; eight members voted 3, meets; and zero members voted
19 2 or 1 or not applicable. The majority finds that this
20 proposal meets Criterion 10.

21 CHAIR BAILET: Thank you, Ann. Are we going to
22 summarize? I believe all of the criterion were met.

23 MS. PAGE: Yes. The Committee found that this
24 proposal meets all 10 of the Secretary's criteria.

25 CHAIR BAILET: Okay. Thank you. We are now

1 going to have the overall vote on the recommendation to the
2 Secretary, and I want to remind the Committee members, as
3 we go through this part of the process, if there are
4 specific points of view relative to recommendations,
5 elements that we want to include in this Secretary's
6 report, and want them on the record, we need to make sure
7 that as we go around -- we will, before we're finished, we
8 will go around and make sure those points are emphasized.
9 And the Committee has an opportunity to weigh in as well.

10 So -- all right. So we're going to do an
11 electronic vote first, and then we go around and speak to
12 it individually on how we voted. So, we're going to switch
13 over here. Matt, the Magician.

14 MS. PAGE: And for the attendees, a summary on
15 this overall recommendation to the Secretary, a two-thirds
16 majority vote rather than a simple majority vote determines
17 the Committee's recommendation.

18 CHAIR BAILET: So, we have a small modification,
19 but I'll just start with -- so, number 1, not recommend the
20 proposed payment to the Secretary; number 2 is recommend
21 the proposed payment model to the Secretary for limited-
22 scale testing; number 3 is recommend the proposed payment
23 model to the Secretary for implementation; and 4 is
24 recommend implementation to the Secretary with high
25 priority.

1 We have an asterisk, which is another category,
2 which we will probably discuss in greater detail as other
3 proposals come forward, which means that certain -- it
4 wasn't the point in this particular proposal, but there may
5 be criteria, which are not applicable. That was not an
6 issue but we will revisit it, but that's why that's up
7 there. I just didn't want to confuse folks as we go
8 through the process.

9 So we're going to go ahead and vote
10 electronically first.

11 [Electronic voting.]

12 CHAIR BAILET: Ann.

13 * **Final Vote**

14 MS. PAGE: Zero members voted not applicable;
15 zero members voted 1, do not recommend; one member voted 2,
16 recommend for limited-scale testing; seven members voted 3,
17 recommend; and three members voted 4, recommend for
18 implementation as a high priority. The two-thirds majority
19 of members find that this recommendation should -- that
20 this proposal should be recommended to the Secretary for
21 implementation.

22 * **Instructions on Report to the Secretary**

23 CHAIR BAILET: Thank you, Ann. Thank you.

24 We'll start -- we'll just go around individually,
25 and again, this is the time, if there are specific comments

1 we want to include in the report, we can go ahead and
2 discuss those as well. So starting with Tim.

3 DR. FERRIS: Okay. We'll get the oddball out of
4 the way first. So I'm very much for this proposal. I
5 think it's terrific and would be good for the public. I
6 think there were sufficient questions in my mind about the
7 implications of all the concerns. I highlighted eight of
8 all the concerns that were listed, that, to me, make it a
9 great proposal for limited-scale testing, so they have an
10 opportunity to work out these things before it goes to full
11 scale. But I'm for this proposal.

12 I would say, in order to get it on the record, as
13 I think our submitters did struggle with the tension
14 between ideal and real, and one of the things that I found
15 about this proposal that I think we should, as a PTAC,
16 think about, is the one-size-fits-all. So they actually
17 made quite a few compromises to make sure that everyone was
18 in. I'm not sure that's the best thing for the American
19 public or the U.S. population as a whole.

20 Something like this could be done very
21 differently and done way more upstream in an integrated
22 delivery system. And I just wonder why every time we have
23 a payment model it's sort of -- we design a payment model
24 for the lowest common denominator, which is sort of an
25 independent rural practitioner. And we, I think, should

1 think about maybe encouraging people to have two different
2 payment models, one in the context of an integrated
3 delivery system and one in the context of that independent
4 rural practitioner, because I actually think that would
5 accelerate progress in the improvement of delivery of care.

6 So I just wanted to make that point about this
7 particular proposal, but I actually think it applies to
8 quite a few of the proposals, because all these proposers
9 have thought through the process about the biggest tent
10 possible for the inclusion of their payment policy, and
11 that's an absolutely laudable goal. There is no criticism
12 of that goal. But I just wonder if we're not -- in that
13 process -- selling the potential for alternative payment
14 models to make a difference for a large swath of the
15 population more quickly and more advantageously. Thanks.

16 CHAIR BAILET: Thank you, Tim. Grace.

17 DR. TERRELL: I really like this proposal a lot,
18 and I felt that the two things that I articulated earlier
19 are things that need to be addressed in the comments. One
20 is with respect to the aspects of early transplant and
21 basically putting something in place that will encourage
22 that, as part of a payment model, it was alluded to that --
23 that could be done through quality metrics. Maybe. If
24 that's not case, but we actually need to tie it to some
25 sort of payment system, then I would like, in whatever

1 testing is done, if this does go to testing, that to be
2 explored with this group to think through that.

3 The other thing that I hope will be in the
4 report, in the oral testimony today I heard that there are
5 certain things that can be done in any practice, all over
6 the country, with respect to care coordination and
7 integration, and there were several things mentioned. One
8 was education. There were several others. I would like
9 those specific things articulated, that came out of the
10 oral testimony that did not come across in the written
11 thing, and so therefore the critique back from the PRT was
12 that it didn't meet the criteria. Because we voted that it
13 did, and I think a lot of that was because we heard that
14 there were things that were across the board.

15 Finally, to get to Tim's point, because I think
16 it was a little of what I was talking about earlier in my
17 initial comments, which is there's a range of possible ways
18 of providing renal care, depending on the setting across
19 the country. It would be also worthwhile for them to be
20 thinking about -- for us to be thinking about, for the
21 Secretary to be thinking about - "How does that relate to
22 quality parameters such that we move the entire country
23 forward, irrespective of where they are?" Should quality
24 benchmarks be the same across the country, or is this a
25 place in space where we could actually be thinking through,

1 you know, gradations of that?

2 CHAIR BAILET: Thank you, Grace. Harold.

3 MR. MILLER: I voted for this as a recommend for
4 testing with priority consideration. I said that because
5 -- the priority part, for two reasons. One is I'm troubled
6 by having payment models from CMMI that are as narrowly
7 focused as the current CEC model is, to suggest that
8 patients can only get the kind of better care that is
9 possible through something like that if they happen to be
10 in an area that is large and has large numbers of patients
11 and large dialysis organizations, or whatever.

12 So I think that it's important that whenever
13 there's clear opportunities in the early results from that
14 model suggests that there are significant savings and
15 quality improvement possible. So I think it's important
16 that other similarly situated patients have the opportunity
17 to benefit from that.

18 I also didn't -- I didn't think that limited-
19 scale testing was appropriate because what we have used
20 that for otherwise was to be able to refine parameters, et
21 cetera. I don't think that that is as important here as I
22 think what we will learn from this is really the issue of
23 how does this work and work differently in different
24 places. And the only way to figure that out is to be able
25 to do it broadly.

1 And I think the other reason, from my
2 perspective, for the high priority, is that CMS ought to be
3 able to move forward quickly on this, because there has
4 been so much thinking already done with respect to this on
5 the CEC model.

6 I would respectfully disagree with Tim about the
7 notion that we're getting lots of things that are designed
8 for the lowest common denominator. I think that general
9 impression in the country is that most everything that CMS
10 has done has been for big organizations and big integrated
11 delivery systems, and that, in fact, the PTAC was
12 specifically established to try to help encourage small
13 providers to come in. And I think that's what we're seeing
14 and I would commend the RPA for actually trying to do
15 something like that.

16 That being said, though, back to the earlier
17 point about separable payment model proposals, et cetera, I
18 don't think we should, in any fashion, implicitly be
19 encouraging applicants to come in with one-size-fits-all
20 models where they don't think a one-size-fits-all model is
21 necessary or desirable. And if they think that there are
22 two different ways one could structure a payment model that
23 could work differently, depending on differently resourced
24 or structured entities, that they should be free to bring
25 those to us. It would actually be, I think, helpful to us

1 in some fashion to say, here's how this can be done in a
2 rural area and here's how it could be done in a larger
3 system, and then potentially have both of those proposals.

4 So that's the explanation for the vote.

5 The one thing I would like to see reflected in
6 the report -- other than what we've talked about already,
7 which is not the transplant bonus and having modifications
8 to the quality measures -- is I think that this -- I am
9 troubled about shared savings models, and I'm troubled
10 about that particularly with this one for small practices.
11 And I think I would really strongly encourage that when
12 something like this is put in place, that it be monitored
13 and modified so that it, in fact, works the way as expected
14 to, and that if practices are suddenly being penalized
15 financially or rewarded in some unusual windfall way
16 because of random variation in the population, that there
17 be rapid modifications to the model to be able to adjust
18 the way the shared savings calculation is done. And there
19 may need to be exclusions of certain kinds of cases, or
20 there may need to be different kinds of risk corridors
21 built into it, or whatever it is, which will probably only
22 be known once the model gets implemented. But I really am
23 troubled by the notion that we would -- that this would be
24 put into place, and put into place for five years or
25 something like that, and evaluated without any

1 modifications to it if along the way problems were
2 developing and that people were being forced to drop out
3 because of that.

4 So the thing I would like to see recommended in
5 the report is that this be modified as necessary along the
6 way to ensure that it is -- practices can, in fact,
7 successfully participate and achieve what they had hoped to
8 be able to achieve from it.

9 CHAIR BAILET: So I guess I want to -- this is an
10 opportunity for the Committee to speak to Harold's point to
11 make sure we get this -- if we have -- so I agree with you,
12 Harold, but I guess the point you're making about the
13 ability to modify as experience builds, I think that's a
14 point that would be applicable to, frankly, any alternative
15 payment model, not specifically this one.

16 MR. MILLER: Well, potentially. But my point is
17 this is a model that has shared savings on a big amount of
18 money for potentially very small practices. And so I would
19 say the same thing for other models like that, but that's
20 specifically the reason why I'm saying it here.

21 CHAIR BAILET: I understand, okay.

22 MR. MILLER: I think that -- and it has already
23 been coming up with respect to the Oncology Care Model, is
24 that practices that are in that are saying, "We are highly
25 subject to random variation in costs that are not

1 accurately captured by the risk adjustment methodology," et
2 cetera. And I think rather than saying, "Sorry, you've got
3 to just continue with that and take it or leave it," that
4 there needs to be a modification.

5 CHAIR BAILET: Thanks for clarifying, Harold.
6 That was a -- So, Grace, you have a point you want to make?

7 DR. TERRELL: Two things. I was instructed that
8 I didn't say what my actual vote was, which was -- I voted
9 highest priority.

10 But the second one is with respect to Harold's
11 comments, PTAC was specifically about small rural
12 practices, there's nothing in the criteria from which we're
13 voting on, nothing in the law that I see that says that.
14 And it may be that it can be inferred or otherwise. But as
15 I'm doing evaluation, I need to be thinking about it across
16 the spectrum of where care is. If it happens to be better
17 for an integrated system or it happens to be better for a
18 small or rural practice, then that's something that we need
19 to understand and think about with respect to our
20 recommendations. But I do not believe my mission is to
21 just be thinking about this within the context of a
22 particular type of practice.

23 So the concept that many of those submitters are
24 thinking about things across the board, as this particular
25 group did, is to my mind not about the lowest common

1 denominator. It's about the flexibility that's part of the
2 criterion from which we're supposed to evaluate.

3 CHAIR BAILET: Thank you, Grace. Paul?

4 DR. CASALE: Yeah, I voted to approve to go
5 forward, and just a couple comments and not to repeat
6 what's already been said, which several I agree with.

7 A couple of points. One is although -- so,
8 sorry, I just want to take a step back. I do think that a
9 lot of experience has been built on the CEC program, so I
10 think in terms of, you know, limited testing versus just
11 full expansion, and I think in our discussions that the PRT
12 had with CMMI, it was clear that there was -- the ability
13 to expand that model was limited, and so this I think
14 clearly expands it significantly. And although only three
15 words, they said, related to virtual in their proposal, I
16 do think the idea of, just as in the CEC, where they're
17 allowing the smaller ESCOs to combine their efforts and be
18 at risk with each other, I think it would be important that
19 we point that out, because we do have concerns around the
20 small -- we've discussed this -- concerns around the small
21 practices and random variation, and these are high-cost
22 patients, so I do think that that is an important point to
23 emphasize in our recommendation.

24 And I do think on the transplant, which has
25 already been mentioned, we can incorporate that into the

1 quality measures.

2 CHAIR BAILET: Thank you, Paul. Bruce?

3 MR. STEINWALD: I voted as Paul did. I didn't
4 see in the proposal and the discussion the same level of
5 concerns that led us in other proposals to recommend for
6 limited-scale testing.

7 In addition to that, the information that could
8 be learned from broader scale, which includes both small
9 practices and integrated delivery systems, might be --
10 might be very informative on going forward to improve the
11 model maybe in different ways in different settings. I do
12 think that the discussion should include, when we talk
13 about potential improvements to care that might be
14 associated with this model, that should include giving
15 patients meaningful choice for the alternatives to in-
16 center dialysis when those choices are clinically
17 appropriate, and that the evaluation, of course, should
18 identify whether those choices are actualized as the model
19 goes forward.

20 CHAIR BAILET: Thank you, Bruce.

21 So I voted for implementation as well, and,
22 clearly, the content, the elements of this model address
23 some of the critical -- the critical elements that I think
24 this Committee really was existed to analyze, which are
25 high-impact, high-cost models that can really improve

1 quality for patients in a broad sense on significant --
2 where not only significant dollar spend but also
3 significant diseases. We've talked about these patients
4 are incredibly -- can be incredibly sick, and the
5 institution of dialysis can be a life-altering up to and
6 including mortality. So I think that this is an important
7 model. I think there's enough information that was already
8 garnered from the ESCO experience where this could move to
9 implementation and doesn't require small-scale testing.

10 I know that the sweet spot for these patients is
11 to get as upstream as possible. I think the country is
12 falling down right now on the care that's delivered. I
13 think there's tremendous opportunity. Ten percent of the
14 nephrologists today are participating in the CEC, so this
15 really broadens the exposure and, I think more importantly,
16 the focus on this particular population. And I'm confident
17 that as more nephrologists can get in and participate, that
18 they will -- we will discover ways to get more upstream,
19 and this will become more visible, and I think it will have
20 a greater impact. So I like the model. I'm fully
21 supportive. Thank you.

22 Elizabeth?

23 VICE CHAIR MITCHELL: Thank you. I also voted
24 for implementation. And not to repeat what's been said,
25 but I would want in the comments to have it reflected that

1 we are -- we recommend exploring incentives and
2 coordination to move this as upstream as possible, so to
3 avoid dialysis.

4 I think there may also be -- it might be
5 worthwhile to look at multi-payer models given the
6 populations that we're talking about. So could this be a
7 good candidate for a multi-payer program?

8 And then, finally, I am actually concerned by
9 just the requirement for reporting on quality metrics. I
10 don't think that's adequate. I think there should be a
11 performance threshold. I understood that it was just a
12 sort of starting point, but I would like to look at
13 requiring some sort of performance threshold as soon as
14 possible.

15 CHAIR BAILET: Len?

16 DR. NICHOLS: So I voted to recommend with high
17 priority because I see this population as incredibly
18 vulnerable, and I applaud the applicants for trying to
19 forestall unpleasant trajectories. I think that's really
20 important.

21 To the general point I think we've spent a lot of
22 time discussing, I personally view our general -- which is
23 sort of for the record, I view our unease with this concept
24 of one size fits all or maybe I'd like to say it our
25 embrace of many sizes fit America. I view that as a

1 strength, and I would suggest we express our awareness of
2 the tension between what integrated practices can do versus
3 what smaller and often rural practices can do in terms of
4 compared to what feasible alternative. Yes, Tim, I agree
5 with you completely, a higher standard for integration
6 would be ideal, but this model, if it had some kind of
7 upfront payment versus risk share options or virtual group
8 type tools, maybe some proper encouragement of transplants,
9 et cetera, could create a delta everywhere, and that delta
10 could be in quality and cost of patient care across the
11 country. And I fear without that flexibility in the model,
12 these rural patients are going to continue on their current
13 paths, which we all agree are not ideal if we set the
14 standards for participation too high and too fast.

15 I think we should think about when we recommend
16 to the Secretary a concept of a dynamic evolution of
17 standards of care, not so much a static ideal that may be
18 achievable now only by a subset, if we think that
19 improvement is possible everywhere, as I think it is in
20 this model's case.

21 CHAIR BAILET: Thank you, Len. Kavita.

22 DR. PATEL: I also voted to approve this model,
23 and just a couple of comments for the Secretary's note.

24 Number one, to highlight something that the
25 submitters said about the lack of even appropriate

1 diagnoses from the primary care settings, so even though
2 this APM is obviously very specifically focused on
3 nephrology, the Secretary has a great bit of latitude to
4 also think about what could we be doing to better identify,
5 even through proper coding, the kind of the patients that
6 really should be in the upstream.

7 And then the second point to the Secretary, I'll
8 just emphasize, because I think where Tim was going -- and
9 he is describing the lowest common denominator -- is
10 actually the approach that most of us have to take in
11 developing alternative payment models. And I think the
12 Secretary should think carefully about how, if they expand
13 or open up the CEC model, how CEC -- and the submitters did
14 a nice job of highlighting this in some of their responses
15 -- how a CEC participant would interact with this model and
16 potentially interact with a larger ACO model, et cetera, et
17 cetera.

18 So I'll just say that highlighting for the
19 Secretary that multi-model overlap is potentially a good
20 thing, but it is complicated and makes these layers of
21 payment difficult for an applicant to understand.

22 CHAIR BAILET: Bob?

23 DR. BERENSON: I supported this, but not at high
24 priority. It's a good model. I would only emphasize one
25 point. As my questioning sort of led me to this, I'm

1 concerned that the high costs associated with patients who
2 have other primary conditions who just need dialysis near
3 the end of life will dominate the spending analysis and the
4 potential for shared savings, having very little to do with
5 what we're hoping to have, which is more attention to
6 upstream preparation for dialysis and is a function with
7 small numbers, as Harold emphasizes, of involvement with
8 those patients. And I'm happy -- I wouldn't want to
9 eliminate them from the calculations at all, but I would
10 have narrow trim points. I find it unlikely that the renal
11 physician is going to be a decisive factor in telling the
12 oncologist or the cardiologist or the family that no --
13 because of your need for dialysis, we're going to want to
14 sort of terminate your -- in other words, I think you can
15 have an influence, but I don't think it's a decisive one.
16 I would want them to be involved with that, but I think the
17 statistical shared savings approach should be emphasizing
18 the cases that are not those. And I won't -- does that
19 make sense? You're looking at me quizzically, Jeff.

20 CHAIR BAILET: I'm just trying to follow, but go
21 ahead.

22 MR. MILLER: Well, can I just --

23 DR. BERENSON: Does anybody know what I'm saying?

24 MR. MILLER: Yes, I endorse --

25 DR. BERENSON: Oh, okay.

1 MR. MILLER: I mean, his point is that the shared
2 savings could be coming from the subset of patients who you
3 just, if you could do it, convinced not to get end-of-life
4 treatment or whatever, not trying to reduce complications
5 from infections, et cetera. And I think that --

6 DR. BERENSON: That's my point.

7 MR. MILLER: And so that, I agree with him
8 wholeheartedly, that's part of the -- it needs to be
9 monitored carefully, and if, in fact, it looks like
10 whatever, somebody's either being penalized or rewarded or
11 diverted into a different direction than was anticipated,
12 that then it be modified, because you could -- you could
13 modify the shared savings model to say we're going to give
14 different weight to different patients in different kinds
15 of circumstances, et cetera. That would make it more
16 complicated, which we always get pushback, because you
17 don't want to make the models complicated. But, on the
18 other hand, if they end up incenting the wrong things, I
19 think that that's a problem.

20 DR. BERENSON: Harold said what I was trying to
21 say. I think if we had the data on the median spending for
22 these patients, it would be very different than the average
23 spending for these patients, and we want to really be
24 moving the median for those patients who actually have
25 chronic renal disease and not those who have other primary

1 diseases who just happen to have dialysis.

2 CHAIR BAILET: Right. So I guess for the
3 Secretary's report, then, I'd like to make this a specific
4 point, that we are calling this out relative to
5 inclusiveness. So we're -- this model could best be served
6 if we actually exclude or make an adjustment for this
7 population in the calculation.

8 MR. MILLER: My proposal would be that -- I was
9 talking about longer term, but maybe there should be some
10 examination of whether some modifications to the shared
11 savings methodology should be made to try to anticipate
12 some issues like that so that it doesn't end up directing
13 in -- but I think that's the question, is whether a sort of
14 a standard just total cost of care no matter what
15 methodology is appropriate when you think that there may be
16 two completely different populations involved.

17 CHAIR BAILET: All right. Rhonda?

18 DR. MEDOWS: So I voted number 3. I thought this
19 proposal was very well done. It addressed a complex and
20 vulnerable population that doesn't always get the attention
21 that it needs. I think that it addresses both Medicare and
22 the dual-eligibles as well as they rise through the ranks.

23 I believe that the questions that I had that I
24 came into the room with were actually addressed in both
25 your opening statement and in your comments later on. My

1 two questions were focused on the importance of patient
2 engagement in shared, informed decision-making, which you
3 addressed very well for me. Thank you very much.

4 In addition, my other question was about patient
5 care coordination with primary care, particularly family
6 physicians as well as internists, and that was also
7 addressed in your comments. I think that was what I needed
8 to hear from you, and I appreciate that. Thank you.

9 CHAIR BAILET: Thank you, Rhonda.

10 And I'd turn to Ann. Ann, do you have what you
11 need?

12 MS. PAGE: I'll turn to Adele [off microphone].

13 CHAIR BAILET: Adele.

14 DR. SHARTZER: Sure. I think so. I will just
15 run through a couple of the major points, but I just want
16 to note that we'll comb through the transcript and all of
17 the detailed notes that we took to make sure that we do
18 include everything that you said. But in terms of
19 discussion, it sounds like obviously the transplant
20 component will be a big element of our conversation. And
21 then sort of this debate about one size fits all and the
22 appropriate --

23 MR. MILLER: Well, can we just be clear what
24 we're -- not a big part. We're saying we don't think it
25 should be included. And, I think everybody has agreed to

1 that.

2 DR. SHARTZER: Right, but that will -- we'll have
3 to be clear about our decision, your decision, and why, and
4 some of the concerns about precedent that I think you
5 mentioned.

6 And I think sort of -- Grace, you mentioned the
7 gradations and adaptability to different areas. I think
8 that will definitely be included.

9 And an emphasis on trying to get the quality
10 measures right, modifying proposals over time if evidence
11 shows that -- that practices are being adversely impacted.
12 The emphasis on patient choice, so -- and some of the, you
13 know, the benefits of focusing on this vulnerable
14 population. So is there anything else big picture --

15 DR. NICHOLS: The one size fits all you started
16 to mention [off microphone].

17 DR. SHARTZER: Okay. So there was some
18 discussion about whether a one-size-fits-all model is what
19 is best for the country, and we will just kind of try to
20 touch on some of the points that were raised. We'll look
21 through the transcript to try to get the exact verbiage. I
22 don't want to mischaracterize it.

23 DR. FERRIS: Since I raised it, it was really not
24 -- I didn't raise it to be a comment about this proposal
25 specifically, so it probably was a mistake to raise it in

1 the context of deliberation of a specific proposal. But it
2 is from my perspective a pattern, and it's a big country, a
3 lot of different ways of delivering care. The idea that
4 any one payment model is going to be useful across the
5 country for any number of reasons is, to me on its face,
6 simpleminded. And so, but that's not a -- I didn't -- I
7 thought I introduced my comment crediting the group who
8 submitted this proposal with doing a great job, and that
9 they were struggling, I think was the word I used, with all
10 the compromises that one is forced to make when trying to
11 be inclusive of everyone.

12 CHAIR BAILET: So, Harold and then Bruce.
13 Harold?

14 MR. MILLER: I actually think we should keep that
15 point, to be honest with you. I guess the way I would make
16 it, though, is I want to be clear, I think what we're
17 saying is the shared -- there's modifications on quality,
18 but the shared savings methodology may need to be modified,
19 both initially and early on after early evaluation of
20 what's happening, and it may need to be differentiated. I
21 guess I would make an amendment sort of along the lines of
22 -- in response to Tim's point. It may need -- There may
23 need to be differentiation in those modifications for
24 different size practices in different places, because in a
25 sense you'd say if, in fact, this is a big nephrology

1 practice but not -- a big integrated group and not big
2 enough to be in the ESCO model but big, you would have less
3 concern about the fact that you had total cost of care for
4 all reasons for patients being admitted than if you had the
5 single nephrologist in the rural area who was really
6 getting hurt by the fact that some of those patients were
7 being dealt with by physicians that he had no relationship
8 with.

9 So, anyway, I do think that rather than saying
10 there has to be one model and that it can -- if it's going
11 to be changed, it has to be changed for everybody, that it
12 could be -- I think we should suggest that, in fact, we
13 think that there could be diversity. But that would be my
14 proposal if you -- you're welcome to agree or disagree with
15 that.

16 DR. FERRIS: Harold, I'd like to nominate you as
17 the person who rearticulates what we're saying so --

18 [Laughter.]

19 DR. FERRIS: So that it makes sense, and then --

20 CHAIR BAILET: All right, very good. Bruce,
21 bring us home.

22 MR. STEINWALD: Adele, I don't know if you
23 intended this, but I think the discussion of patient
24 choice, particularly the choice of dialysis modality, could
25 be part of the discussion of upstreaming, because -- and

1 it's really, I think, part of that same issue.

2 DR. FERRIS: That was how I intended it [off
3 microphone].

4 MR. STEINWALD: Oh.

5 DR. FERRIS: That was how I intended it, is the
6 ability to move upstream, as my comments and their response
7 was -- my question to them was about that issue. That is
8 the issue, which I think the delivery, the care delivery
9 system is less or more, well able to deal with, depending
10 on how integrated you are. And I would just love to see us
11 move more, but I do want to emphasize I don't want the
12 perfect to be the enemy of the good here. I think this is
13 good. I'm just thinking: What could be better?

14 MR. STEINWALD: Yeah. I was just trying to be
15 helpful to Adele. But it's nice that you agree with me.
16 Thanks.

17 MR. MILLER: Can I just say -- because I think
18 just to be clear on Tim's point, because I agree with Tim's
19 point. I think what we're saying, to make sure I
20 understand, is we're not saying we think this model should
21 be modified to upstream, but that we think that we should
22 not sort of stop at this point and say all we're ever going
23 to do is fix dialysis forward, but that there should be
24 some supplemental effort to look at other things. At least
25 that's what I would want.

1 CHAIR BAILET: Alrighty. I think we have
2 completed our analysis and our deliberation. Again, I want
3 to compliment the submitters on this model, and I look
4 forward to what's possible as this goes now downstream for
5 consideration by the Secretary.

6 [Laughter.]

7 CHAIR BAILET: Now, let's not -- well, upstairs.
8 There we go. It's going to go upstairs.

9 So what we're going to do is we're going to take
10 a break until 1 o'clock, which is a half-hour earlier than
11 the original schedule, but we're trying to move along.

12 And, again, thank everybody for their attention and
13 participation, and we'll be back at 1 o'clock. Thank you.

14 [Whereupon, at 11:55 a.m., the meeting was
15 recessed, to reconvene at 1:00 p.m. this same day.]

16

17 **AFTERNOON SESSION**

18 [1:04 p.m.]

19 CHAIR BAILET: We're going to go ahead and
20 reconvene the PTAC.

21 So welcome back. The next proposal that we're
22 looking at is the New York City Department of Health and
23 Mental Hygiene, a multiple-provider, bundled episode-of-
24 care payment model for treatment of chronic hepatitis C,
25 using care coordination by employed physicians in hospital

1 outpatient clinics.

2 The review team is comprised of Rob -- Dr.
3 Berenson, Robert Berenson; Jeff Bailet; and Grace Terrell.

4 Before we officially launch into the review
5 process, what I would like to do is have everyone go around
6 the room on the Committee and introduce themselves, and at
7 the same time, if there's a disclosure, could you please
8 read your conflict-of-interest disclosure.

9 **New York City Department of Health and Mental**
10 **Hygiene (NYC DOHMH): Multi-Provider Bundled**
11 **Episode-of-Care Payment Model for Treatment of**
12 **Chronic Hepatitis C Virus (HCV) Using Care**
13 **Coordination by Employed Physicians in Hospital**
14 **Outpatient Clinics**

15 * **Committee Member Disclosures**

16 DR. BAILET: And I will start. I am Dr. Jeffrey
17 Bailet, the Executive Vice President of Health Care Quality
18 with Blue Shield of California, and I have nothing to
19 disclose on this particular proposal.

20 Tim.

21 DR. FERRIS: Tim Ferris, CEO of Mass General
22 Physicians Organization. Nothing to disclose.

23 DR. TERRELL: Grace Terrell, practicing general
24 internist, part of the Wake Forest Baptist Health System
25 and CEO of Envision Genomics. No disclosures.

1 MR. MILLER: Harold Miller, CEO of the Center for
2 Healthcare Quality and Payment Reform. I have no
3 disclosures.

4 DR. CASALE: Paul Casale, Executive Director of
5 New York Quality Care, the ACO for New York-Presbyterian,
6 Columbia, Weill Cornell.

7 I noticed in the proposal, they mentioned Weill
8 Cornell was sort of part of it. So I do have a faculty
9 appointment and see patients at Weill Cornell Medicine, and
10 as I mentioned, I direct their ACO.

11 MR. STEINWALD: I'm Bruce Steinwald. I have a
12 little consulting practice here in D.C., and I have nothing
13 to disclose.

14 CHAIR BAILET: Elizabeth?

15 VICE CHAIR MITCHELL: Elizabeth Mitchell, CEO of
16 Network for Regional Healthcare Improvement, nothing to
17 disclose.

18 DR. NICHOLS: Len Nichols. I direct the Center
19 for Health Policy Research and Ethics at George Mason
20 University, and I have nothing to disclose.

21 DR. BERENSON: I'm Bob Berenson. I'm a Fellow at
22 the Urban Institute, and I have nothing to disclose.

23 DR. MEDOWS: Rhonda Medows, Executive Vice
24 President, Population Health, Providence St. Joseph Health.
25 I have nothing to disclose.

1 MR. STEINWALD: And I'm Mary Ellen Stahlman. I'm
2 the ASPE lead on PTAC.

3 CHAIR BAILET: Sarah?

4 MS. SELENICH: I'm Sarah Selenich, and I am an
5 analyst at ASPE, and I supported this PRT.

6 MS. PAGE: And I'm Ann Page, and I'm the
7 Designated Federal Official for this Federal Advisory
8 Committee Act Committee, PTAC.

9 CHAIR BAILET: Thank you, everybody, and I just
10 want to go on record and compliment the staff that worked
11 tirelessly to support our efforts. The information comes
12 in fast and furious, and these guys really go above and
13 beyond to support us. And we're all very appreciative, so
14 thank you for that.

15 So I'm going to turn it over to Dr. Berenson to
16 lead the discussion and summarize the proposal review
17 team's report.

18 Bob?

19 * **PRT Report to the Full PTAC**

20 DR. BERENSON: Okay. So that's the title, the
21 Multi-Payer - *"Multi-Provider, Bundled Episode-of-Care*
22 *Payment for the Treatment of Chronic Hepatitis C, Using*
23 *Care Coordination by Employed Physicians in Hospital*
24 *Outpatient Departments."* It's a proposal that comes from
25 the New York City Department of Health and Human Services.

1 This is the typical presentation overview that we
2 will go through. I won't go through this one in detail,
3 just to say that we did take advantage of obtaining
4 additional information from a hepatologist. We had good
5 phone conversations with the proposers. I want to thank
6 them for their participation. You represent various
7 institutions and had a coordination issue of your own.

8 I think we got the information that we wanted, so
9 thank you very much, and just to reemphasize, the PRT
10 report is not binding on the PTAC, as you know. PTAC may
11 reach different conclusions from those contained in the PRT
12 report.

13 All right. So there's a lot of information on
14 this slide. The proposal is based on the HCIA Round 2
15 Demonstration Project, Project INSPIRE. The proposal
16 focuses on integrated care coordination of patients,
17 particularly higher need patients, especially dual eligible
18 patients with behavioral health and substance abuse
19 disorders, with HCV to ready them, to initiate, and adhere
20 to life-saving pharmacology.

21 The intervention is that patients would undergo a
22 comprehensive psychosocial evaluation to identify barriers
23 to care and medical evaluation to determine the complexity
24 of their liver disease. The care team would then assist
25 patients in overcoming barriers through various means, such

1 as referrals for psychosocial issues or other comorbid
2 conditions, direct counseling services, helping patients
3 navigate appointments, importantly assistance with
4 obtaining prior authorization for costly pharmacotherapy,
5 which is an issue for sure in New York. Primary care
6 physicians would take on a greater role in managing
7 patients with HCV. They will be trained by hepatologists
8 and other gastroenterologists through tele-mentoring,
9 although our view was that there was less emphasis on the
10 tele-mentoring in the proposal compared to the INSPIRE
11 model. We will be discussing that, I believe, with the
12 proposers.

13 Nonclinical care coordinators would also play a
14 key role, and we would observe that nonclinical staff
15 cannot be billed using the chronic care management codes,
16 and that becomes an issue as well.

17 The next one -- we're still talking about the
18 overview. The payment, which is core to the proposal
19 obviously, is that the expected participants are employed
20 physicians in the hospital outpatient clinics who treat
21 HCV. The APM Entity would receive a bundled episode
22 payment and actually specified at \$760 for each eligible
23 patient that agrees to participate.

24 The episode is comprised of three phases:

25 Pretreatment assessment involving care coordination; the

1 treatment period; and the report of a sustained virological
2 response at 12 weeks postpartum, which is abbreviated as
3 SVR12, sustained virological response. The episode is not
4 expected to exceed 10 months, and often is 9 months.

5 The APM Entity would be eligible for bonus
6 payments and at risk of paying penalties based on its risk
7 adjustment SVR rate. The proportion of participating
8 patients who complete a full course of antiviral treatment
9 and have undetectable HCV, ribonucleic acid 12 weeks after
10 treatment cessation, so a very concrete performance measure
11 that is the basis for determining bonus payments.

12 The APM Entity's SVR rate would be compared to
13 the benchmark set by CMS. An APM Entity with an SVR rate
14 at or below the benchmark would receive a bonus payment.
15 An APM Entity with a rate below the benchmark would be
16 required to pay back a penalty.

17 The bonus payments for each patient who achieves
18 SVR target would be calculated by applying a CMS-determined
19 shared savings rate or rates through the product of the
20 following formula, and you've all seen a lot of detail on
21 this formula. But the key thing is the expected annual
22 cost avoided from treating HCV times the life year
23 estimates of the life years gained with the successful
24 treatment. Whoops.

25 CHAIR BAILET: Bob, I don't mean to interrupt,
This document is 508 Compliant according to the U.S. Department of
Health & Human Services Section 508 Accessibility guidelines.

1 but I just, I'm just processing one word that you said when
2 you said 12 weeks "postpartum." Was I the only person that
3 heard that?

4 DR. BERENSON: Did I say 12 weeks postpartum?

5 CHAIR BAILET: Yes, you did, Doctor.

6 [Laughter.]

7 DR. NICHOLS: We all knew what you meant, so it's
8 okay.

9 DR. BERENSON: What did I mean?

10 CHAIR BAILET: But I just want the record -- for
11 the people on the phone who might have been listening in, I
12 just want to make sure --

13 DR. BERENSON: What did I mean?

14 CHAIR BAILET: Post-treatment. Post-treatment.

15 DR. BERENSON: Oh, post-treatment. Oh, my
16 goodness. That's interesting. I'll have to think about
17 that one.

18 DR. NICHOLS: Don't think too hard.

19 DR. BERENSON: So, as you can see, we're going to
20 go through each one of these. We found the proposal
21 deficient on a number of the criteria. We'll go over those
22 in more detail now.

23 Whoops. I keep pressing the wrong button.

24 All right. The key issues identified by the PRT.
25 One is that care coordination of these higher-need patients

1 with HCV is important, has the potential to improve quality
2 and reduce costs.

3 The efficacy of pharmacotherapy for HCV enables
4 payment to be tied to a meaningful outcome measure.
5 However, the PRT is not convinced that a new payment model
6 is necessary to support the care model. The PRT believes
7 the proposal could be accommodated within current payment
8 methods if you take away the shared savings component, and
9 we will be talking about that. But that the care
10 coordination support could be accommodated within current
11 payment methods.

12 The PRT has specific concerns regarding the
13 payment methodology, including the shared risk arrangement,
14 and associated with that, the attribution methodology and
15 the lack of sufficient risk adjustment.

16 Shared savings are based on expected annual costs
17 from continued HCV infection avoided and the number of life
18 years gained with the SVR, with SVR, meaning no more virus.
19 Our view was that the approach is untested, unprecedented
20 in Medicare, and imprecise. To the extent that it has
21 merit, it should first be tested in a manner that is
22 specifically designed to study the feasibility of such an
23 approach and how to incorporate this methodology within an
24 APM.

25 The shared savings rate or rates have not yet

1 been determined, but rewarding facilities for practicing
2 high standards of care with potentially huge bonus is based
3 on savings that are not in fact attributable in large part
4 to these high standards of care is problematic. Such a
5 precedent would likely lead other parties, including drug
6 manufacturers and providers, to advance similar claims to a
7 share of these savings.

8 Very specifically here, the major advance to
9 produce a cure is medication, and so we think there's a
10 mismatch between what's largely responsible for the savings
11 and giving the bonus to the physicians who do a better job
12 in managing patients.

13 Physician-determined attribution and a lack of
14 adequate risk adjustment could lead to patient selection
15 imbalances that could undermine accurate evaluation.
16 Beneficiaries with HCV frequently have substantial
17 comorbidities, including behavioral and mental health
18 conditions, but there does not seem to be continuity
19 between care coordination for purposes of accomplishing HCV
20 treatment and what should be ongoing care coordination for
21 HCV patients with comorbidities.

22 So now going through each criterion, scope is the
23 first one. HCV is a high-impact condition, affecting
24 nearly a quarter of a million beneficiaries in 2016. Many
25 of these beneficiaries have substantial comorbidities, and

1 this patient is high cost. So that's a positive.

2 There are issues in payment policy regarding HCV,
3 particularly due to the high cost of pharmacotherapy.
4 However, the PRT believes that care coordination can be
5 accommodated under current payment methodologies. I'll be
6 getting back to that one. While the proposal could in
7 theory be generalizable, it seemed very much designed for
8 employed physicians and hospital outpatient clinics, not
9 all physicians providing care for patients with HCV, and
10 seems rather specific to the large integrated health
11 systems in New York City and to circumstances somewhat
12 specific to the New York practice environment.

13 On the criterion -- so we said this does not meet
14 the criterion, unanimously.

15 The next one is quality and cost, where we said
16 it does meet the criterion. Coordinating care for higher-
17 need patients with HCV in a careful and concentrated way
18 and providing health education, appointment navigation, and
19 connection to supports and services seems likely to
20 increase the proportion of patients who achieve SVR.
21 Activities that increase the number of patients who are
22 treated and cured would reduce costs associated with
23 complications. Higher cure rates would reduce disease
24 transmission and subsequent costs.

25 Medicare beneficiaries with HCV frequently have

1 substantial comorbidities, including behavioral and mental
2 health conditions, and are high cost. Focusing on this
3 patient population seems likely to reduce certain costs,
4 such as those associated with avoidable emergency
5 department visits for comorbid conditions.

6 The final HCIA evaluation would help the PRT
7 better understand the model's potential impact on quality
8 and cost, and our understanding is those results will be
9 forthcoming soon but are not yet available. Interim
10 findings have been available.

11 The next is the payment methodology, and here's
12 where we spend the most time and say it does not meet the
13 criterion. On the one hand, the proposal directly ties
14 payment to a meaningful outcome measure and uses a
15 straightforward episode-based approach for providing care
16 coordination funding.

17 However, we think that billing the current
18 complex chronic care management codes would seem to provide
19 payment in line with the proposed episode payment. The PRT
20 recognizes that there are some restrictions on how the
21 current codes can be used, suggesting that fixes to the
22 predominant fee schedule-based payment model are worthy of
23 consideration.

24 And here, we were negligent in not including a
25 bullet that makes clear that the current payment for the

1 chronic care management codes actually exceed by a few
2 hundred dollars, what they have been requesting, what they
3 are requesting at the episode-based payment. In their
4 proposal, they actually have provided some information
5 about suggesting that it comes short by about \$400, but
6 they've included only the professional component of the fee
7 and not the facility fee. Our calculations are that using
8 the relevant 99487 code produces revenues that exceed what
9 they're requesting under this proposal.

10 Patient eligibility and attribution are unclear,
11 and there does not seem to be any risk adjustment to the
12 episode payment. Physician-determined attribution and a
13 lack of adequate risk adjustment could lead to imbalances
14 in selection.

15 Now, this again is sort of a state-of-the-art
16 shared savings model, and our view is that shared savings
17 based on annual -- on expected annual cost from continued
18 HCV infection avoided and the number of life years gained
19 is untested, unprecedented in Medicare, and imprecise. To
20 the extent that it has merit, as I said in the summary,
21 this isn't the place to test it.

22 The shared savings rate or rates have not yet
23 been determined, but rewarding facilities for practicing
24 high standards of care with potentially a huge bonus is
25 based on savings that are due to many factors, including

1 the success of the pharmacology to care coordination under
2 the auspices of physicians doesn't seem to us an
3 appropriate method for determining shared savings and again
4 is maybe a bridge too far.

5 Value over volume does meet criterion. We are
6 concerned about the potential for avoiding patients who are
7 more complex and high cost. That's what we were alluding
8 to with the risk adjustment issue.

9 CHAIR BAILET: Bob, you need to advance the
10 slide.

11 DR. BERENSON: Oh, I forgot. I'm moving my
12 slides but not your slides. There we go.

13 On flexibility, we said it meets criterion. The
14 care team appears to have broad flexibility in meeting the
15 unique needs of each patient. Delivery model supports
16 tele-mentoring of PCPs to enable them to take on a greater
17 role in managing patients with HCV.

18 The ability to be evaluated, we said it does not
19 meet criterion, largely because the shared savings are
20 based on expected annual cost from continued HCV infection
21 avoided and the number of life years gained. Given the
22 relative newness of the use of HCV drugs, the initial
23 modeling may prove to be inaccurate, and the inaccuracy
24 could result in -- we really wouldn't know what the impact
25 is for many years.

1 Integration and care coordination. The proposal
2 does focus on integrated care coordination of patients,
3 particularly higher need patients with HCV. The proposal
4 supports tele-mentoring. The submitter notes that an
5 advantage of implementing the model in hospital-based
6 clinics is the ability for care coordinators to make
7 referrals to other diagnostic and treatment services within
8 the same facility. These facilities are also likely to
9 have integrated EHR systems.

10 But our major concern is that beneficiaries with
11 HCV frequently -- more than frequently, it turns out that
12 something like national numbers -- and they confirmed this
13 is also their situation -- most of these patients are
14 Medicare-eligible by virtue of having disabilities. That's
15 the original reason. They are frequently dual eligible.
16 They have serious mental health and other conditions, and
17 we did not see that the proposal addressed how care
18 coordination occurs across outpatient department settings
19 with other providers.

20 The proposal seemed to focus on care coordination
21 for managing the treatment of HCV but very little attention
22 to the overall, and what we think should be ongoing care
23 coordination using existing payment codes that Medicare
24 makes available in the fee schedule.

25 Patient choice meets criterion. There was not

1 much of an issue so I'll skip over that. Patient safety
2 clearly is a positive from the model. It targets a
3 population with high rates of mental and behavioral health
4 issues, coordinating care for these patients and helping
5 them overcome issues that may interfere with their
6 readiness to initiate and adhere to pharmacology could
7 improve patient safety.

8 Health information technology. Most of this care
9 is within health systems. It's not an interoperability
10 outside. Doesn't appear to be a major issue. We thought
11 this met criterion.

12 And that is the summary of our review.

13 * **Clarifying Questions from PTAC to PRT**

14 CHAIR BAILET: Thank you, Bob. We're going to
15 open it up to the Committee to ask the PRT questions or
16 clarifying questions before we have the submitters come to
17 the table.

18 I just want to remind everyone that we, as a
19 Committee, have not discussed this proposal until right
20 now, and while the PRT has had a very exhaustive analysis
21 and talked amongst themselves and talked with the submitter
22 and an outside expert and looked at the literature, et
23 cetera, we, as a Committee, have not indulged in the
24 analysis. And so this is really live, and I just wanted to
25 make that point, because I think there's been some

1 speculation that perhaps the Committee has been meeting
2 off-camera and deliberating, and I want to make sure that
3 that has not, will not happen. We have a very good DFO who
4 keeps us on task for that.

5 So I would like to now open it up to Committee
6 members for clarifying questions of the PRT. Bruce.

7 DR. BERENSON: I should have asked my fellow
8 reviewers if they have any comments they would want to
9 make. Grace and Jeffrey?

10 DR. TERRELL: I've just got a quick comment, and
11 you talked about it in ways, as you were talking about the
12 problem with the payment methodology. I've been thinking a
13 lot, over the last few days, about the fact that it's an
14 incredibly good thing that this proposal came to us,
15 because it means that there's a new technology, in this
16 case a drug out there, that's going to make a great deal of
17 difference in the lives of a lot of people, if they take
18 the drug, and therefore don't get cirrhosis or transplant
19 or other things that are related to having chronic
20 hepatitis C.

21 The thing that is worrisome for me is the concept
22 of the technology and tying that to life years saved, which
23 I think has got some real strong ethical things that have
24 to--to the point that we made in the PRT--have to be
25 thought through at a much broader, larger level than this

1 one thing. You can imagine that a surgeon who does an
2 appendectomy on somebody with a technology called a scalpel
3 has saved many life years, and you can imagine that a
4 general internist who is checking feet compliantly and
5 therefore somebody doesn't have an amputation is saving
6 much to the system.

7 So part of the real issue with respect to this, I
8 think the reason it came up, is because it came up because
9 it's a new technology and we know that if we can figure out
10 how to coordinate this across a group of patients that it
11 is a great thing for them. But I absolutely believe that
12 the way that it was articulated with respect to the payment
13 system is something that is a large, broad, ethical issue
14 that needs to not be sort of determined by this particular
15 PRT.

16 CHAIR BAILET: Thank you, Grace, and I would just
17 -- I would echo your comments and just add that this is a
18 very challenging population for the compendium of
19 additional medical maladies -- illnesses, and also the
20 behavioral health component with this population. And so I
21 applaud the proposers and the submitters for bringing this
22 forward. I think it's a unique circumstance in that
23 there's actually a cure, and that not only helps the
24 individual patients, it also limits the exposure and the
25 risk of downstream infections.

1 So again, I think it has tremendous merit on that
2 alone. What I do struggle with, as a PRT Committee member,
3 is the payment methodology. Again, this life savings has a
4 lot of challenges associated with it, some of which we're
5 going to discuss in more detail as we deliberate. I think
6 that's the only other comment I would make at this point.

7 Bruce.

8 MR. STEINWALD: Thank you. Once again, if the
9 answer to my question is in the materials and I missed it,
10 please forgive me.

11 Are the chronic care management codes already
12 being used to bill for services to hep C patients?

13 DR. BERENSON: Are they being used by these
14 particular facilities, or are they being the old -- in
15 general?

16 MR. STEINWALD: In general.

17 DR. BERENSON: Yes.

18 MR. STEINWALD: They are. Okay.

19 DR. BERENSON: And, in fact, I would quote from
20 the proposal, which is now a number of months old, "With
21 recent expansion of the Medicare monthly chronic care
22 management codes, key supportive services such as health
23 promotion and medication adherence support that are
24 critical for patients to achieve self-sufficiency and
25 treatment completion are now reimbursable to providers and

1 can foster creation and adoption of a payment model to
2 support integrated care leading to a cure of HCV."

3 So it seemed to us that the proposal itself was
4 saying that the chronic care management codes, with this
5 issue of non-clinical staff, I think there's an answer to
6 that one, which we can get into. It seemed like they were
7 saying we already have the ability, under the Medicare fee
8 schedule, to support this delivery model. And so in
9 discussions I think we should sort of probe a little more
10 as to why they need a new payment model. Our view was
11 largely for the shared savings component, which we have
12 problems with.

13 CHAIR BAILET: Harold.

14 MR. MILLER: I am going to -- most of my
15 questions I'm going to direct to the applicant, but the one
16 thing I wanted to ask Bob and colleagues for, if I read
17 this correctly -- and maybe I'm just completely
18 misperceiving this -- it's not a shared savings model.
19 They are -- the way I understood the way this is written is
20 that it is -- there is an outcome and they get a bonus or a
21 penalty based on whether they achieve the outcome, and
22 they're trying to calculate the magnitude of the bonus or
23 penalty based on an estimate of some amount of savings.
24 The actual amount that they get is not related, in terms of
25 how much they actually save. It's simply an estimate.

1 And I think, if I read it correctly, that they
2 could have come in and simply said it's a \$200 bonus if we
3 make it and it's a \$200 penalty if we didn't, but they
4 tried to sort of relate it to something. Which, in a
5 sense, if you'd say, well, we have the whole MIPS system,
6 which makes up the number four percent, nine percent, you
7 know, like so what's that based on? But here they tried
8 to, in fact, say that the bonus or penalty was related to
9 something. Whether it's related to the right thing or not
10 is a different question that we'll come back to.

11 But am I misperceiving that? It's not actually
12 -- it was not intended to be based on actual savings. It's
13 simply a calculation of a bonus or penalty amount.

14 DR. BERENSON: I think that is correct, and so
15 it's not really shared savings. It is they get a portion
16 of estimated savings over what could be a lifetime of
17 illness or burden.

18 MR. MILLER: But it doesn't change based on what
19 anything actually happens. There could be no savings and
20 they would get the bonus and they're --

21 DR. BERENSON: No, but I would say, in defense,
22 that the SVR measure is a good surrogate measure for
23 successful treatment and predictability of what spending
24 would be, but to go out many years I think is problematic.

25 But to your other point, if this were a simple,

1 like pay-for-performance model, that they would get a bonus
2 if they hit the target, with some penalties if they don't,
3 that would have been a different thing to consider. But
4 they felt very strongly that this was the payment model
5 they wanted to go forward with.

6 MR. MILLER: Okay. I'll ask them more questions
7 about that whenever they come up.

8 CHAIR BAILET: Any other comments from the
9 Committee members before we invite the submitters?

10 [No response.]

11 * **Submitter's Statement, Questions and Answers, and**
12 **Discussion with PTAC**

13 CHAIR BAILET: Okay. We'd like to invite you
14 folks up to the table, and flip over your table tent
15 nametags there and introduce yourselves. And you guys have
16 10 minutes and then we'll open it up for questions. Thank
17 you.

18 And just to be clear, there's you guys here, in
19 person, and there are about four or five folks on the phone
20 as well. So we want to make sure everybody has an
21 opportunity to participate. Thank you.

22 DR. WINTERS: Hi. On behalf of all the partners
23 associated with Project INSPIRE, we'd like to thank the
24 PTAC members for reviewing our payment model and the PRT
25 for providing their preliminary findings.

1 My name is Dr. Ann Winters and I'm the Principal
2 Investigator on INSPIRE and the Medical Director of the
3 Viral Hepatitis Program at the New York City Department of
4 Health. Joining me today from the Health Department is
5 Marie Bresnahan, program director, and Dr. Kyle Fluegge,
6 health economist. From Weill Cornell Medical College, Dr.
7 Bruce Schackman and Dr. Czarina Behrends, and, most
8 recently from Montefiore Health System, now transplanted to
9 South Carolina, Dr. Alain Litwin.

10 Our colleagues joining by phone are, from
11 Montefiore, Dr. Shuchin Shukla, primary care provider; and
12 Mr. Paul Meissner, program administrator. From Mount Sinai
13 Medical Center, Dr. Ponni Perumalswami, liver disease
14 specialist; and Dr. Jeff Weiss, behavioral health
15 specialist. And from our payer partners, Lauren Benyola
16 from VSNY Health, and Rashi Kumar, from Healthfirst.

17 INSPIRE stands for *Innovate and Network to Stop*
18 *Hepatitis C and Prevent complications by Integrating care,*
19 *Responding to needs, and Engaging patients and providers.*

20 It was based on the Ryan White HIV Care Coordination
21 Program, which is a proven model of integrated medical and
22 behavioral health service for people with HIV/AIDS.

23 INSPIRE is an approach to the treatment of patients
24 chronically infected with the hepatitis C virus that
25 includes comprehensive care coordination services to

1 support patients through treatment and educational or
2 mentoring sessions for clinicians learning to treat
3 patients with hepatitis C.

4 This collaborative effort was funded for three
5 years by the Centers for Medicare & Medicaid Innovation, as
6 a Health Care Innovation Award designed to develop new
7 payment and service delivery models. It was a time-limited
8 intervention that officially ended on August 31, 2017. It
9 is our goal to share clinical and payment innovation with
10 physicians and payers more broadly to create a sustainable
11 path forward, ultimately leading to the elimination of
12 hepatitis C.

13 Given the population health burden of this
14 disease and the availability of new therapies used to cure
15 it, we felt it imperative to move this work forward in
16 hopes of creating a national model to support care for
17 hepatitis C.

18 We also feel it is important to highlight the
19 timeline of our evaluation activities. In our final
20 written communication with the PRT on December 8th, we
21 provided preliminary results of the analyses supporting our
22 proposal. We regret that we were not able to provide this
23 information sooner. However, we are happy to engage with
24 the PRT and the full PTAC to discuss these findings to help
25 the Committee more fully understand the nuances of our

1 proposal.

2 We also want to emphasize that although the
3 results are new, they don't change our original payment
4 model in any significant way. They only provide empirical
5 support for the model as it was originally proposed. Given
6 the time limitation of our Health Care Innovation Award and
7 the urgency of hepatitis C as a public health crisis, we
8 wanted to take this opportunity to present to you all
9 today.

10 Now I will turn the floor over to my colleague,
11 Dr. Alain Litwin, who will discuss hepatitis C and the
12 Project INSPIRE intervention in more detail.

13 DR. LITWIN: Great. Thanks so much, Ann. I'm
14 Dr. Alain Litwin. I worked until recently at Montefiore
15 Medical Center, and as was pointed out previously, have now
16 moved down to the Vice Chair of Department of Medicine at
17 University of South Carolina School of Medicine and
18 Greenville Health System and Clemson University. I was one
19 of the lead clinical partners, along with Mount Sinai
20 Medical Center, on Project INSPIRE and I want to take a few
21 minutes today to describe a bit more about Project INSPIRE
22 and to highlight and clarify some key aspects of our
23 proposal.

24 Deaths associated with hepatitis C in the United
25 States have reached an all-time high of 19,659 in 2014.

1 That is the most deadly infectious disease in America
2 today. This number exceeds those attributable to 60 other
3 reportable infectious diseases, including HIV and
4 tuberculosis. An estimated 3.5 million Americans are
5 living with chronic hepatitis C, which is the leading cause
6 of liver failure and hepatocellular carcinoma, and accounts
7 for approximately 40 percent of liver transplants in the
8 United States. Liver cancer is one of the fastest-growing
9 cancers in the U.S., and 50 percent of cases are related to
10 hepatitis C infection.

11 Approximately 75 percent of persons with chronic
12 hepatitis C infection were born from 1945 to 1964, the baby
13 boomer cohort, and this aging population is more likely to
14 have other chronic illnesses that could be complicated by
15 hepatitis C infection. An estimated 40 percent of persons
16 living with hepatitis C have comorbidities, including
17 behavioral health problems, substance use disorders, and
18 chronic conditions such as HIV, diabetes, and kidney
19 disease. Persons with a history of injection drug use who
20 tend to have numerous comorbidities are at the greatest
21 risk for hepatitis C infection.

22 Both the World Health Organization and the
23 National Academies of Science, Engineering, and Medicine
24 agree that aggressive treatment of hepatitis C is necessary
25 to eliminate the disease as a public health problem by

1 2030. Guidelines from the Infectious Disease Society of
2 America and the American Association for the Study of Liver
3 Diseases recommend treatment for nearly all individuals
4 affected with hepatitis C, given the highly effective
5 treatments currently available and the large burden of
6 hepatitis C in the United States, especially among the baby
7 boomers, a sizeable portion of the Medicare population. We
8 feel strongly that now is the time to move forward on this
9 proposal.

10 In addition, the treatments are so effective.
11 We've heard that. But if we don't match the care delivery
12 systems to these treatments we're really not going to meet
13 those goals. And, you know, our patients are dying over
14 the next, you know, five years. Many have cirrhosis. Half
15 of our patient population has cirrhosis. And so it's
16 really -- we know, with the current models of care, there's
17 no Ryan White system for -- you know, as there is for the
18 HIV population. The majority of patients have a history of
19 injection drug use and there's no health care system. It's
20 a fragmented health care system, and I'll talk a little bit
21 more about how the care coordinators are helping, you know,
22 across these comorbidities.

23 Historically, treatment for hepatitis C has been
24 limited specialists, which has resulted in long wait times,
25 low rates of cure for patients, since they're not getting

1 seen. One of INSPIRE's main strategies is to increase
2 provider capacity for hepatitis C treatment by training
3 primary care providers, addiction medicine, and infectious
4 disease physicians to manage patients, and to allow
5 patients to remain connected to the outpatient clinic where
6 they are likely already comfortable receiving care.

7 The INSPIRE model is led by a liver disease
8 specialist, usually a hepatologist. This specialist meets
9 regularly with primary care, addiction medicine, infectious
10 disease, and other physicians via in-person meetings,
11 webinars, or teleconferences during which they learn how to
12 treat hepatitis C and connect to a liver disease expert to
13 support and mentor them. In addition to providing this
14 mentorship, a specialist remains available to accept timely
15 referrals for patients with advanced liver disease.

16 You know, one of my patients we treated with
17 triple therapy and then developed liver cancer, but because
18 we were screening appropriately we were able to get the
19 patient to see a colleague, Dr. Jonathan Schwartz, in a
20 timely manner, you know, undergo chemoembolization and
21 radiofrequency ablation, and then when it was needed for a
22 liver transplant, able to get a transplant for the patient.
23 It's not just about handing over to the specialist, but the
24 primary care and specialist can work together, hand in
25 hand, because there are a lot of issues of fear, of

1 mistrust. And even at the time when the transplant was
2 available, you know, the patient had some barriers with
3 transportation, needed to take the subway, and, you know,
4 we were able to, you know, hold that liver so that he
5 could, you know, get that, you know, transplant, and he is
6 doing very well today. So I just wanted to -- it's really
7 about, with the screening, you want to be able to work hand
8 in hand so we can optimize our screening protocols.

9 In New York City, in addition to providing some
10 mentorship, the specialist remains available to accept
11 timely referrals, as I mentioned. The call for specialist
12 support of primary care physicians and other non-
13 specialists has been a recurring theme for the U.S. health
14 care system for years. Our care delivery model directly
15 addresses this largely unmet need.

16 In New York City, this model was implemented at
17 23 participating primary care, infectious disease, and drug
18 treatment clinics affiliated with Mount Sinai Medical
19 Center and Montefiore Medical Center. Even in a dense
20 urban environment such as New York, providers with limited
21 time cannot easily travel across town to consult with and
22 learn from a specialist. All of our tele-mentoring
23 sessions were conducted using readily available,
24 inexpensive teleconferencing, webinar, and screen-sharing
25 technology. And we feel confident this model can easily be

1 replicated in other settings, including the urban,
2 suburban, and rural settings, just as Project ECHO proved.

3 Let me provide a bit more detail about how the
4 intervention works. The tele-mentoring services were
5 designed based on the Project ECHO program, which sought to
6 improve access to care for rural, underserved hepatitis C
7 patients in New Mexico. As in Project ECHO, the webinars
8 included presentations by hepatitis C specialists,
9 hepatologists, infectious disease specialists, and
10 behavioral health providers, as well as others working with
11 chronically infected patients. Primary care and other
12 physicians were able to present cases for discussion during
13 the webinars and receive real-time feedback on care and
14 treatment options from the other clinicians, including
15 liver disease and behavioral health specialists.

16 In our surveys with clinicians who participated
17 in tele-mentoring, they reported an increased confidence in
18 their ability to identify and treat patients with hepatitis
19 C, and along with gains in knowledge they spoke about the
20 sense of community that developed with their INSPIRE
21 colleagues as a result of the tele-mentoring sessions and
22 ongoing transfer beyond the sessions. They reported the
23 satisfaction of being able to receive real-time feedback on
24 how to treat some of their more complicated patients as
25 compared to traditional consultation. And after a few

1 months, most of the clinicians involved felt ready to
2 mentor other physicians interested in treating hepatitis C
3 and began serving as an expert within their clinic for
4 hepatitis C-related questions from other staff.

5 In this model, the other significant benefit to
6 the physicians was working alongside the care coordinators
7 who provided health promotion and coaching, and the
8 promotion is along multiple domains. It's around mental
9 health, around substance use and alcohol use, diet and
10 exercise, alcohol- and substance-use counseling, medication
11 adherence support, appointment reminders, referrals to
12 medical and social services.

13 You know, with respect to the point of kind of
14 care coordination across these other comorbidities, 80
15 percent of our patients who are currently injecting were
16 seen by substance abuse treatment, and 40 percent of who
17 were former injectors were also in care, so that was really
18 crucial in taking care of this population.

19 The liver education related to hepatitis C
20 reinfection risk as well as guidance on future liver
21 health, including the ongoing need for liver cancer
22 screening after cure for patients with advanced fibrosis
23 and cirrhosis. And, again, 51 percent of our patients had
24 advanced fibrosis and cirrhosis, and we were able to
25 demonstrate we could take care of these patients in a

1 collaborative manner.

2 A coordinator's guide to their patients to
3 effectively navigate the health care system by keeping them
4 connected to the outpatient clinic and out of the hospital
5 and emergency room, in particular because of focus on those
6 comorbidities.

7 In addition, a key role of the care coordinator
8 is to support the clinical team and patient navigating the
9 health insurance system, the hepatitis C medications and
10 prior authorization requirements that require significant
11 time and attention on the initial paperwork and subsequent
12 appeals that, in some cases, are required. Having a
13 supportive role of the care coordinator to handle these
14 issues allows the clinical providers to focus on optimal
15 care delivery.

16 Just some brief comments on our proposed payment
17 model but I think important. Overall, the proposed INSPIRE
18 advanced alternative payment model is designed to support a
19 more efficient and effective approach to hepatitis C care
20 and treatment by allowing physicians and liver disease
21 specialists to work at the highest level of their training,
22 thereby ensuring overall care is streamlined for the
23 sickest patients. The bundled payment will support tele-
24 mentoring and care coordination of people with complex
25 needs. There are critical elements that are inextricably

1 linked in getting eligible patients access to treatment,
2 you know, motivating them to want treatment, which, in
3 fact, many do not; supporting them through therapy and
4 achieving cure.

5 The PRT did ask us to consider existing payment
6 methodologies, but we found that a reimbursement approach
7 using the Physician Fee Schedule and the Outpatient
8 Prospective Payment System would not fully support the
9 INSPIRE bundle of services as providers would lose an
10 average of \$98 per patient. Our bundle includes tele-
11 mentoring to provide the team-based training necessary to
12 expand hepatitis C treatment into primary care settings and
13 the care coordination services. We feel a one-time bundled
14 payment is necessary to cover the cost of these two
15 critical elements.

16 With respect to the risk component of the payment
17 model, we recognize the PRT's concern with our shared
18 savings definition, which is based on future medical cost
19 savings associated with this curative treatment. However,
20 this approach project . . . projects benefits in a manner
21 consistent with value-based payment methodology and
22 represents a particularly innovative path beyond
23 traditional fee-for-service reimbursement in Medicare.
24 Furthermore, these savings calculations reflect the recent
25 advances in hepatitis C pharmacotherapy options, which

1 consistently achieve cure rates of 95 percent, and also
2 slow progression of disease and liver complications by more
3 than 80 percent, with some patients experiencing regression
4 of liver cirrhosis after therapy.

5 In our proposal, the estimate of future cost
6 savings is based only on the presence of cirrhosis and age.
7 These data are easily extractable from a claim form,
8 thereby enhancing our model's transparency. The savings
9 are calculated using only medical costs for hepatitis C-
10 related disease avoided due to cure and do not attribute
11 any economic value to the life years gained and are not
12 estimates of lifetime savings.

13 Furthermore, to ensure that savings estimates are
14 conservative, they have also been revised downward to
15 account for the fact that additional years of life saved
16 do, in fact, result in additional medical care costs to
17 Medicare for other diseases. The revised estimates in the
18 savings table from our original proposal may be further
19 revised downward to reflect a more modest assessment of a
20 total savings potential to Medicare.

21 We want to emphasize that although the amounts
22 seem large for the type of intervention we have conducted,
23 the bonus and payback rates set by CMS can impart a very
24 reasonable average bonus and payback structure, and we have
25 demonstrated this in our payment model simulation results

1 sent to the PRT on December 8th. In this way, the proposed
2 payment model is very flexible in its design.

3 So I want to thank everyone for the opportunity
4 to clarify important information about our proposed payment
5 model supporting and expanding treatment of hepatitis C in
6 primary care and other settings, and we look forward to the
7 questions you might have. Thank you.

8 CHAIR BAILET: Thank you.

9 So, we now open it up to the Committee for
10 questions. Harold, it looks like you're first up.

11 MR. MILLER: Thanks. So, first of all,
12 commendations to you for the work that you've been doing on
13 an important problem and for trying to think through a way
14 to support it. As I read through all the material, and I
15 guess it sort of struck me, as I was reading through it,
16 that there seemed to be -- I'm just going to sort of tell
17 you my impression, then you correct me where I'm wrong --
18 that there's really two things going on here. One is
19 you're trying to get people to take and complete the course
20 of medication to be able to successfully do that. And,
21 second, you're trying to help manage their overall care to
22 keep them from showing up in the emergency department,
23 hospitals, et cetera. And those are two very different
24 things, which have some -- a little bit of overlap in the
25 sense that what you're calling care coordination involves

1 contacting the patients; some of which is take your meds,
2 finish the course; some of which is, you know, see your PCP
3 or don't go to the ED or whatever. So there's kind of like
4 the same person is doing some of those things, but they're
5 two really very different things, which you've sort of
6 lumped together in a way that I think kind of is a little
7 bit confusing and problematic.

8 The first part I think is an innovative concept.
9 You're basically, it seems to me -- it sounds like you're
10 creating an outcome-based payment that says if you actually
11 achieve not just process measure, did they actually take
12 their meds, but if they actually achieved SVR, then there's
13 a bonus or a penalty, so it's an outcome-based payment,
14 which we have almost nothing like that in Medicare, and my
15 impression again, which I appreciate your reaction to, as I
16 said earlier, is that it's simply a bonus or a penalty
17 based on whether you did it or didn't and you've tried to
18 figure out the amount of that based on this rationale, but
19 fundamentally that's determined in advance. There's an
20 amount that you calculated, this is the bonus, this is the
21 penalty.

22 Then, the second part -- and I'll just try to lay
23 out my understanding of this, and you can tell me where I'm
24 wrong. So then the second part is you're -- oh, and part
25 of that is that there's a mentoring process for the PCPs or

1 FQHCs or whoever it is that you're doing -- that also needs
2 to be paid for in some fashion. It sounded to me like a
3 lot of that mentoring is coming from the specialist, a
4 little bit maybe from the care coordinator, but I wasn't
5 quite clear on that.

6 And then the second piece is there's care
7 coordination to try to keep people out of the ED, et
8 cetera, but it seems oddly focused just during this period
9 of time when they're taking their medications; whereas, it
10 didn't sound to me as though the risk associated with going
11 to the ED, et cetera, was somehow uniquely associated with
12 that period of time. And the notion that somehow we're
13 going to pay for this care coordination during that
14 particular window of time -- not before, not after, but
15 only during that window of time -- seemed odd -- odd to me.

16 And so in some sense it seems to me that -- and
17 I'll have some further questions, but there may be value in
18 trying to pay to get people to take their medication
19 because today nobody gets rewarded if they actually
20 successfully do that, right? So there might be some value
21 to doing that. And there might be some value to trying to
22 do care coordination with this population if they're highly
23 at risk.

24 So the question is, after all that is, am I, in
25 fact, correct that there's like those two pieces and you

1 kind of sort of mushed them together into this model? Or
2 have I missed the boat?

3 DR. LITWIN: Sure, I can start. So many of our
4 patients, 65 percent of our patients, have a history of
5 injection drug use, and so with that comes a lot of
6 comorbidities and so forth. And the actual period of
7 engagement is -- and correct me if I'm wrong -- about 10
8 months, so it's really the pre-treatment period which may
9 last up to 24 weeks. Treatment actually now, you're
10 correct, is quite short. It could be even as short as 8 to
11 12 weeks; and post-treatment, where people are at risk of
12 reinfection. So it's really a moment, kind of a long
13 period of time in which we can engage patients who
14 otherwise have not been able to be engaged. And so in many
15 ways, the hepatitis C becomes kind of the vehicle and the
16 foundation for being able to -- people, you know, although
17 some need to be motivated, others are already motivated and
18 just need that access to care because they're being denied
19 it by other providers because of certain behaviors, and
20 then now can engage in other areas, in other comorbidities,
21 whether it's their addiction or mental health. And there's
22 been, you know, literature out there to show that there's
23 kind of upward spiral, transformation, because people are
24 used to -- unfortunately, in the United States, many states
25 restrict people that are actively using drugs to even get

1 the hepatitis C treatment. But by allowing them to have
2 that treatment, which is what the guidelines say, then you
3 can work on other areas. So I think --

4 MR. MILLER: But am I correct, I'm just asking,
5 are there two goals? One is get people to finish their
6 meds and get SVR --

7 DR. LITWIN: Yes.

8 MR. MILLER: -- and the other is to try to manage
9 them to keep them out of the ED, out of the hospital, et
10 cetera?

11 DR. LITWIN: Yeah. I think there's more than
12 that, though. I think the overall goal is to improve the
13 health of --

14 MR. MILLER: Okay, at least two goals.

15 DR. LITWIN: Yes. Those two goals are correct.

16 MR. MILLER: At least two goals, okay.

17 DR. LITWIN: Absolutely.

18 MR. MILLER: So let me just focus on the first
19 one for a second. I have a couple questions about that.
20 So you didn't mention at all -- I didn't find it -- any
21 statement about what the start and not complete rate was
22 for people. Is that high in this population or not?

23 DR. LITWIN: Sure.

24 DR. WINTERS: Start and not complete for patients
25 who enrolled in our intervention or in general patients

1 with hepatitis C --

2 MR. MILLER: Who take -- who start the medication
3 but don't finish all the dosage.

4 DR. WINTERS: So we --

5 MR. MILLER: Or does everybody who starts it
6 automatically get to the end, almost always?

7 DR. WINTERS: So definitely everyone who starts
8 does not get to the end.

9 MR. MILLER: What percentage would you guess that
10 would be?

11 DR. WINTERS: So it's difficult to look at that
12 over a large population because we don't have all of the
13 claims data from all payers to look at everyone who's ever
14 been started on treatment. But we can say that -- looking
15 at New York City, we can say that our care cascade shows
16 that we estimate 146,500 patients living with chronic
17 hepatitis C and using a combination of surveys, where we
18 think about 60 percent of patients know their status, going
19 from there we think only about 17 percent of those patients
20 have completed treatment, and that's as of 2016. We've had
21 good, direct-acting antiviral therapy available since 2014.
22 So even though we have these excellent drugs available, we
23 know that patients are not getting treated, and there are a
24 lot of barriers involved to that.

25 So while I agree with Dr. Berenson that this

1 medication is really magic, that's not all it is.

2 MR. MILLER: But my question, I just want to be
3 precise about my question. How many people start but do
4 not finish therapy? Just your guess. Is it 10 percent, 50
5 percent?

6 DR. WINTERS: Actually, we have some of our payer
7 colleagues on the line, and I'm wondering if one of our
8 colleagues from Healthfirst might be able to answer that.
9 Sort of into the air.

10 MS. KUMAR: Yes, hi. This is Rashi. Can you
11 hear me?

12 DR. WINTERS: Yes.

13 MR. MILLER: Yes.

14 MS. KUMAR: Okay, good. So I'm actually seeing
15 if I can look up the data right now, but from my
16 recollection, it was really only a handful of patients who
17 started the therapy and didn't complete.

18 DR. WINTERS: Rashi, are you talking about
19 patients on INSPIRE or patients in general?

20 MS. KUMAR: I'm talking about INSPIRE patients
21 who were in Medicaid.

22 MS. BRESNAHAN: And then can you tell about the
23 Medicare study that you also looked at, Rashi?

24 MS. KUMAR: Sure. So we're based in New York,
25 and a lot of our members are in the Bronx, and we looked at

1 one delivery system in the Bronx, and there it's Medicare
2 beneficiaries who were infected with hep C, and we actually
3 saw that only about a third of them had actually accessed
4 in recent years a beneficial drug therapy for that -- for
5 that condition. And we also noticed that a lot of them
6 that were on the treatment -- not a lot, but a decent
7 proportion, maybe 10, 15 percent, it looked like they
8 either didn't complete treatment or had interrupted their
9 otherwise inefficient treatment.

10 MR. MILLER: Okay. I was just wondering because
11 if simply getting them to start is the key thing, that's
12 different than saying that they started and stopped,
13 because you presumably have wasted a very expensive
14 medication. And I didn't see that mentioned in terms of
15 what you were achieving, is that that might be involved
16 with that.

17 DR. LITWIN: I would say 10 to 20 percent, I
18 mean, different -- you know, from our experiences because
19 of intersection with the criminal justice system because of
20 drug use, you know, going on binges and maybe being out of
21 care, lost to follow-up, mental health conditions, being
22 hospitalized across different sectors. Many patients will
23 get into one institution or another or go away to rehab.

24 MR. MILLER: Okay.

25 DR. LITWIN: So it does happen. It's not 50

1 percent, but it's a significant problem.

2 MR. MILLER: Okay. Just two more questions. The
3 second one, I didn't quite understand how -- you didn't
4 seem to be stratifying the patients in any fashion or
5 stratifying the payment. There was sort of a payment for
6 everybody, as opposed to saying, boy, this subset of
7 patients are going to really need intensive support, these
8 aren't; and these patients are going to be much less likely
9 to complete or whatever, or need much more care
10 coordination. I didn't quite see that, and I wasn't sure
11 why.

12 DR. FLUEGGE: Hello. I'm Kyle. We've -- So
13 we've done some additional work on that. You didn't read
14 it in the proposal because it wasn't fully outlined.

15 MR. MILLER: Why don't you pull the microphone a
16 little closer to you?

17 DR. FLUEGGE: Sorry. So we have -- Is this
18 better?

19 MR. MILLER: Mm-hmm.

20 DR. FLUEGGE: Okay. So we have kind of thought
21 about this issue further in terms of how we would try to
22 get away from solely having a physician attribution system
23 for payment -- or for patients, and we've come up with
24 having two bundles essentially. So we have the Bundle 1,
25 which comprises sort of the care trajectory for more

1 complex patients, so these would be dual-eligible patients,
2 patients with substance abuse disorder with a prior
3 treatment failure for hepatitis C, and other really complex
4 conditions. And then we have a second bundle that is for
5 less complex patients, so those who would not fit into that
6 category.

7 So we did a cost analysis that would adjust the
8 episode of care payment that we originally derived and
9 included an adjustment for that. In terms of, you know,
10 carrying the two-bundle approach forward, we would
11 recommend having a different -- potentially a different SVR
12 benchmark for the patients enrolled in Bundle 1 versus
13 Bundle 2, and then also having some modification with the
14 shared savings payback amounts based on the type of bundle
15 we're talking about.

16 MR. MILLER: When I was reading the evaluation,
17 the evaluator's report, the second-year report on the HCIA
18 award, it described you as working on a three-phase payment
19 model, and you didn't propose that, and I'm curious as to
20 why. You didn't propose that to us, but it sounded when I
21 read the report as though that's what you had been working
22 on.

23 DR. FLUEGGE: You're correct. That is accurate.
24 But we had designed it in terms of three phases, like you
25 mentioned, but for the third phase, it was mostly just

1 focused on SVR where there wouldn't be a tremendous amount
2 of interaction between the patient and the provider, and so
3 that portion of the -- we just weren't confident that that
4 portion of the bundle would be covered by something like
5 complex chronic care management codes. So that's why we
6 wanted to create a bundle that includes the entire episode
7 from enrollment to SVR documentation.

8 MR. MILLER: Yeah, but then you were kind of
9 going through all kinds of machinations to figure out how
10 you were going to give it back if you didn't complete.
11 That's why I was wondering why you -- because your original
12 model sounded like it would be a more natural -- as the
13 person reached each stage of what you were trying to get
14 them to, you would get another payment associated with
15 that, which seemed to me it was better matched -- because
16 to me, payment should be matched to what you're trying to
17 do rather than us trying to "let's see if we can figure out
18 how to make the chronic care management code fit this thing
19 that we're trying to do". But your episode payment didn't
20 quite fit it either because it presumed that people were
21 going to do everything whenever they weren't, and then you
22 had to figure out how to give it back or to adjust your
23 methodology. So it just seemed to me that that was better
24 aligned with the way you were actually treating patients
25 and spending dollars.

1 I'll stop there. Thank you.

2 CHAIR BAILET: Thank you, Harold. Len?

3 DR. NICHOLS: Thank you. So I was intrigued --
4 first of all, cool. Second, I was intrigued with the costs
5 that you left out, and in particular, I guess what struck
6 me was, if I read the sentence right, the payment model
7 will not cover labs, imaging. I get that. Medication,
8 which is surprising, and I'll come back. Mental health and
9 psychiatric services, and then some cancer I can't
10 pronounce.

11 So, what I'm really curious about is two parts:
12 One, the mental health; and the second then are the
13 medication, because if I understand, if you will, the logic
14 of the expected future savings, a lot of that has to do
15 with the services that will not be delivered because the
16 person gets medication and gets cured. But you've taken
17 the cost of the medication out and yet Gilead priced it to
18 capture that value you're trying to claim. So there's kind
19 of a potential double counting here. So --

20 DR. SCHACKMAN: So, the market is acting very
21 quickly in terms of the pricing of the medications right
22 now, so the prices have come down substantially due to
23 competition and new introduction of new treatments. The
24 list price has dropped from, I think it was \$90,000
25 originally, was the original and directed price, to

1 something around \$26,000 now. And we felt that the market
2 dynamics are such that the market is, in fact, sort of
3 speaking in terms of what is going to happen in terms of
4 that valuation. And so it would be very hard to predict
5 what those prices would be -- cost would be going forward,
6 and to introduce Part D considerations into this payment
7 model would add too much complexity.

8 DR. NICHOLS: I totally get the complexity and I
9 love the way the market's actually working. That's a good
10 thing. We're happy about that. In [unintelligible] school,
11 right? But the point is, yes, those prices have come down.
12 They should come down more. But the larger point is those
13 prices were set originally and are still to some degree
14 fighting over the potential savings to the patient, which
15 your model is trying to claim. That's what I'm getting.
16 Why not have that cost be part of the calculation that then
17 offsets some of the gain that has been -- because you
18 wouldn't get the gain without the medication. That's the
19 question.

20 DR. FLUEGGE: So I think one of the ideas we had
21 to include that was to adjust the bonus payment table by
22 the amount -- essentially the non-adherence that generated
23 missed, you know, medication. So, yeah, that's one avenue
24 that we're considering, but, again, it adds complexity that
25 we didn't necessarily want to --

1 DR. NICHOLS: Okay, okay. And so, obviously, you
2 settled on this really novel notion of expected future
3 gains, which in principle I'm attracted to, but I guess
4 maybe you could go through some rationale. Why did you
5 reject a more traditional shared savings calculation so
6 that we could understand why you chose what you did as
7 opposed to --

8 DR. FLUEGGE: Yeah, sure. So --

9 DR. NICHOLS: -- what we're used to.

10 DR. FLUEGGE: Right. Well, so we're focused in
11 this intervention on a cure, which a lot of APMs that have
12 been proposed to you previously, really that's not
13 something that you see a lot of, and so we wanted to
14 recognize that and incorporate it into our payment model.
15 We wanted to align a payment model with our national
16 elimination goals. We wanted to give physicians the
17 opportunity to see that there is a potentially great bonus
18 to be had by identifying and following up with patients
19 with the use of tele-mentoring, with the use of care
20 coordination, and so we really feel like that gives the
21 appropriate incentive to actually attain that.

22 CHAIR BAILET: So we have Bob, Grace, and then
23 Paul.

24 DR. BERENSON: Yeah. I want to try to pin down
25 this issue of the applicability of the chronic care

1 coordination codes because I just have this feeling that
2 you've come up with shortfalls by not including the
3 facility fee that, my guess -- and this is purely a guess
4 -- is being kept by central administration at Montefiore
5 and Mount Sinai and isn't flowing to the clinics, but the
6 payments are being made. For every \$53 that you did
7 acknowledge in your proposal for the 99487 code, complex
8 chronic care management, \$72 is being paid to your
9 institutions. Those payments together make up
10 significantly more than the \$760 you're requesting, would
11 support the \$98 shortfall for tele-mentoring, and so my --
12 so I have two questions.

13 One, is my logic right or wrong? And two, are
14 your institutions actually actively using the complex
15 chronic care management codes today? So rather than
16 estimating shortfalls based on just what's printed in the
17 Federal Register, you're actually having experience by
18 using it. As Harold said and as our PRT report said, these
19 patients need complex chronic care management before,
20 during, and after their treatment for hepatitis C, and I
21 haven't gotten any sense -- and we've asked -- that that's
22 actually happening. So if somebody would try to handle
23 those two issues.

24 DR. FLUEGGE: So I can try to address your first
25 question. I think somebody on the call, on the phone, can

1 probably address whether they're being used or not.

2 So we actually -- we took the PRT's advice and
3 tried to cost this out based on our internal analysis to
4 see whether the combination of codes within the physician
5 fee schedule and the outpatient prospective payment system
6 could actually support the intervention as we've designed
7 it.

8 And what we've found was that in the initial
9 phase -- so this is the pretreatment phase, when care
10 coordination is at its most intensive effort -- the use of
11 monthly chronic care management codes is not sufficient to
12 support that effort, but then if you factor in that all
13 patients actually enter into Phase 2, that is to say, they
14 are treatment eligible, then hospitals and providers would
15 be able to recoup the entire cost of the intervention.

16 But the problem with that is not all patients
17 start treatment, and so as we've outlined in our final
18 written response to the PRT was there's about \$100 loss per
19 patient, and so we don't feel like that is -- we feel that
20 is enough of a deterrent that using the complex chronic
21 care management codes wouldn't be --

22 DR. BERENSON: But the complex chronic care
23 management code could be used for patients who don't enter
24 treatment, so okay.

25 DR. LITWIN: Paul Meissner, are you on the call

1 there?

2 MR. MEISSNER: Yes, I am. Hi. Good afternoon.

3 I'll just say this from the Montefiore
4 perspective. We have not billed for this, and because the
5 code takes the place of all levels of services and it can
6 only be assigned to Medicare patients, and so this has
7 always created an issue for us. And so it has not really
8 -- we really only get a Level 2 billing or a Level 4
9 billing, and so one level of billing is what we would be
10 allowed to do.

11 And it is done in the outpatient ambulatory
12 facilities, and in our state in New York, we are Article 28
13 clinics only. And so that is only a part of the Montefiore
14 enterprise. I mean, those are the parts that serve as our
15 Medicaid-serving facilities.

16 DR. BERENSON: But surely you're not asking for a
17 payment model from Medicare to pay for Medicaid patients,
18 are you?

19 MR. MEISSNER: No. No, no.

20 DR. BERENSON: Is that what you're doing?

21 MR. MEISSNER: No. No, no, no.

22 DR. BERENSON: But many of these patients are
23 Medicare duals, and I don't understand why you couldn't get
24 the CCM (Chronic Care Management) payments for that
25 significant population. In any case -- go ahead.

1 MS. BRESNAHAN: We understand that most
2 facilities aren't using the CCM codes at their. . . . that
3 they're difficult to implement and not easy to use.

4 DR. BERENSON: Well, that's what I was
5 suspecting.

6 And my supposition or at least view that in fact
7 a facility fee is going somewhere but not -- so you're not
8 using it, so it's not going anywhere, so never mind.

9 CHAIR BAILET: Grace.

10 DR. TERRELL: So one of the things that you
11 commented on was actually tying this to real outcomes and
12 having physicians benefit from that. I want to really pin
13 you down on that a little bit because I really think this
14 is a big, big issue.

15 So the cost of services is what we're actually
16 talking about right now, and there may be semantics. It
17 may be PRT got it wrong; PRT got it right; you're not using
18 the code that you could have, would have, should have,
19 whatever. But there's a cost to this service that you all
20 can measure and then figure out whether you're getting paid
21 adequately for it also. Okay. That should be a baseline
22 thing.

23 The thing that bothers me a lot is the idea that
24 the cost of services that happens to have an awesome
25 outcome ought to necessarily always be correlated with an

1 awesome payment if the cost recovered.

2 As I mentioned earlier, examples like
3 appendectomy, let's go -- I'm a general internist, so
4 there's a lot of things I do that probably have a big
5 outcome that maybe could be measured, like a vaccine or
6 something, for which the cost is in the Medicare fee
7 schedule covered. But it's not this big, big amount of
8 shared savings on top of that, that's related to outcome.

9 At the level of when you all were thinking about
10 this, which I think's a radical idea -- it may not be a bad
11 idea, but it's radical -- Did you think about the
12 implications of that? I'm talking about at a deep ethical
13 level with respect to trying to value what you're doing,
14 which has enormous value, in something that's not tied to
15 the actual cost of providing it, because it's a big deal.

16 DR. FLUEGGE: Yes. So, we did consider that. I
17 did consider that, but I really want to stress a point that
18 I think might have been overlooked in the PRT review
19 process, and that is there was -- I get the sense that
20 there was a hyper-focus on the amounts in the bonus payment
21 table, that these are huge savings that will be
22 distributed, and in reality, so we -- I included it in our
23 final written communication, an actual simulation of this
24 payment model in terms of what would potentially be the
25 outcomes, whether it's a bonus or a payback. And the

1 simulation for just using the Medicare beneficiaries and
2 accumulating all this data on their liver disease stage and
3 their age and the top performing clinics and INSPIRE
4 generate -- they met the benchmark, as we defined it here.
5 And they received about a \$340 bonus per patient for those
6 high-performing facilities. It depends on what you set the
7 savings rate at or the payback rate at, but these are not
8 intended to be tens of thousands of dollars in potential
9 bonuses.

10 DR. TERRELL: But there's nothing particularly in
11 your methodology that would prevent it from being tens of
12 thousands of dollars; for example, if 100 percent of the
13 savings over a lifetime. So it could be 1/1,000,000th of
14 what that number would be or it could be 100 percent of it,
15 right?

16 DR. FLUEGGE: Well, in theory, it could be 100
17 percent, but we would advise adding a cap to that --

18 DR. TERRELL: Okay.

19 DR. FLUEGGE: -- so that there isn't -- you know,
20 you can only go up to a certain level before -- I mean,
21 there's opportunity to grow and earn a higher bonus, but
22 then once you reached a certain cap, you can't go any
23 higher than that.

24 DR. TERRELL: Yeah. But the general principle is
25 in there, okay, that there would be an outcome payment

1 that's based on a total savings to the Medicare medical
2 system over time that's related to the outcome as opposed
3 to the cost of providing the service.

4 DR. FLUEGGE: Yes.

5 DR. TERRELL: Okay.

6 DR. LITWIN: I just wanted to say that hepatitis
7 C, again, is a public health crisis in that 20,000 deaths
8 per year, more deaths in 2007 for HIV, and the current
9 system and current paying models have not adequately
10 addressed. And so that's why we're -- this radical,
11 innovative model is necessary because, you know, we've been
12 working -- I've been working in this space for 17 years,
13 and patients are not getting cared for. Only 10 to 20
14 percent of people are getting care, and meanwhile, my
15 patients' average age -- 50, 55, 60 -- they're dying of
16 liver cancer. They're dying of -- they're not getting
17 transplants because they don't have the social support.
18 There's not enough organs out there. They're using drugs
19 or drinking alcohol.

20 And so I do think, just to separate a little bit,
21 I think there's a window. If we don't get this right in
22 the next 5 to 10 years, you know, our fellow Americans,
23 they're going to be dead. And these other conditions you
24 bring up, I'm not certain that there's the same barriers
25 that were seen, you know, with appendectomy, for instance.

1 DR. TERRELL: Okay. Let's talk about Pap smears
2 for a minute. Okay. If women didn't get Pap smears, there
3 would be a lot of people out there with cervical cancer
4 that are not there now. We've done tremendous things as a
5 result of this public health, private screening,
6 preventative care since 1940s, when it was first in place.
7 When that first came out, should those physicians have
8 gotten outcomes payments because it hadn't yet crossed the
9 system?

10 I mean, the issue is that you're talking about, a
11 current crisis with a new cure, it's not embedded itself
12 yet into the medical system with a solution that you all
13 have that's making a big impact. So this is a big deal,
14 but these are big questions with respect to how it ought to
15 be -- how it ought to be thought through above and beyond
16 hepatitis C because what if we -- what about the next thing
17 that comes out and the next and the next? That's what I'm
18 getting at.

19 You're saying it's a crisis now, so we ought to
20 do this, but there will be new crises. And one day, maybe
21 this will be routine care. So can you address that from
22 that point of view?

23 DR. LITWIN: Sure.

24 I'm just going to say one thing and starting
25 over, but I do think it potentially could be a model for

1 other important problems, whether it's on the prevention
2 side or treatment side, that are not being addressed
3 adequately, and thousands, tens of thousands of lives are
4 at stake.

5 But I'm going to turn it over to --

6 DR. WINTERS: Yeah. I just was thinking about
7 what you were saying, sort of the ethical side of having
8 this SVR as the outcome and paying based on that, and I
9 think Kyle has clarified that there can definitely be a
10 limit on that, so that people are not making this 100
11 percent of the possible bonus.

12 But I think, you know, I sort of like flipped it
13 a little bit to think about, "Why do we even need this when
14 we have had curative therapy?" In the testimony from your
15 expert, Dr. Goldberg, he noted that gastroenterologists do
16 not want to treat these patients, and they don't treat
17 these patients because there's a lot that comes with
18 treating the patients that they can't take on, that the
19 care coordinators in our model are taking on. And so I
20 think, you know, we are just trying to think of an
21 innovative way to get people interested in these patients
22 and to take something that's easily measurable with
23 electronic health records and to set a hospital facility-
24 level mark, and that can be adjusted down.

25 So if you have a clinic that serves 100 percent

1 in active injection drug users, you know you're not going
2 to get an SVR of 80 percent, so this can be adjusted in the
3 model.

4 But I think the ethical question for us is, you
5 know, we don't want to pay providers hundreds or thousands
6 of dollars to do this. We just want them to do it, so
7 we're trying to figure out how to motivate them.

8 DR. TERRELL: And a regular pay for performance
9 couldn't do that, performance not based on years lives
10 saved, medical treatment, just standard of care?

11 DR. FLUEGGE: Well, I think how we devised the
12 model was with a -- very much a population health
13 objective, and we wanted to base potential bonuses on that
14 as opposed to individual outcomes.

15 But I just want to add one other thing. You
16 mentioned about the outcomes-based payment, and I really
17 don't know of another payment model where testing that
18 approach would be appropriate because, like I said earlier,
19 we are focused on a cure, and there aren't -- there simply
20 aren't that many, at least now, hardly at all -- I don't
21 know of any -- that focus on that as the outcome.

22 And so if you were looking at our payment model
23 for a potential limited-scale implementation, I think it
24 really speaks to that kind of experimental approach to see
25 whether this outcomes-based reimbursement would actually

1 work and what kind of quality outcomes it can deliver.

2 DR. WINTERS: Just one more comment, is that I
3 think the precedent is already set with the pricing of the
4 medication, so -- I mean, we aren't the first to sort of
5 think about this and kind of what costs are averted, and
6 ours is a much smaller consideration.

7 CHAIR BAILET: Thank you.

8 Paul.

9 DR. CASALE: So I'm married to a hepatologist, so
10 that can be very dangerous because I have a little bit of
11 knowledge but maybe not enough to understand what I'm
12 talking about.

13 But you mentioned about supporting the tele-
14 monitoring of PCPs. So it's my understanding that at least
15 there's this movement. As you said, the
16 gastroenterologist, the average gastroenterologist may not
17 be interested or is not interested in treating, but there's
18 been this sort of movement to train the nurse practitioners
19 in particular, internal medicine, as you've mentioned.

20 So I guess I'm looking for some comments. Isn't
21 there already a movement to -- whether it's not necessarily
22 tele-monitoring, but develop team members, nurse
23 practitioners, specialists in particular to help do all of
24 the things that you are describing to do in this model in
25 terms of improving treatment rates, helping to coordinate,

1 get the authorization for the right medicine, all the
2 things that are difficult to do but need to be done?

3 DR. LITWIN: That's a great question.

4 The fundamental problem is that the majority of
5 the patients who were affected, infected with this virus
6 and by this disease in the community were not even yet
7 engaged in care, and so to move patients from Point A to
8 Point B out of their kind of place or their neighborhood
9 and their patient-centered home where they get their care,
10 whether it's a drug treatment center or an HIV clinic, ID
11 (infectious disease) clinic, or an FQHC, that's where the
12 patients are comfortable. And when we've looked at
13 referring people to capable people, whether they're nurse
14 practitioners or hepatologists to another place, where they
15 might not have wrap-around services, the cascade of care is
16 just dismal.

17 So I do think it's a piece of it, and that's part
18 of it, but that's not going to get us to where -- that's
19 been happening for some time, and that won't get us to
20 where we need to go.

21 Dr. Perumalswami or Dr. Weiss, do you have any
22 comments on this question?

23 DR. PERUMALSWAMI: Alain, this is Ponni
24 Perumalswami from Mount Sinai.

25 I would completely agree with you. I think

1 definitely figuring out ways to engage these patients,
2 where they reside is a really important part. One of the
3 strengths really of the tele-educational piece to this
4 model, where we could really work with primary care
5 physicians in the community, where these patients are
6 located, to engage them and really get them optimized
7 before we start them on treatments or health promotion and
8 then coordinate their care and get them initiated and
9 through treatment to cure.

10 MS. BRESNAHAN: And I just wanted to add that
11 with this model, we were really looking at cost savings,
12 and we found that care coordinators are less expensive than
13 other health professionals, and they're often -- we
14 recruited them from the communities. Many of them are
15 bilingual. They speak Spanish. They know the
16 neighborhoods, and we found it so effective in helping
17 these patients. And yet really their cost is minimal in
18 terms of -- than other people. The other health care team
19 can work to the level of their license rather than doing
20 the kind of health promotion and other work that the care
21 coordinators have done in our work.

22 DR. LITWIN: I just want to point out that Dr.
23 Perumalswami is a transplant hepatologist at Mount Sinai.

24 DR. CASALE: Great. That's helpful.

25 And just one other, Jeff, if you don't mind.

1 Thinking not just in New York or in a big urban
2 center, but thinking of hep C nationally -- and as you
3 mentioned, it's the baby boomer population, and again, a
4 little bit of knowledge may not be a good thing. But
5 there's a lot of baby boomers who may have done a little
6 bit of IV (intravenous) drugs back in the '60s, and they've
7 gone on and they don't realize that they have hep C. And
8 you're trying to get to them too, right? So they don't
9 have necessarily the complex -- you know, the mental
10 health, the ongoing IV addiction, et cetera, and this would
11 be for that group as well, presumably.

12 And so in the whole sphere of hep C treatment for
13 U.S., what percentage makes up the very complicated sort of
14 metropolitan New York versus this other group? Which is
15 they don't know they have hep C. We're trying to get them
16 in. They are identified. They get treated, and off they
17 go because they don't have all of that. So I'm trying to
18 understand that issue.

19 DR. LITWIN: I think, you know, it's certainly a
20 mixed bag here. I think setting up a system like this, and
21 a model, will incentivize institutions to incorporate, you
22 know, a cohort screening within the EMR (electronic medical
23 record), and, you know, things that we've done at
24 Montefiore and Mount Sinai, so that we can pick up those
25 people that are otherwise, you know -- before they get

1 cirrhosis, and unfortunately we see these patients all the
2 time. Our model also accounts for the two different
3 bundles. I don't know if you went into that, Kyle, yet?

4 DR. FLUEGGE: Yes.

5 DR. LITWIN: Go ahead.

6 DR. FLUEGGE: So yes, the two-bundle definition
7 is intended to address that issue, and I can't quite speak
8 to the proportion, in terms that you're requesting, but,
9 yeah, the bundle two, the less-complex patient, is intended
10 to be at a reduced cost, and, like I say, have potentially
11 higher quality metrics associated with it, you know, less
12 risk adjustment because, like you say, you know, these
13 patients did drugs one year in their life and, you know,
14 have been straight -- on the straight and narrow since.

15

16 So, yeah, the two-bundle approach is how I --

17 DR. LITWIN: And increasingly across America, you
18 know, clearly there are pieces that are undiagnosed and
19 that would be a great outcomes that they get diagnosed and
20 into care, and won't need the level of services. But many
21 of the people that don't have those comorbidities, who, you
22 know, maybe had in the distant were cured, and so now we're
23 trying to work with the 80 percent of patients who do have
24 comorbidities who will really need these models of care.

25 And it is the majority in urban centers, but beyond that,

1 you know, suburban and rural areas as well.

2 DR. FLUEGGE: There is that significant under-
3 diagnosis problem with hepatitis C. So I don't think -- I
4 think even if we gave you any kind of initial idea, we
5 could be wrong.

6 DR. PERUMALSWAMI: This is Ponni Perumalswami,
7 hepatologist from Mount Sinai. You know, data from the
8 National Academy of Medicine and Centers for Disease
9 Control and Prevention still estimates that, you know, 50
10 percent of people have not yet been successfully diagnosed
11 and transitioned into care. So I do think that what we've
12 certainly seen at centers such as ours, where we do see a
13 number of patients with hepatitis C, a large majority of
14 the patients who we are now having to engage do have a lot
15 of active comorbidities, psychosocial issues, and really,
16 you know, from a clinical standpoint, can benefit from
17 really having care coordination models integrated into
18 their care, so that they can be referred to other social
19 services, make sure that they make their other appointments
20 in order for them to prioritize hepatitis C care,
21 evaluation, and management. So I do think that's an
22 important piece to this.

23 DR. WINTERS: I'd just like to add one more
24 thing, just, again, in regard to Dr. Goldberg's comments.
25 So I think that patients who appear at a private

1 hepatologist, at a medical center like University of
2 Pennsylvania, or who, themselves are now getting
3 transplants -- so those are the populations that he was
4 referring to -- those patients, you know, who are
5 presenting themselves for care and are making it to the
6 appointments, I think we feel like a lot of those patients
7 in New York have been treated. So the very private
8 hepatologists are not seeing the same volume that they saw
9 a couple of years ago.

10 On the other hand, patients who are in substance-
11 use programs, or in opioid replacement therapy, patients
12 who are not yet diagnosed but have known substance-use
13 issues, and homeless and other communities, I think these
14 are the patients that we want to treat where they are or
15 where they're comfortable being, and not just for
16 themselves but to prevent transmission. I think that's a
17 really major, an important piece of all of this.

18 So I think patients who have been easy to treat,
19 many of those patients have been treated.

20 DR. LITWIN: And we really need this model now to
21 address -- you know, in some of our Sinai clinics and
22 Montefiore clinics we've treated many of our patients, but
23 just across the country, in FQHCs and substance use
24 treatment programs there's, you know, hundreds and
25 thousands of patients that are sitting around, progressing

1 to cirrhosis, and it's -- you know, we need to incentivize
2 and motivate our providers through an innovative model, is
3 our belief.

4 CHAIR BAILET: Thank you. Tim?

5 DR. FERRIS: So I'm going to ask you a question
6 that's based on the notion of if you were in our shoes. So
7 clinical model, outstanding. Absolutely critical public
8 health problem, and you've got a clinical model that
9 addresses that, and I haven't heard anything here that
10 disputes how fantastic your clinical model is. Most of the
11 discussion is about the payment model.

12 And I want to ask you, so the CCM codes are
13 difficult to implement. We've implemented them and it took
14 us years after they were first rolled out. If -- and say
15 the CCM code were simplified and you could bill it -- and,
16 by the way, just to clarify a comment that was made by
17 someone on the phone earlier. You definitely can bill for
18 services in addition to the CCM code. That is the intent
19 of the CCM code. It's care coordination services on top of
20 the usual services.

21 So if such a code existed and it was usable, and
22 it fully reimbursed the costs -- and this is where the put
23 yourself in our shoes -- if that existed and that was
24 applicable to heart failure, COPD (chronic obstructive
25 pulmonary disease), all the other things that both require

1 significant adherence issues -- daily Lasix, volume status
2 up and down, same set of issues -- and the care
3 coordination issues, but was based on more of a cost-plus
4 model, which is more of a standard way to think about
5 here's your costs and then there's some incentive that's on
6 top of it, to make sure that people are excited about doing
7 it, right. Now, I'm not going to represent that the CCM
8 code necessarily does that, but it is existing, and they
9 actually have changed the rule. They've simplified the
10 rules related to its use and clarified some things over
11 time, which is the standard way policies work in the world.

12 If such a code did meet these needs, would it
13 might be your first choice for a national policy related to
14 how to address this issue?

15 DR. FLUEGGE: I can speak to that. No, is my
16 short answer, and the reason is because our model is not
17 specifically a care coordination-only model. And I think
18 we're at fault, to some degree, because in our original
19 proposal we didn't emphasize this enough. But there is a
20 significant tele-mentoring component that is very
21 instructive for how we expand access to care. And beyond
22 that, I've heard -- I've watched you guys online before --
23 and I've heard this mentioned before, that, how can we --

24 MR. MILLER: So, what did you think?

25 [Laughter.]

1 DR. FLUEGGE: I have to admit it, though. It was
2 enthralling to watch.

3 [Laughter.]

4 DR. FLUEGGE: Oh, bravo. Fantastic. But you all
5 have mentioned that it would be ideal to sort of have these
6 various payment models and accumulate the best attributes
7 of some of those.

8 So, what the tele-mentoring component provides in
9 our model is not only a way to train primary care
10 physicians for treatment of hepatitis C but it is bigger
11 than that. It could include PCP training and mentoring for
12 other complex chronic conditions that currently are not
13 being reimbursed within CMS, according to the Social
14 Services Act.

15 So we really think that, you know, unfortunately
16 we didn't emphasize it enough in our original proposal, but
17 we really think that's on par with the value that care
18 coordination offers. So I would say, again, no.

19 CHAIR BAILET: Harold.

20 MR. MILLER: So, Tim and I are thinking along
21 similar lines. So if the CMS administrator were to show up
22 on your doorstep tomorrow and say, "We really like what
23 you're doing. We'd like to offer you a \$700 per payment,
24 patient payment, that you can use for tele-mentoring and
25 for care coordination, and we'll give you a \$200 bonus if

1 you successfully hit SVR status for the patient, and we'll
2 give you another \$200 bonus if you keep their rate of ED
3 and hospitalization below an average level," would that
4 support your program?

5 DR. FLUEGGE: I don't think so. It's not -- I
6 mean, this was --

7 MR. MILLER: It sure sounds like it's paying for
8 the cost. It's giving you the incentive to be able to get
9 people to complete treatment. It's giving you the
10 incentive to manage their care effectively.

11 DR. FLUEGGE: But it's not transparent, and
12 here's why. You're throwing numbers out there as if, you
13 know --

14 MR. MILLER: You can change the numbers.

15 DR. FLUEGGE: Right. But we wanted to create a
16 payment model that was based on actual claims and clinical
17 data that would suggest the value of an SVR. And, you
18 know, the \$200, well, what --

19 MR. MILLER: I understand what you want. I'm
20 just asking you a separate question.

21 DR. FLUEGGE: Right.

22 MR. MILLER: If somebody came to you with that
23 model tomorrow and said, "Here it is," would it support
24 your program, which I understand the funding has ended for.
25 If somebody came and said, "We'll give you \$700 per

1 patient, and we'll give you a bonus for success, and we'll
2 give you a bonus for reducing ED visits," would it support
3 the continuation of the good work that you're doing?

4 DR. FLUEGGE: I would think it probably would.

5 DR. WINTERS: Is somebody coming to offer us that
6 plan?

7 MR. MILLER: We are hoping that someone will come
8 and offer someone something, based on what we do here, but
9 we need to figure out what it is that we're doing first.

10 CHAIR BAILET: All right.

11 DR. WINTERS: I would just also add that, you
12 know --

13 MR. MILLER: We'll bring you, at most, one \$700.

14 DR. WINTERS: -- just to be able to answer a
15 question like that is really challenging. I mean, I think
16 you can tell that Kyle has spent a lot of time thinking
17 through and doing a lot of analytical work, so it's a
18 little bit challenging to be able to say "yes" or "no" to a
19 theoretical question like that.

20 MR. MILLER: I understand that. So just one
21 quick follow-up. I mean, you said that the costs that you
22 needed to support were roughly \$700 per patient, or so on,
23 right? The rest of it was, quote/unquote, "an incentive."
24 So I'm simply asking, you are doing good work, you need to
25 be able to cover that cost. We can debate about whether

1 the chronic care management code does or doesn't do it, and
2 whatever. I'm just saying that if, in fact, that's what it
3 costs -- because at least from my perspective, I understand
4 what you're trying to do and I think there's some merit in
5 thinking about how you price an incentive, based on
6 something.

7 But, fundamentally, what we're trying to deal
8 with is if there is good care to be delivered that cannot
9 be supported under the current payment system, what is the
10 nature of the payment that needs to be able to be done to
11 do that? And if we get into really complex incentive
12 models and payment amounts that are unnecessarily
13 complicated, that your whole thing falls apart because you
14 didn't achieve some ideal that you wanted when we could
15 give -- because somebody might say, "It's worth \$700,
16 right? We agree and we're going to give you an incentive
17 to make sure that you achieve the outcome. Be done with
18 it." And if that would work, then --

19 DR. WINTERS: I think when we started thinking
20 about that, that wasn't something that we had available to
21 us. So I think that we're trying to think creatively about
22 it.

23 CHAIR BAILET: Bob?

24 DR. BERENSON: Yeah. Just a couple of points.

25 One is, to just pick up on Kyle's point, the -- we -- about

1 a year ago I did a disclosure here that I was doing work
2 with Project ECHO, and I was actually disappointed that
3 this proposal really didn't emphasize tele-mentoring. And
4 we didn't explore it, and tele-mentoring might be a very
5 good payment model that we would -- I mean, a delivery
6 model that we would want to support.

7 The presentation -- I mean, the proposal
8 basically -- even the title of it is "Using Care
9 Coordination." It wasn't part -- it was mentioned. It was
10 sort of a given that we do tele-mentoring, and we need care
11 coordination support. So that's point number one, and if,
12 in fact -- so I think that would be a different proposal,
13 actually, if it was emphasizing tele-mentoring.

14 And then the second. I've got a real problem
15 with the fact that the administrations, apparently, of
16 these two institutions have found the complex chronic care
17 code too difficult to work with. It got a lot simpler in
18 2017. A place like Partners is able to do it.

19 [Laughter.]

20 DR. BERENSON: These are patients who not only
21 need care coordination for their hepatitis C treatment, but
22 as the PRT emphasized, they should have ongoing care
23 coordination because they have -- by far the leading cause
24 of hospitalization in patients with hepatitis C is
25 psychosis, and you can go down the list of non-liver-

1 related conditions that these patients have. Sixty-seven
2 percent of them are on Medicare for disabilities, not
3 because they aged in, and yet these two institutions
4 somehow can't bill for the code and can't otherwise
5 support, so that you're going to lose \$98. I just find the
6 whole thing --

7 So I don't think you're asking for a new payment
8 model. I think your savings thing is a new payment model,
9 which a lot of us have expressed some concerns about. But
10 care coordination is not a new payment model. In Medicare
11 it may be too complicated, it maybe should be simplified.
12 You're just looking for some cash flow, and that's my
13 concern. I think that's the issue here, is that -- now
14 tele-mentoring would be new, but just figuring out how to
15 send a check for care coordination strikes me as not
16 innovative.

17 CHAIR BAILET: Thank you, Bob. Elizabeth.

18 VICE CHAIR MITCHELL: Thank you. I also want to
19 compliment you on what is obviously excellent and important
20 work.

21 I guess I would just note that I think a
22 significant portion of our conversation is talking about
23 elements of the proposal that aren't actually in the
24 proposal, that they could have, or should have, or would
25 have been, or Harold's going to go to your institution and

1 write you a check? I don't know. But I think that there's
2 clearly merit here. The fact that we're actually talking
3 about a cure at all is remarkable. But I guess I would
4 just suggest that we needed to keep this to the actual
5 proposal in front of us, and I think that we might need to
6 move to public comment.

7 * **Comments from the Public**

8 CHAIR BAILET: Your timing is impeccable,
9 Elizabeth, because I see no other placards up, and that's
10 the next move.

11 We have two people on the phone. Yeah, so maybe
12 before we start we're going to ask you guys to return to
13 your seats. That would be great. And thank you, again.
14 Thank you for coming, and we appreciate all the dialog.

15 So we have two people on the phone, and as
16 they're taking their seats, the first person is Annette
17 Gaudino, Treatment Action Group, and we're going to go
18 ahead and, please, you have three minutes to make your
19 comments. Thank you.

20 UNIDENTIFIED SPEAKER: Three minutes.

21 CHAIR BAILET: I said three.

22 UNIDENTIFIED SPEAKER: I thought you said 30.

23 CHAIR BAILET: No, no. I said three. I said
24 three. Some might have heard 30.

25 Please, go ahead. Thank you.

1 MS. GAUDINO: Good afternoon, everyone. Thank
2 you for providing me the opportunity to make a public
3 comment. I apologize for the background noise. I had to
4 sneak away to participate. I will also submit comments in
5 writing.

6 I'd like to just speak in strong support of the
7 payment model and the work that's being done by the New
8 York -- sorry, by New York City DOHMH. I truly believe
9 that care coordination is the evidence-based intervention
10 that we need in order to scale up hepatitis C treatment and
11 to start to move towards elimination of hepatitis C as a
12 public health threat, which the WHO (World Health
13 Organization) has set as a target, and which we think is
14 feasible in the United States and in New York State.

15 I believe that the piece that the payment model
16 is trying to address, the care coordination, which has been
17 discussed, is something that the other health care
18 paraprofessional can do is that kind of one-on-one
19 interaction with patients that not only can help them deal
20 with their other health needs but them engaged in care, to
21 know that there is cliff, two cliffs in the care cascade.
22 First is diagnosis. Second is getting people started on
23 treatment, and with all the barriers that exist for
24 treatment, but particularly with patients who are dependent
25 on the public health care system for their care.

1 I really appreciate the comment that was made
2 about a significant number of patients who haven't aged
3 into Medicare but are actually -- have a disability
4 diagnosis, and that is how they are getting their care
5 through the Medicare system. These are patients that have
6 a lot of needs, and a care coordination model can meet
7 those needs. I think it's a really creative way to price
8 into the health care system care coordination and that kind
9 of extra support.

10 I appreciate the comments that have been made in
11 terms of, you know, the details of that payment model and
12 how you balance the cost and sustainability of that care
13 versus just a pure incentive. Smarter minds than mine can
14 speak to those details, but I think the overall direction
15 and approach that has been taken in New York City and New
16 York State has been one that we really want to build on and
17 want to encourage.

18 So, again, I just want to wrap up and say I
19 strongly support, and Treatment Action Group strongly
20 supports this payment model and we really hope that CMS
21 will take a good look at this payment model and consider
22 supporting it, not just for hepatitis C but for other
23 chronic conditions, particularly with marginalized patients
24 and patients that struggle with psycho-social issues.
25 Thank you very much.

1 CHAIR BAILET: Thank you. The next person on the
2 phone is Edwin Corbin-Gutierrez from the National Alliance
3 of State and Territorial AIDS Directors.

4 MR. CORBIN-GUTIERREZ: Hi. Can you hear me?

5 CHAIR BAILET: Sure, we can.

6 MR. CORBIN-GUTIERREZ: Thank you. I would like
7 to start by thanking the Physician-Focused Payment Model
8 Technical Advisory Committee for the opportunity to share
9 comments on Project INSPIRE, led by the New York City
10 Department of Health and Mental Hygiene.

11 NASTAD is the association that represents public
12 health officials who administer HIV and hepatitis health
13 care, prevention, education, and supportive service
14 programs in state, local, and territorial health
15 departments. NASTAD works closely with health departments
16 across the country to build sustainable financing
17 mechanisms to provide access to hepatitis C prevention and
18 care and its related support services. And hepatitis and
19 health systems integration programs at NASTAD collaborate
20 to increase the coordination across public health programs,
21 to leverage existing infrastructure and expertise, to
22 improve health outcomes, identify strategies to maximize
23 public and private insurance coverage options, and identify
24 promising practices to engage health care systems and
25 payment delivery and evaluation mechanisms that will

1 support health outcomes for individuals living with
2 hepatitis C.

3 As has been mentioned, more Americans now die as
4 a result of hepatitis C infection than from 60 other
5 infectious diseases reported to the CDC (Centers for
6 Disease Control and Prevention) combined, and we also know
7 that in over just five years, the number of new hepatitis C
8 infections reported to CDC has nearly tripled, reaching a
9 15-year high.

10 Yet despite the looming public health crisis that
11 this epidemic poses, there is much more that we can do as a
12 nation to ensure that we are deploying the most effective
13 models for care, to ensure that vulnerable populations
14 living with hepatitis C have access to a cure.

15 And given the prevalence of hepatitis C and the
16 rising mortality stemming from the epidemic, particularly
17 among baby boomers who make up a significant portion of the
18 Medicare population, Medicare payment models must ensure
19 that patients are linked to care, retained in care, and
20 adherent to treatment. Models that provide financial
21 incentives for care coordination activities are critical to
22 ensuring that the most vulnerable populations infected by
23 the epidemic have the support they need to achieve a
24 sustained virologic response to treatment.

25 From our experience with HIV care through the

1 Ryan White HIV/AIDS program, we understand how important
2 comprehensive care coordination and service integration
3 models are to supporting individuals living with HIV to
4 achieve viral suppression.

5 NASTAD applauds and unequivocally supports
6 Project INSPIRE's integrated model of primary care,
7 addiction medicine, and infectious disease providers, and
8 believes that this model has great promise for Medicare and
9 other health care payers. By incentivizing an
10 interdisciplinary approach to hepatitis C prevention and
11 treatment, including through an innovative care
12 coordination plan, we believe that this model will also
13 support hepatitis C elimination plans across the country.

14 Furthermore, Project INSPIRE's effort to screen
15 for comorbidities and its strategies to leverage the public
16 health surveillance program is a great example of how
17 public health and health care providers can work in close
18 collaboration to reduce costs and improve individual and
19 population-level health outcomes.

20 To conclude our comment, I want to reiterate how
21 critical Project INSPIRE's model of care coordination is
22 for vulnerable Medicare beneficiaries infected by hepatitis
23 C to successfully navigate a complex health care system to
24 complete their treatment, and NASTAD urges the Committee to
25 expand coverage for these essential services through the

1 Medicare program.

2 Thank you.

3 CHAIR BAILET: Thank you.

4 Any other comments? Folks on the phone? Folks
5 in the room?

6 [No response.]

7 * **Committee Deliberation**

8 CHAIR BAILET: Okay. So, as a Committee, are we
9 ready to move forward with deliberations? Yes.

10 All right. So let's go ahead and start with
11 Criterion 1 and just note that Dr. Kavita Patel is not
12 participating in this vote, so there will be 10, not 11
13 folks voting.

14 Matt the Magnificent.

15 [Pause.]

16 * **Voting**

17 CHAIR BAILET: There we go. I'm feeling it.

18 [Electronic voting.]

19 CHAIR BAILET: Alrighty. So just to reiterate,
20 on the voting, 1 to 2, Numbers 1 and 2 do not meet; 3, 4
21 meets; 5 and 6 meets and deserves priority consideration.
22 You also see an asterisk, which indicates not applicable.
23 That is another element, which we haven't discussed. We
24 touched on it a little bit this morning, but will become
25 more relevant as we get into the proposals later in the

1 day. But it is there, and it is available.

2 So, we are going to go ahead and start voting on
3 Criterion 1, which is Scope, which we see as a high
4 priority that directly address an issue in payment policy
5 that broadens and expands the CMS APM portfolio or includes
6 APM Entities whose opportunities to participate in APMs
7 have been limited. So, we're ready to vote on scope.

8 Here we go. Ann?

9 MS. PAGE: Zero Committee members have voted 5 or
10 6, meets and deserves priority consideration. Zero members
11 have voted 4, meets; five members voted 3, meets; five
12 members voted does not meet. According to the rules of the
13 Committee, we need a simple majority of six members, six
14 votes to determine a category, so that will roll down to
15 does not meet, unless you want a revote.

16 CHAIR BAILET: I believe this is an opportunity
17 for us as a Committee to discuss it and then revote for
18 sharing points of view, and I see that Harold is activated.
19 Harold?

20 [Laughter.]

21 MR. MILLER: Activated. So what's the value of
22 that?

23 So I voted 3. The reason I -- I think we've all
24 struggled -- I certainly have -- with trying to rate the
25 criteria separately, and I -- part of the reason why I

1 asked the questions I asked earlier were that I think there
2 are at least two or three different pieces to this model.
3 Not clear to me that care coordination per se does anything
4 to expand the CMS APM portfolio for all the reasons
5 described earlier, but something that's designed to be able
6 to get people to take their hepatitis C medication,
7 particularly amongst a high-risk population does seem to me
8 to do that, something that enables hepatologists to
9 participate, something that enables PCPs to treat patients
10 with HCV, et cetera, all seems to me to be -- to broaden
11 the portfolio.

12 So whether one likes the payment model or not, it
13 does seem to me that if, in fact, there was the right
14 payment model that this would, in fact, expand the
15 portfolio. That's why I voted the way I voted.

16 CHAIR BAILET: Len?

17 DR. NICHOLS: So rather than line up and explain
18 why we voted for, I want to hear why somebody voted no and
19 then have 45 seconds to rebut.

20 I can't imagine, this is a population of great
21 need. They're not being addressed at the moment in New
22 York City. Jesus, how hard is this?

23 CHAIR BAILET: Well, so, Bob?

24 DR. BERENSON: Yeah. I would say that I would
25 give that credit under Criterion 2, Quality and Cost.

1 Here, the scope goes to whether this is a new payment model
2 that deserves high priority, and I guess some of us don't
3 think there's -- in what we've reviewed or liked, this
4 potentially is a -- I mean, clearly, the lines aren't clear
5 because payment model might be where that negative shows
6 up, but I don't think the scope -- so I would put what you
7 said and what Harold said in Number 2 is why, so we can
8 quibble.

9 CHAIR BAILET: I'm looking to Ann for
10 clarification.

11 DR. MEDOWS: I move that we re-vote.

12 CHAIR BAILET: Yes. We will re-vote, but I want
13 to make sure, before we get another outcome, where this is
14 going to go.

15 So help me understand because this is the first
16 time we've had a split like this.

17 MS. PAGE: Right.

18 So the decision rules say -- so we tend to roll
19 down, starting at the highest meets -- and deserves
20 priority consideration, meets, and then the third rule is
21 if the majority of votes are 1 or 2 or if the majority of
22 votes is 1 or greater but not 3 or 4 or 5 or 6, the
23 proposal does not meet the criterion, so that's what our
24 decision rules say.

25 But, of course, our decision rules allow for what

1 you all are just talking about. If there's a split, if
2 there's a significant disagreement, the Committee has the
3 option to talk about it and revote.

4 CHAIR BAILET: And I'm hearing, then, that we're
5 going to revote. One more time with feeling.

6 [Electronic voting.]

7 CHAIR BAILET: One more.

8 Well, that cleared it up.

9 [Laughter.]

10 CHAIR BAILET: Ann?

11 * **Criterion 1**

12 MS. PAGE: Zero Committee members voted 5 or 6,
13 meets and deserves priority consideration. Zero members
14 voted 4. Six members voted 3, meets. Three members voted
15 2, does not meet. One member voted 1, does not meet; and
16 zero Committee members voted not applicable.

17 A simple majority is six, and so six members have
18 voted that it meets this Criterion 1. That is the
19 Committee's decision.

20 CHAIR BAILET: Okay. We're going to go on to
21 Criterion 2, Quality and Cost, which is a high-priority
22 item anticipated to improve health care quality at no
23 additional cost, maintain quality while decreasing cost, or
24 both improving quality and decreasing cost.

25 Go ahead and vote, please.

1 [Electronic voting.]

2 * **Criterion 2**

3 MS. PAGE: Zero Committee members voted 5 or 6,
4 meets and deserves priority consideration. Two members
5 voted 4, meets. Seven members voted 3, meets. One member
6 voted 2, does not meet; and zero members voted 1 or not
7 applicable.

8 The majority finds that this proposal meets
9 Criterion 2.

10 CHAIR BAILET: Thank you, Ann.

11 Moving on to Criterion 3, Payment Methodology.
12 Pay the APM Entities with the payment methodology designed
13 to achieve the goals of the PFPM criteria addresses in
14 detail through this methodology. Medicare and other
15 payers, if applicable, pay APM Entities and how the payment
16 methodology differs from current payment methodologies and
17 why the physician-focused payment model cannot be tested
18 under current payment methodologies.

19 A high-priority item, please vote.

20 [Electronic voting.]

21 * **Criterion 3**

22 MS. PAGE: Zero members voted 5 or 6, meets and
23 deserves priority consideration. Zero members voted 4,
24 meets. One member voted 3, meets. Five members voted 2,
25 does not meet. Four members voted 1, does not meet; and

1 zero members voted not applicable.

2 The majority of Committee members have determined
3 that this proposal does not meet Criterion 3, Payment
4 Methodology.

5 CHAIR BAILET: Thank you, Ann.

6 We're going to go on to Criterion 4, Value over
7 Volume. Provide incentives to practitioners to deliver
8 high-quality health care.

9 Please vote.

10 [Electronic voting.]

11 CHAIR BAILET: Ann?

12 * **Criterion 4**

13 MS. PAGE: Zero Committee members voted 6, meets
14 and deserves priority consideration. One member voted 5,
15 meets and deserves priority consideration. Three members
16 voted 4, meets. Six members voted 3, meets; and zero
17 members voted 1 or 2, does not meet. And zero members
18 voted zero, not applicable.

19 The majority has determined that this proposal
20 meets Criterion 4.

21 CHAIR BAILET: Thank you, Ann.

22 Criterion 5, Flexibility. Provide the
23 flexibility needed for practitioners to deliver high-
24 quality health care.

25 Go ahead and vote.

1 [Electronic voting.]

2 * **Criterion 5**

3 MS. PAGE: Zero members voted 5 or 6, meets and
4 deserves priority consideration. Six members voted 4,
5 meets. Three members voted 3, meets. One member voted 2,
6 does not meet. Zero members voted 1, does not meet; and
7 zero members voted not applicable.

8 The majority finds that the proposal meets
9 Criterion 5.

10 CHAIR BAILET: Thank you, Ann.

11 Criterion Number 6 is Ability to Be Evaluated.
12 Have the evaluable goals for quality-of-care cost and any
13 other goals of the PFPM.

14 Please vote.

15 [Electronic voting.]

16 * **Criterion 6**

17 MS. PAGE: Zero members voted 5 or 6, meets and
18 deserves priority consideration. One member voted 4,
19 meets. Three members voted 3, meets. Five members voted
20 2, does not meet; and one member voted 1, does not meet.
21 And zero members voted not applicable.

22 The majority determined that this proposal does
23 not meet Criterion 6.

24 CHAIR BAILET: Thank you, Ann.

25 Criterion Number 7, Integration and Care

1 Coordination. Encourages greater integration and care
2 coordination among practitioners and across settings where
3 multiple practitioners or settings are relevant to
4 delivering care to the population treated under the PFPM.

5 [Electronic voting.]

6 * **Criterion 7**

7 MS. PAGE: Zero members voted 6, meets and
8 deserves priority consideration. One member voted 5, meets
9 and deserves priority consideration. Zero members voted 4,
10 meets. Seven members voted 3, meets. One member voted 2,
11 does not meet. One member voted 1, does not meet; and zero
12 voted not applicable.

13 The majority finds that this proposal meets
14 Criterion 7.

15 CHAIR BAILET: Thank you, Ann.

16 Criterion Number 8 is Patient Choice. Encourage
17 greater attention to the health of the population served
18 while also supporting the unique needs and preferences of
19 individual patients.

20 Please vote.

21 [Electronic voting.]

22 * **Criterion 8**

23 MS. PAGE: Zero members voted 5 or 6, meets and
24 deserves priority consideration. Four members voted 4,
25 meets. Six members voted 3, meets; and zero members voted

1 1 or 2, does not meet. Zero members voted not applicable.

2 The majority finds that the proposal meets
3 Criterion 8.

4 CHAIR BAILET: Thank you, Ann.

5 Criterion 9, Patient Safety. Aim to have
6 maintained or improve standards of patient safety.

7 Please vote.

8 [Electronic voting.]

9 * **Criterion 9**

10 MS. PAGE: Zero members voted 5 or 6, meets and
11 deserves priority consideration. Three members voted 4,
12 meets. Six members have voted 3, meets. One member voted
13 2, does not meet. Zero members voted 1, does not meet.
14 Zero members voted not applicable.

15 The majority finds that the proposal meets
16 Criterion 9.

17 CHAIR BAILET: Thank you, Ann.

18 And the last, Health Information Technology,
19 encourages the use of HIT (health information technology)
20 to inform care. Please vote.

21 [Electronic voting.]

22 * **Criterion 10**

23 MS. PAGE: Zero members voted 5 or 6, meets and
24 deserves priority consideration. One member voted 4,
25 meets. Nine members voted 3, meets; and zero members voted

1 1 or 2 or not applicable.

2 The majority finds the proposal meets Criterion
3 10.

4 CHAIR BAILET: Thank you, Ann.

5 Do you want to summarize on all 10 real quick?
6 Thank you.

7 MS. PAGE: The Committee found that the proposal
8 met 8 of the Secretary's 10 criteria. The two criteria
9 that the proposal did not meet is the payment methodology
10 and the ability to be evaluated.

11 CHAIR BAILET: Thank you, Ann.

12 I look to my colleagues before we vote on the
13 final recommendation, if there are any other additional
14 comments based on the voting. Are we ready to go ahead and
15 move into the --

16 [No response.]

17 CHAIR BAILET: Very good. So the way this will
18 work, we will vote initially electronically, and then we'll
19 go around the room individually and talk about our vote.
20 And included in those comments specifically, we're going to
21 record comments that we would like to be incorporated into
22 the letter to the Secretary, and we're going to make sure
23 that we take the appropriate time to bookmark those so that
24 there's no confusion after the fact, because we can only
25 deliberate in public, so --

1 MS. PAGE: And a reminder to those in attendance
2 that on this recommendation, the Committee's decision is
3 based on a two-thirds majority rather than a simple
4 majority, so we will need seven votes in favor of a
5 particular recommendation.

6 CHAIR BAILET: All right. So 1, we will not
7 recommend it to the Secretary; 2, recommend for small
8 limited-scale testing; 3, recommend to the Secretary for
9 implementation; 4, recommend the payment to the Secretary
10 for implementation with high priority.

11 And I'd like to clarify the differences between 2
12 and 3. While the wording -- 2 is if it's pretty much
13 untested or there are elements that are untested, where a
14 small -- smaller limited implementation would allow
15 learnings to be able to sharpen the proposal to a larger-
16 scale testing or larger-scale implementation. That was the
17 middle ground. Three, although you don't see the word
18 "testing" in 3, that doesn't mean that in the
19 implementation process, there wouldn't be a testing. It's
20 just the limited-scale testing that we wanted to call out
21 specifically in 2.

22 So, we are ready to vote, please.

23 [Electronic voting.]

24 * **Final Vote**

25 MS. PAGE: Zero members voted 4, recommend the

1 proposed payment model to the Secretary for implementation
2 as a high priority. Zero members voted 3, recommend to the
3 Secretary for implementation. One member voted 2,
4 recommend the proposed payment model for limited-scale
5 testing; and nine members voted 1, do not recommend
6 proposed payment model to the Secretary.

7 Those nine members constitute more than a two-
8 thirds majority, and so that is the recommendation of the
9 PTAC to the Secretary.

10 * **Instructions on Report to the Secretary**

11 CHAIR BAILET: Thank you, Ann.

12 I'd like to start with Rhonda. If we could then
13 speak to our individual votes. Thank you.

14 DR. MEDOWS: So I'm the sole 2 vote, recommending
15 -- What am I trying to say?

16 CHAIR BAILET: Limited-scale testing.

17 DR. MEDOWS: Yes, that's what I wanted to say.
18 Because I am most interested in naturally seeing put to
19 test the measures that are based on life years gained with
20 SVR and seeing a different way of taking a look at this
21 population.

22 CHAIR BAILET: Bob?

23 DR. BERENSON: Yeah, just a couple of points.

24 One is that this is one of a number of proposals we've seen
25 where the burden of trying to use the Medicare chronic care

1 coordination codes has come up. I think our comments
2 should reflect the -- I mean that fact and the need to see
3 if -- there have been improvements already, and some
4 institutions like we've heard are now moving to use those
5 codes. But it seems to me that we've had an inordinate
6 number of proposals to use for new payment models when
7 solutions may be found with changing the rules. So I think
8 we'd want to emphasize that and that that was one of the --
9 I hope there's agreement, one of the primary reasons we did
10 not recommend this.

11 And then the second thing I would say is it would
12 be great if we had proposals, more than one, on tele-
13 mentoring as a potential innovation that deserves its own
14 consideration as a payment model, and I am just wondering
15 if we are allowed today and whether we would be allowed
16 with some prospective changes in our authority to actually
17 send our solicitations for we would like to see proposals
18 on such and such a topic.

19 Are we allowed to do that rather than be passive
20 recipients of proposals that come in over the transom, to
21 send out a request for proposals on Topic A or B?

22 MS. PAGE: We would need to check with counsel on
23 that.

24 DR. BERENSON: You're shaking your head, Mary-
25 Ellen.

1 MS. STAHLMAN: I suspect not because PTAC, it's
2 not in your statutory charge to send out. An RFI (request
3 for information) or an RFP (request for proposal) would be
4 a government function.

5 DR. BERENSON: Yeah, yeah.

6 MS. STAHLMAN: So I'm guessing not, but we will
7 definitely follow up with general counsel and confirm back
8 with you all.

9 But I will say that there are other opportunities
10 for you to -- in your -- the material that you put on the
11 website, submitter's instructions or other documents, or
12 speaking engagements that you have as private and in your
13 own careers, that would allow you to encourage models, not
14 --

15 DR. BERENSON: Well, okay. I get that.

16 So I just -- I would like our report to the
17 Secretary to reflect the fact that in fact this was
18 presented as a care coordination proposal, was emphasizing
19 care coordination, and that we were interested more than we
20 had an opportunity to delve into the potential of broad
21 application of tele-mentoring as an innovation that needs
22 support, something like that.

23 CHAIR BAILET: Len.

24 DR. NICHOLS: So I voted to not recommend, but I
25 do so with a heavy heart because this population should be

1 addressed. I'd like those people involved when it gets
2 addressed, and what really breaks my heart is that they've
3 been doing it with this HCIA funding, and that's about to
4 die, and we're not going to be able to continue it in time.
5 So that's bad.

6 I would also say the main reason I voted no was
7 because I'm really worried about the principle of basing a
8 payment on projected savings that can be attributed to a
9 number of different activities. In this case, the real
10 savings is from the medication. I get that they wouldn't
11 get the medication without your intervention. That's why I
12 want you to be funded. But we can't base payment based
13 upon prospective value because then we're back to what's
14 the value of penicillin. It's pretty high. So we got to
15 be really careful about that. But it seems to me in about
16 an hour we could come up with a better way to work this
17 out, and Harold's already put together a possibility. It
18 just seems to me that I would say to the Secretary this
19 principle is important for us to establish, that we
20 shouldn't base things on future value of life saved, but
21 this population and these people need to be connected to a
22 payment model that will work. And I would be thrilled to
23 lay down some principles to make that happen, and I think
24 we should encourage the Secretary and the Department to
25 work out another alternative and have them come back with a

1 different proposal. That's what I would like to say.

2 CHAIR BAILET: Elizabeth?

3 VICE CHAIR MITCHELL: I'm on the same team. I'm
4 really supportive of the care model, concerned about the
5 payment model. Maine tried to fund a state health program
6 once with projections of avoided spending. Didn't work.
7 And I think that there are possible solutions that
8 hopefully will be found and would just recommend, I guess,
9 expedited attention to how do you fund a program with this
10 high clinical value.

11 CHAIR BAILET: I echo my colleagues' comments,
12 and the interesting -- This has a lot of merit. You have a
13 circumstance where the consequences of not treating these
14 patients is dire. On the flip side, treating them actually
15 leads to a cure, which is it's not every day in medicine
16 that we have those, both of those ends of the spectrum in
17 front of us, and so, clearly, to me that speaks to the
18 merit to move forward.

19 I, too, struggled with the payment part of the
20 model, and I want to make sure that we include that that's
21 an opportunity for the Secretary to potentially find an
22 avenue to recognize the work and the effort that this model
23 embodies. But given the model as it's constructed and
24 proposed today, I voted not to recommend it.

25 MR. STEINWALD: I don't have much new to add. I

1 agree with Bob we need to emphasize the use of the care
2 coordination codes. It seems like this is a population
3 that ought to benefit from the availability of those codes,
4 and if not, we should certainly find a way to fix them.

5 Second, I also agree with Len and others that to
6 base a payment on projected future savings is, I think,
7 fraught with difficulty, and the things that happened in
8 Maine could happen here as well.

9 I would also agree with emphasizing that it's a
10 population of great need, and with a potential cure for
11 many of those who are not receiving the appropriate drug,
12 there ought to be some suggestion in our language of our
13 report that the Secretary might seek other ways of finding
14 out how to diagnose and treat those patients.

15 CHAIR BAILET: Paul?

16 DR. CASALE: Yeah, I also said do not recommend,
17 but also like Len, you know, a bit of a heavy heart for a
18 lot of reasons. One is I'm old enough to remember when
19 there was no name to this virus. It was non-A, non-B. And
20 then they identified the virus, and then they used to treat
21 it with interferon, which was, you know, very difficult
22 treatment. And to have this cure in 6, 8, 10, 12 weeks is
23 unbelievable. And again, being married to a hepatologist,
24 I hear -- you know, I sort of relate and understand. So,
25 they are doing tremendous work.

1 In terms of ongoing -- they may potentially be
2 able to continue with trying the complex care management
3 codes, you know, in the interim, you know, once the grant
4 expires to see as an interim potentially. I had the same
5 issues around tying the shared savings to life years
6 gained.

7 And then, finally, to the tele-mentoring, I think
8 that should be an important part of our discussion with
9 this Secretary, and I think it really highlights the
10 critical issue of access to specialty care, which was
11 brought up, you know, amongst many fields. And so I think
12 we should use this opportunity to really emphasize that,
13 and tele-mentoring is a way to really approach that.

14 CHAIR BAILET: Thank you, Paul. Harold?

15 MR. MILLER: I voted to not recommend. I would
16 recommend that in our report we explicitly encourage the
17 applicant to come back with a revised proposal. I would
18 further recommend that we suggest to them that if they do
19 come back, that they describe a payment model in three
20 components, however they wish, but -- because I think we
21 heard there is a component of the model, which is designed
22 to get people to take and complete their treatment. There
23 is a component of the model, which is the tele-mentoring
24 thing, which has been discussed, which is how to reach out
25 to a broader range of primary care physicians for that

1 process, and there is a care coordination process for
2 patients, and they may or may not choose to propose all
3 three, I don't know. But it just seems to me that if -- my
4 recommendation would be if it comes back, it would be
5 helpful to see those things clearly articulated in those
6 buckets, because I found it very difficult to understand
7 kind of the mashed-together concept.

8 I would endorse and maybe put a fine point on it,
9 I do think that we need to say something in our report to
10 the Secretary about the continuing concerns that we have
11 heard here and that I have heard in other settings about
12 the care coordination codes, that they are either too
13 narrowly defined or too complicated to administer, et
14 cetera, which is, from everything I have heard, diminishing
15 their ability to achieve whatever it was that they were
16 supposed to achieve. And I understand the desire to try to
17 define codes narrowly, but it seems to me that it's not
18 working terribly well. And I think we in some fashion,
19 whether it's in the report or in a separate communication,
20 we should be asking applicants who want to do care
21 coordination to come in and clearly describe what they can
22 and can't do with those care coordination codes.

23 I am troubled by us suggesting that somehow
24 whatever someone wants to do could be squeezed into
25 existing codes when it can't. But I'm also troubled by

1 applicants coming in and saying, "No, we just don't bother
2 with those things. We want to have a different model for
3 it." And I do think that if someone attaches an outcome to
4 that, that is, in fact, different. If somebody has a care
5 coordination model that is accountable for outcomes, that's
6 different than what's in the fee schedule because there's
7 no accountability for outcomes there.

8 The third thing is I would like to have in the
9 report -- my colleagues may not agree with this, but I
10 would like to have in the report -- and if it's not in the
11 report, then I want to be on the record that I think it is
12 -- I am disappointed that the Center for Medicare &
13 Medicaid Innovation has funded many, many projects with the
14 Health Care Innovation Awards, which seem to have had good
15 results, and they're coming out to us with payment models.
16 We are getting no indication from CMMI as to whether they
17 think the payment model -- the project should be continued.
18 It appears that they are simply being allowed to disappear,
19 which the history of health care reform is littered with
20 these projects that were funded with one-time grants and
21 had wonderful results and then just disappeared. And the
22 notion that that is happening again and that they were
23 supposed to be -- it was an integral part of those programs
24 to develop a payment model. And the fact that people are
25 coming to us with payment models that are problematic

1 suggests that whatever was being done in those projects was
2 not being done well. And I think that those HCIA awards
3 need to have much closer coordination between us and CMMI,
4 and there needs to be a clearer statement from CMMI as to
5 whether or not they think those projects should continue,
6 because we're being stuck in this weird limbo of trying to
7 decide what needs to be done to support a project. But I
8 think we need to make a statement in there about the fact
9 that it is problematic that those projects are ending and
10 coming to us with no clear indication from CMMI as to
11 whether they have intentions with respect to them, whether
12 they think they should be continued or not, because we may
13 be getting more of them, and as everybody said, with a
14 heavy heart, it's unfortunate to be looking at a project
15 that's clearly ending its funding and maybe at a big
16 institution that can continue it for a while, but if it's
17 smaller institutions, it wouldn't be able to do it, and
18 that's a real problem to put on the burden of us to look at
19 something and say, well, it's not a good payment model,
20 but, gee, it'd be really sad if we're the ones that are
21 saying, no, you can't continue simply because you don't
22 have, you know, the exactly right payment model. So that's
23 what I would like to have in the report.

24 CHAIR BAILET: And, Harold, since you focused on
25 that, I think -- are there other points of view relative to

1 what Harold said? Because we want that to go specifically
2 in the letter to the Secretary. Any other additions? Like
3 I said -- Len, you've got a comment?

4 DR. NICHOLS: I'm with Harold a hundred percent,
5 and I think putting it in the Secretary's letter is the
6 place to put it. I would put it also in the class of
7 things like tele-mentoring that are things we should try to
8 encourage on a proactive basis. There must be other HCIAs
9 that are in different forms of death throes here. Let's
10 find out what they are and try to save some of them.

11 MR. MILLER: This is at least the third. I can't
12 remember for sure. I think we have at least three that I
13 remember right now.

14 CHAIR BAILET: Paul.

15 DR. CASALE: Yeah, no, I'm just -- I would also
16 support that, and anticipating what Harold said, we would
17 likely continue to see more as these grants sunset.

18 CHAIR BAILET: Elizabeth?

19 VICE CHAIR MITCHELL: I would pile on, absolutely
20 agree, and I think that that lack of clarity from CMMI is
21 actually creating stress and anxiety for those who are
22 trying to sustain a really important program. And I think
23 they really deserve some sort of clarity about how to
24 maintain the gains they've achieved.

25 CHAIR BAILET: And I think to sharpen the

1 message, I guess, because of what I'm hearing, I guess I
2 would ask the Committee, should this be -- should this be
3 portrayed as a unanimous perspective that the entire
4 Committee feels that this -- Grace?

5 DR. TERRELL: No [off microphone].

6 CHAIR BAILET: Okay. Very good. No.

7 DR. TERRELL: And maybe this is a little bit of a
8 different issue, but a lot of what I was hearing today was
9 about timing. You know, this may have been a little bit
10 early because they didn't have the results --

11 CHAIR BAILET: Right.

12 DR. TERRELL: -- completely done. So I don't
13 know, the Committee may be right that there's all these
14 projects that are -- have great outcomes for which they're
15 dying because there's not a process to go forward. So
16 they're saying, well, go to PTAC or whatever, and we don't
17 have the information. But before we put a unanimous, you
18 know, seal of approval on those comments, I think there
19 needs to be some qualification about is there a process
20 that could take into account something's winding down, but
21 the results of that tend to be a little bit later versus
22 what I'm hearing is almost the desperation that some of
23 these people have in getting something in place that's
24 ongoing.

25 So before we just sort of make the assumption

1 that the process needs something else, we need the
2 understanding if there was a mistake based on their urgency
3 that was related to this coming to us too early, if that
4 makes sense to you, relative to the outcomes and data that
5 would -- you know, because some of the information we
6 didn't get 'til after we had issued the PRT report, for
7 example.

8 CHAIR BAILET: Paul and then Harold.

9 DR. CASALE: No, I understand -- I recognize that
10 point, Grace, but I think part of the reality is they've
11 had this funding, they built the infrastructure, and now
12 they don't have the funding, but it's important work they'd
13 like to continue. So, even if the results have this -- now
14 lag, they're looking for a way to continue that work. So I
15 think that's the concern. We don't clearly have an
16 understanding from CMMI, you know, if they're going to
17 provide any -- what they're thinking.

18 CHAIR BAILET: Well, and to be fair, the results
19 aren't entirely -- they're not complete yet. The data's
20 not complete. Harold?

21 MR. MILLER: So that is not unique to this
22 project. I mean, the whole structure is -- they're all
23 done now, and we're going to wait for another year to find
24 the evaluation. And so do you say to people, "Gee, sorry,
25 you know, figure out how to continue your program for a

1 while until we get the evaluation results"? I think
2 preliminary evaluation results should say, okay, we need to
3 continue this until the final evaluation results are in.

4 I think the problem is we're being stuck in the
5 middle of any project like that is going to come to us for
6 continuation funding before there is definitive evaluation
7 information available, and that's the problem that I'm
8 trying to describe, is I think that it's a problem that
9 people are coming to us for a payment model with no
10 indication of whether or not it should be sustained from
11 CMMI, whether they have a payment model in mind, whether
12 they have been already thinking about doing the payment
13 model, because if you read the evaluation report, they've
14 been working on a payment model, and all of a sudden it
15 comes to us, and we get no signal whatsoever. That's the
16 issue, is I think that -- it is not -- if it were unique to
17 this project, it would be different. But it is common to
18 that program.

19 CHAIR BAILET: Okay. And, Grace, when you're
20 done with your comment, then we can finish up as well.

21 DR. TERRELL: He's got [off microphone].

22 CHAIR BAILET: Oh, my goodness.

23 [Laughter.]

24 CHAIR BAILET: I got left-sided neglect here.

25 Sorry, guys. Go ahead, Grace.

1 DR. TERRELL: Unless there is an implicit policy
2 change where they're wanting our analysis before they go
3 forward with something, and if that's the case, CMMI needs
4 to tell us that, which is a little bit of a different and a
5 nuanced -- not that folks were spontaneously just coming to
6 us out of desperation, but if they're being told, well, go
7 to PTAC now, or if they're feeling that, it would be nice
8 for some clarification from CMMI if that's the case,
9 because if we're part of a process, then we need to do it
10 in a much more coordinated way, and that I agree with
11 everybody on. But if this is just sort of random
12 spontaneous, "What do we do next? Well, let's go to the
13 PTAC 'cause, you know, we don't know what to do," then
14 that's something different. So some clarification on that
15 particular aspect from CMMI I think would be useful.

16 CHAIR BAILET: Thank you, Grace.

17 Rhonda, and then work our way towards Len.

18 DR. MEDOWS: [Unintelligible], I just wanted to
19 make sure that it's in the record, whether we agree about
20 the wording around CMMI or not, that the concern is not
21 only that the programs are not funded but there's the risk
22 of care disruption. That's what I heard from the
23 presentation today, and that actually causes me great
24 concern. I know that it's not in the purview of this
25 Committee to make decisions based on trying to preserve

1 care, but you cannot listen to this and not understand that
2 something has to be done, particularly when we know that we
3 have a cure.

4 CHAIR BAILET: Right. Thank you, Rhonda. Bob?

5 DR. BERENSON: Yeah, well, I wanted to pick that
6 up and repeat what I was implying earlier, is that I find
7 it remarkable that two not-for-profit institutions with
8 requirements for doing community benefits, given results of
9 a successful demonstration which saves lives, aren't
10 willing to carry this program for a year or two until
11 either the CCM codes are modified or a new payment model is
12 developed, that it's all on Medicare's payment to make this
13 whole. We're talking about chump change. And yet
14 apparently these terrific people are being asked to beg us
15 to have some interim payment because those institutions
16 somehow aren't able to continue funding. I just find -- I
17 wanted to have that in the record because I find that
18 unconscionable.

19 CHAIR BAILET: Len.

20 DR. NICHOLS: So I think what we got Grace to
21 agree to is asking CMMI for an inventory of HCIA projects
22 that are still extant and for whom there could be some --
23 and then the question about what is the plan for working in
24 the payment models that were part of the proposal. I would
25 observe every project has an evaluation that's going to be

1 formal and finished a year later, but all projects that are
2 multiyear -- and this was at least three years -- surely
3 have interim results that you can use to judge the
4 reasonableness of continuing.

5 I agree with Bob, in a perfect world, but we
6 don't live in a perfect world, and the do-gooders get cut
7 off when stuff stops flowing. That's what happens, even in
8 those big institutions. So I think the urgency is real.

9 DR. TERRELL: You got me to agree with that, with
10 the caveat that they make -- they make it explicit, whether
11 they see -- what they see our role in --

12 DR. NICHOLS: No, Grace. Grace, they don't get
13 to tell us what our role is. They get to tell us what
14 they're doing, and then we talk about how to navigate the
15 role.

16 CHAIR BAILET: All right. So thank you, guys,
17 for that.

18 Grace, we need you to go on record relative to
19 your vote, and Tim as well, so please.

20 DR. TERRELL: Yes, so I voted against this for
21 the payment model aspects. I think most of the reasoning
22 has already been well articulated by the others. There is
23 a couple of things that I heard that I think need some
24 comment on perhaps, and one of it had to do with the
25 concept of covering the cost of care versus I think it was

1 Kyle who said motivating physicians to do the right thing.
2 And that is a bit of a theme that I think that we will
3 either have had or will be getting from various payment
4 models with respect to care that in some cases evidence-
5 based, in some cases just a new model of care.

6 But we've got to understand our role in that.
7 The statute was about the physician-focused payment model
8 and to come up with new, innovative ways to think about how
9 physicians may be paid. We as a Committee, the way our
10 vote went, did not like this particular option that was out
11 there. But that issue is a pretty inherent and important
12 one. I actually think when it's easy for physicians, they
13 do do the right thing. Nobody's ever had to pay me to, you
14 know, give a vaccine so long as my cost of care and the
15 administration is covered and it's easy for me to do.

16 So the issue, as it was talked about with respect
17 to the difficulty of the chronic care codes, is relevant to
18 what makes it easy for physicians to do the right things
19 for patients. And if we can, as we're deliberating on
20 various things, come up with an approach to that, I think
21 we'll be doing a service not only to this, but it's going
22 to help us with other models that come up.

23 The second point that Dr. Litwin referred to was
24 related to this as a public health problem, and it is. And
25 one of the things that we have not talked about explicitly

1 is if this is a public health problem because we've got a
2 cure out there, there's a portion of the population that's
3 not getting it because of a public health policy issue or
4 because private or in this case government payment isn't
5 covering those services, then that may need to be thought
6 about outside of this particular Committee as it relates to
7 policy in terms of how public health is prioritized and
8 how, if anything, the way physicians are paid ought to be
9 part of the way we think about public health policy. We
10 haven't talked about that, but that may be something that's
11 important for us to think about.

12 CHAIR BAILET: Thank you, Grace. Thank you for
13 that. Tim.

14 DR. FERRIS: So my vote is not a surprise. But I
15 voted similarly. It was because of the payment model. I
16 want to associate myself particularly closely with Grace's
17 last comments. I think they were right on point. Our
18 presenters, who are doing amazing work, referred multiple
19 times to the Ryan White Act. I would say the Ryan White
20 funding is highly, highly successful, and does not use any
21 projected savings as the basis for the model. And so, as
22 just one example of the framing of the incentive, both the
23 cost and then what you need to do to incent, and it really
24 is around the infrastructure necessary to make it easy and
25 the right thing to do.

1 I do -- and also, so two more points. One is
2 Kyle, who I have to say it was so cool and creative what he
3 did, that I'm feeling a little bit as if I'm being, in my
4 sort of response to his model, I'm being overly
5 conservative, because I want to just acknowledge, that was
6 a really cool idea, to do that.

7 I will say, though, that he referred to it -- he
8 said, you know, someone else has done it. Private industry
9 did this when they were pricing Sovaldi, right. We're not
10 talking about private industry here. We're talking about
11 U.S. taxpayer dollars and the mechanism by which we
12 calculate incentives for U.S. taxpayer dollars. I think
13 that's a really different thing and a different set of
14 criteria that one would use to look at the basis, the
15 principle around the basis for payments.

16 I'm sorry. Two more things. One is this
17 separation of the screening from the care coordination
18 really is a separate issue. Screening should be universal.
19 There should be either pay-for-performance or mandated
20 rules around hepatitis C screening for the at-risk
21 population. We've required it in our health system for
22 several years. And so the screening piece of this really
23 -- I see as a different mechanism for implementation and
24 incentives than the others.

25 And then I just want to be clear, because -- so
This document is 508 Compliant according to the U.S. Department of
Health & Human Services Section 508 Accessibility guidelines.

1 that we're not all on record as being in agreement. So
2 Harold said that there are three different components or
3 phases. I wouldn't recommend coming back with this broken
4 into three parts. I prefer more of a lumpier than a
5 splitter. The three different activities that they talked
6 about are all part of what one needs to do to take care of
7 these patients, and we actually fund the ECHO model
8 underneath our care coordination activities because it's --
9 it's sort of part of it. So I'm not sure I would
10 necessarily say to anyone, you know, break this down into
11 the three components, because then the next one comes and
12 it's eight components, or whatever. I would say they've
13 identified adherence, mentorship, and care coordination as
14 critical pieces of this. I completely agree those are
15 critical pieces. I wouldn't necessarily come back with
16 funding for each of those separately. I'm not sure that is
17 the most productive way forward.

18 Thanks.

19 CHAIR BAILET: Thank you, Tim. Len, your placard
20 is up. Did you have a -- you were just testing me?

21 DR. NICHOLS: I'm nodding.

22 CHAIR BAILET: Very good. All right. So again I
23 want to extend appreciation to our proposer/submitters for
24 coming, participating, the folks on the phone who have been
25 here for the whole ride, and everybody's attention and

1 engagement as we work through the model.

2 Any other last points? Sarah, because this is
3 the report to the Secretary. You guys --

4 MS. SELENICH: Sorry.

5 CHAIR BAILET: It's okay. No, I got it. I got
6 it. Go ahead, Sarah.

7 MS. SELENICH: So you all were very clear on the
8 key points that you wanted to make in the report, so I
9 don't think I need to rehash them. But one area I would
10 like you to talk a little bit more about was on the care
11 coordination criteria. This is where the full PTAC
12 diverged from the PRT. And so if you could just provide
13 additional comments.

14 MR. MILLER: I don't understand.

15 DR. BERENSON: Yeah, if I could just summarize.
16 The PRT failed it on care coordination because the care
17 coordination for hepatitis C didn't seem in any way related
18 to care coordination for these patients ongoing. I mean,
19 you actually made this one before and after the nine-month
20 period. So the vote was not to have a problem with that,
21 and that's what you're asking about.

22 DR. NICHOLS: I think I learned things from the
23 presentation I didn't get from the proposal and the PRT
24 report, and so I was persuaded, they knew what they were
25 doing.

1 MR. MILLER: I would say this is maybe, yeah, one
2 more example of don't let the perfect be the enemy of the
3 good, is that it seemed to me that there ought to be more
4 care coordination than just during that period, but it
5 sounded like what was being done was helpful. It wasn't
6 clear exactly what all was being done there but it was
7 clear that the care coordinator was critical to that. And
8 so it seemed to me that it sort of met the threshold to say
9 there is clearly something good enough going on there
10 that's desirable. Maybe there could be more, maybe there
11 could be more, but it was enough of that, so at least
12 that's the way I looked at it.

13 MS. SELENICH: Great. Thanks. One other --

14 DR. TERRELL: One more aspect of it is, both of
15 the proposals that we have seen today have one thing in
16 common with respect to care coordination, which is they are
17 talking about it around the critical point in time with
18 respect to a disease and the potential overall outcome.
19 And I think when I was hearing the conversation today about
20 this one, it became more apparent in that, that's something
21 that perhaps we were thinking about it a different way at
22 the level of the PRT, which was, well, what about the
23 universe and beyond?

24 But one thing that I'm learning today from -- is
25 that there have been strategies around particular points in

1 time for which certain types of coordinating activities may
2 have an impact, and that is something that if you can get a
3 care model and a payment model right around those two
4 components, that are time-limited, that will be something
5 that I think that we should explore in detail as we go
6 forward.

7 CHAIR BAILET: Thank you, Grace, and --

8 DR. CASALE: Sorry. Just kind of --

9 CHAIR BAILET: Paul.

10 DR. CASALE: -- just one other comment, and
11 again, I think this goes back to the tele-mentoring part of
12 it, because, you know, when I asked about the -- you know,
13 the NPs treating and such, you know, the remark was a lot
14 of their patients don't want to leave their clinic to go
15 somewhere else, which I get. But by using the tele-
16 monitoring, now you can coordinate not just their hep C
17 care but, you know, their cardiology care and their heart
18 failure, et cetera, because now it's sort of coordinated in
19 sort of their home base.

20 CHAIR BAILET: Thank you. So we've completed our
21 process. I see Ann, Dr. Winters, up at the microphone, and
22 I can't read your mind so I don't know what you're going to
23 say. But, yeah, just -- but -- so -- all right.

24 DR. WINTERS: Sorry. I know this is probably not
25 the right procedure but we're taking advantage of having

1 all of you here. First of all, we just want to thank you
2 so much for thinking so carefully about this, but also we
3 did want to clarify, for the record, that our clinical
4 partners, Mount Sinai and Montefiore, have been extremely
5 supportive, and though they haven't been able to make use
6 of the CCM, the codes, they are continuing to support the
7 program through 340B pricing, but this is not a permanent
8 solution.

9 CHAIR BAILET: Thank you for that clarification.
10 I think it lifts a little of the heaviness. But you're
11 right, it's not a sustainable model going forward, so thank
12 you for that, Dr. Winters.

13 So we are going to take a 10-minute break and be
14 back for the remaining two models, to deliberate on. Thank
15 you, guys. Appreciate it.

16 [Recess.]

17 CHAIR BAILET: All right. We're going to go
18 ahead and reconvene. So the next proposal is Dr. Yang,
19 Medicare 3-year Value-Based Payment Plan, abbreviated
20 Medicare 3VBPP. Bruce Steinwald is the lead, and I'm going
21 to turn it over to Bruce to walk through the proposal
22 review team's recommendations.

23 MR. STEINWALD: Thank you very much.

24 CHAIR BAILET: Oh, I'm sorry. We have to do
25 introductions and disclosures, Bruce, but go ahead. You've

1 got the microphone.

2 **Zhou Yang, PhD, MPH: Medicare 3-Year Value-Based**
3 **Payment Plan (Medicare 3VBPP)**

4
5 * **Committee Member Disclosures**

6 MR. STEINWALD: I'm Bruce Steinwald. I have a
7 health economics consulting practice in Washington, D.C.,
8 and I have nothing to disclose on this proposal.

9 DR. CASALE: Paul Casale. Nothing to disclose.

10 MR. MILLER: Harold Miller, CEO of the Center for
11 Healthcare Quality and Payment Reform. Nothing to
12 disclose.

13 DR. TERRELL: Grace Terrell, internist at Wake
14 Forest Baptist Health and CEO of Envision Genomics.
15 Nothing to disclose.

16 DR. FERRIS: Tim Ferris, primary care doctor at
17 Mass. General and CEO of the Mass. General Physicians
18 Organization. Nothing to disclose.

19 CHAIR BAILET: Jeff Bailet, Executive Vice
20 President of Health Care Quality and Affordability with
21 Blue Shield of California. Nothing to disclose.

22 DR. MEDOWS: Rhonda Medows, EVP (Executive Vice
23 President), Population Health, Providence St. Joseph
24 Health.

25 DR. BERENSON: Bob Berenson, Institute Fellow,
26 Urban Institute. Nothing to disclose.

1 DR. NICHOLS: Len Nichols, Director of Center of
2 Health Policy Research and Ethics, George Mason University,
3 and I have nothing to disclose.

4 VICE CHAIR MITCHELL: Elizabeth Mitchell, CEO,
5 Network for Regional Healthcare Improvement. Nothing to
6 disclose.

7 CHAIR BAILET: Bruce.

8 * **PRT Report to the Full PTAC**

9 MR. STEINWALD: Okay. I'm going to give an
10 overview of this proposal, and I invite my fellow members
11 of the Preliminary Review Team -- Bob Berenson and
12 Elizabeth Mitchell -- to jump in whenever you feel like
13 jumping. Okay?

14 And I'm not going to go over the PRT composition
15 and role -- no, I'll do it. I'm not going to go over that
16 because we've done that enough. I am going to slowly go
17 over the composition of the proposal, however. I'm not
18 going to read the slide, but I'm going to take my time so
19 that you can read what the elements of this proposal are.

20 This is a proposal that essentially is for
21 restructuring Medicare in significant ways, at least on a
22 demonstration basis, for three years. Enrollment would be
23 open to beneficiaries 85 years or younger. You can read
24 the rest of that yourself. Each 3VBPP participant would be
25 given a Medicare spending account to cover services over

1 those 3 years. Each participant would be given options for
2 plan selection, and you can see what the nature of those
3 are: an HMO plan, a PPO, a high-deductible -- thank you,
4 Harold -- PPO plan, and a low-premium fee-for-service plan.

5 Covered services would include all traditional A
6 and B services. It could include prescription drugs and
7 other services. You can read the rest of that.

8 There would be an option to waive some premiums
9 and deductibles for plans to encourage patients to select
10 their plans; a financial reward for wellness care; reduced
11 Medicare contributions to premiums and reimbursement after
12 the initial account balance is exhausted if -- for high-
13 user beneficiaries; catastrophic coverage over the three
14 years if expending exceeds certain amounts during a
15 demonstration period. If there --

16 MS. PAGE: Click.

17 MR. STEINWALD: Oh, yeah, I didn't do it. Why
18 don't you do it?

19 So if there's a plan balance, in other words, if
20 the spending account isn't exhausted after three years,
21 what's left in the balance could be used to purchase
22 Medicare coverage in subsequent years.

23 There are opt-out provisions. Beneficiaries
24 don't have to opt in, and they can opt out at any time.
25 And then there's a financial reward for postponing Medicare

1 initiation until after age 65. And I hope you had enough
2 time to read all of those elements. Let's go on.

3 This is the first of what we have provisionally
4 termed within PTAC as an "atypical proposal," and you will
5 see that the PRT rated each of the elements of the
6 Secretary's criteria, each of the criteria as not
7 applicable. The reason for that is that the proposal is
8 extensive in its expansion of -- or in its creation of a
9 new set of benefits and participation rules for Medicare.
10 But what it doesn't have is a physician-focused payment
11 model. In fact, the proposal pretty much leaves payment up
12 to the plans and the beneficiary's selection of the plan,
13 and payment of the physicians within those plans would be
14 up to the plans. In other words, there's nothing in the
15 proposal that specifies exactly how payment would be
16 altered of the physicians. And because of that, we didn't
17 see a way that we could evaluate the proposal against all
18 of the Secretary's criteria individually.

19 A rationale for that is covered in the PRT report
20 under Item 3, Criterion 3, Payment Methodology. But the
21 same reasoning applies to each of the criteria. And we
22 came up with the term "not applicable" in large part
23 because we wanted to be -- we wanted a neutral term to
24 express our conclusion that this is not a proposal that we
25 think should fall within the purview of PTAC. And so

1 that's our rationale for the use of the term "not
2 applicable."

3 The other important thing that we concluded is
4 there is -- the PRT strongly believes that there should be
5 no suggestion implied by us or inferred by anyone else that
6 there's something about the proposal that we don't like
7 qualitatively. It may have merits, and there may be other
8 venues where a proposal of this nature could be evaluated.
9 We just don't think it should be within PTAC. But just to
10 emphasize that our conclusions on this, which would -- and
11 specifically the use of the term "not applicable" is not
12 meant to imply any qualitative judgment about the merits of
13 the proposal, only that we don't think it's appropriate for
14 PTAC to be reviewing it and recommending to the Secretary
15 either adopt it or don't adopt it. We think we should just
16 rate it as "not applicable" and go from there.

17 Bob and Elizabeth, would you like to add
18 anything?

19 DR. BERENSON: Yeah, I would just -- in the
20 proposal summary, there's 11 points of what this proposal
21 does and about eight of them are really restructuring the
22 Medicare program. The first two are a core where people
23 get a spending account to then choose between whether they
24 go into traditional Medicare, into what would be an updated
25 sort of Medicare Advantage program, and other alternatives.

1 This is a much broader notion than a physician-focused
2 payment model, is I guess what we concluded. And I would
3 reemphasize what Bruce said, is it may have terrific merit.
4 We don't know. We're not the right group of people to be
5 considering this proposal.

6 It is conceivable that CMMI would want to do a
7 demonstration of this, but this is not our strength. This
8 is not why we were empowered by the Congress to be -- to
9 assist in reviewing physician-focused payment models. This
10 is not a physician-focused payment model. It is a much
11 broader restructuring of how the Medicare benefits work.
12 It does have some elements that relate to physician
13 payment, but pretty marginal.

14 VICE CHAIR MITCHELL: The only thing I would add,
15 I think, again, to underscore we're not weighing in on the
16 merits of the proposal, just that it is beyond our
17 authority or scope or purview. I think there would likely
18 be several statutory changes required to implement this.
19 So I think it, again, just doesn't fit the physician-
20 focused payment model.

21 * **Clarifying Questions from PTAC to PRT**

22 CHAIR BAILET: Thank you. Thank you, Bruce.

23 Any other questions from the Committee for the
24 PRT? Tim?

25 DR. FERRIS: So this is just a comment and a

1 question for the PRT about our process, because this is the
2 first time that I think we've come to this - the PRT has
3 come to this conclusion. But I expect it won't be the last
4 time, and we're sort of making case law here about what is
5 and -- what we think is and is not applicable. But others
6 could disagree. We don't have -- and we are interpreting
7 regulations that were written, and I just wonder if the PRT
8 in choosing this process had concerns about how this might
9 -- how this process -- again, I'm not speaking about the
10 proposal at all -- how this process might be, A, you know,
11 problematic for us going forward, and, two, is there any
12 way -- and maybe this is directed at our staff and DFO. Is
13 there any way to clarify if our process -- or maybe you
14 already did this -- if this is a good -- does anyone else
15 think this is a good -- I mean, maybe we should put it out
16 for public comment. I'm just -- I'm just thinking about
17 setting -- setting -- what injury might we be causing by
18 choosing this process, and it may be none. And is there
19 any other way to get feedback about whether or not this is
20 the best way to handle when we are faced with this
21 situation now and in the future?

22 MS. STAHLMAN: So you are putting it out for
23 public comment as soon as it can go live. We sent out a
24 draft document last week. We're going to post it on the
25 website hopefully this week under the public comment tab to

1 get comments from the public on what this process --

2 MR. STEINWALD: Also, we do think we followed due
3 process, and your expression of "building case law" I think
4 is a good one. You will see that every criterion is
5 evaluated. They're all evaluated the same way, but we
6 think we gave the proposal a fair review, especially, you
7 know, some considerable discussion about whether we thought
8 we should be evaluating it.

9 We also decided that it was premature to try to
10 develop a policy for that a priori that would cover every
11 proposal, and even though there are at least two or three
12 atypical proposals, they're all different. And so it --
13 the struggle that we may face as a Committee is to figure
14 out if we can develop policies or guidelines that identify
15 uniquely the proposals that we should be reviewing and the
16 proposals that we don't think we should.

17 CHAIR BAILET: Grace?

18 DR. TERRELL: With respect to what those may be,
19 it appears to me that the issue with this particular
20 proposal is that it's a benefits design proposal change,
21 which is not within the scope of how you pay physicians or
22 qualified providers. So as we're building what the points
23 in case law would be as to what distinguishes something, I
24 think that, you know, there may be different reasons
25 related to different proposals, but I think you all did a

1 good job at, in your first statement, making explicit that
2 this was not about physician -- payment to physicians but
3 about a benefits design for Medicare beneficiaries. So
4 perhaps that would be one criterion if we're going to be
5 creating things over time for which there may be others on
6 a list.

7 CHAIR BAILET: Len?

8 DR. NICHOLS: So all this talk about case law has
9 gotten me excited thinking about bright lines, you know.
10 I'm not married to a lawyer, but I dated one once, so I'm
11 even more dangerous than you. But I would say, look, we're
12 looking for bright lines, and I would ask the question of
13 the PRT: If the proposal had included a specific physician
14 payment model that was unique and, you know, APM-like, et
15 cetera, then what? Then you would need to evaluate that
16 piece of it, but there would still be these issues related
17 to the benefit design and the bigger picture.

18 So it seems to me we've got -- you got to have a
19 payment model that actually affects the way physicians are
20 paid and yada, yada. You cannot ask for statutory changes
21 in the benefit design, it seems to me. And maybe it's
22 worth trying to articulate those in the rationale for why
23 this one was not considered in the purview. I'm just
24 asking that question.

25 MR. STEINWALD: Well, it's a good question. If
This document is 508 Compliant according to the U.S. Department of
Health & Human Services Section 508 Accessibility guidelines.

1 it proposed a benefit design redesign but within that there
2 was a physician-focused payment model, we might -- I don't
3 know what we would have done. You know, it could have been
4 a dilemma.

5 DR. NICHOLS: It would be more than this [off
6 microphone].

7 MR. STEINWALD: Yeah, it would be more than this.
8 But it's a good question, and it's probably one of the
9 reasons why we need to look at different proposals that are
10 atypical and see if we can come up with some standard
11 policy.

12 DR. BERENSON: And my comment would be we did
13 have a discussion, which I think Tim would resonate to,
14 which is that we didn't want to have a proposal that had to
15 describe how an intermediary organization was going to pay
16 its individual constituent members, but -- so we don't want
17 to go that far. So paying -- how it pays an intermediary
18 organization might satisfy, but I would have a problem with
19 a proposal that had fundamental changing of benefits. This
20 is a defined contribution proposal. And the fact that
21 there's a -- that the payment model, I don't know that it
22 could be pulled out from the broader structure that's
23 envisioned. I mean, in this proposal, again, I don't have
24 any opinion about the merits of it. It seemed to be
25 integral; the payment model and the incentives that would

1 be placed through the health savings account would change
2 behavior.

3 I would want us at some point in the relatively
4 near future to be able to try to head these off so we
5 wouldn't have that problem and basically take the position
6 that payment models should not include fundamental
7 restructuring of Medicare, fundamental changes in the
8 benefit design, et cetera, et cetera. And I don't have
9 that language today.

10 CHAIR BAILET: Do you have a specific comment?
11 Go ahead, Len.

12 DR. NICHOLS: Yeah. So, Bob, I'm not sure we
13 want to get in the business of precluding people proposing,
14 let's just say, an MSA-based model or a health savings
15 account-based model with -- if it was also coupled with a
16 fundamental change in the way physicians are paid. So, you
17 know, if you look at the RFI from CMMI, this administration
18 is looking for different creative ways to use those kind of
19 accounts. I don't think we should rule them out. I think
20 as long as the core of the proposal brought before us has
21 to do with the payment itself, and then it's up to
22 Medicare, CMS, to decide if they're willing to grant a
23 waiver.

24 I totally agree we're not about evaluating the
25 large scope of the benefit package changes that were

1 contemplated in this particular proposal. But I don't
2 think we want to say don't bring us a --

3 DR. BERENSON: No, I think I would say that, so
4 we have a disagreement. I don't think we are constituted
5 to have the expertise to be reviewing some of those, and to
6 the broader restructuring of Medicare, I don't think we
7 should be getting into that territory. So I think we
8 disagree.

9 DR. NICHOLS: No, no, no. I'm talking about if
10 it was fee-for-service Medicare and we had a savings
11 account component --

12 DR. BERENSON: Within traditional Medicare?

13 DR. NICHOLS: Within fee-for-service Medicare,
14 that's what I'm talking about.

15 DR. BERENSON: Okay. All right. We agree on that.

16 CHAIR BAILET: Harold.

17 MR. MILLER: So I think this is along the same
18 lines. I guess I would be cautious about using the term
19 "benefit design" too -- loosely or broadly, because I think
20 there's a difference between saying specific value-based
21 benefit design elements that may accompany a payment model
22 that -- for example, it's a problem that patients have to
23 pay cost sharing on their care coordination fees, et
24 cetera. And CMMI is, in fact, testing some of those kinds
25 of changes.

1 I don't know what the right terminology is to use
2 here, which is big benefit design change versus little
3 benefit design change. But I would be cautious that
4 somehow we're not -- I would not want us to be saying that
5 no one can bring us a suggestion for a change in benefit
6 structure that would complement a payment model. I think
7 the issue is sort of if there's a payment model and then
8 there's benefits that would go along with it, then that
9 might be something that we would be able to recommend.
10 That's different than saying big benefit change and, oh, by
11 the way, that might lead to some payment changes. That's
12 kind of, it would seem to me, what we're trying to
13 preclude.

14 The other thing I would say, to Mary Ellen's
15 point, is I think all we're asking for public comment on,
16 though, at the moment is the notion that we would have a
17 "not applicable" category as opposed to I guess I would
18 suggest that maybe we want to simply ask for some public
19 comment about whatever comes out of the discussions that we
20 have about the case law, the rationale for the things that
21 we said were not applicable, to see whether anybody has
22 comments about those things for the future. But I'm not
23 sure -- I'm not sure if I were asking for public comment on
24 it, having us have a "not applicable" category -- I'm a
25 member of the public. I'm going to be saying, "Well, how

1 are they going to use that?" You know, and if we don't
2 actually ask for input on how we're going to use it, I'm
3 not sure how people will say good idea or bad idea. So we
4 may need to think about whether there's some follow-up
5 questions that we ask after we get through today and
6 tomorrow on that, just to get feedback on that, because
7 these proposals came in and they were out for public
8 comment, but our reaction to them is not really -- I mean,
9 I guess people could have sent in comments on the PRT
10 reports, but I think, you know, the notion that there is
11 some precedent here is -- you know, might not be obvious to
12 people.

13 CHAIR BAILET: Thank you, Harold. We'll follow
14 up on that. Bob?

15 DR. BERENSON: Yeah. So I agree with Harold on
16 the benefit design terminology. That's why I've been
17 tending to call this "fundamental restructuring," and yet
18 I'm not sure that exactly works. I'm just wondering
19 whether we can do -- that we're not going to come up with
20 the right terminology, so we might come up with some
21 examples. A value-based insurance design as part of a new
22 payment model would be something that would be inbounds. A
23 defined Medicare converted into a defined contribution
24 program would be out of bounds. In other words, we -- it
25 will take a while to get this right, but I am with you in

1 terms of I don't think benefit design works.

2 CHAIR BAILET: Okay. Grace.

3 DR. TERRELL: Well, to get a little David Hume-
4 ian on you, it really depends on what's a priori, right,
5 with respect to an algorithm of what logically follows
6 what, and if in this particular case, if it's a Medicare
7 beneficiary, benefits design that is fundamentally a
8 benefits design for which a physician-focused payment model
9 is subservient to that within the context of the
10 beneficiary design, that's one thing.

11 If it's a payment model with respect to how a
12 physician is paid for which there is something underneath
13 it -- so I really think it's the logic of what follows
14 what. So I'm not sure it's so much about the terminology
15 per se, but if in this particular case it was about a
16 fundamental redesign of the -- of how Medicare
17 beneficiaries interact with their entitlement, right? And
18 so within that context, I think that would be the way to
19 think through the language.

20 MR. STEINWALD: Yeah, that's helpful.

21 You prompted a thought. It wasn't that Hume --
22 David Hume, the British philosopher of three centuries ago.

23 DR. TERRELL: Right.

24 MR. STEINWALD: You're a well-read person. I'll
25 say that.

1 But what's my point?

2 [Laughter.]

3 DR. TERRELL: Well, Kant, depending if you want
4 to get into Immanuel Kant --

5 MR. MILLER: Wait until she starts talking about
6 the Jeremiah. Then you might be in trouble.

7 MR. STEINWALD: All right. All right. All
8 right.

9 So you made this point about the payment model
10 being subservient to the benefit redesign as an element
11 that may help us decide whether this is something we should
12 be reviewing or not. I can't talk anymore.

13 CHAIR BAILET: Are you okay, Bruce? I'm losing
14 you, man. I'm going to have to trach you. I'm going to
15 trach you in a minute!

16 [Laughter.]

17 * **Submitter's Statement, Questions and Answers, and**
18 **Discussion with PTAC**

19 CHAIR BAILET: All right. So at this point, I'd
20 like to have Dr. Yang come on up and address the Committee.

21 Hi. Thank you for coming. We really appreciate
22 it, and you have 10 minutes. And then after that, the
23 Committee will ask questions.

24 Thank you.

25 DR. YANG: I will use less than 10 minutes.

1 So, first of all, I want to thank you for, in
2 particular, the preliminary review committee for reviewing
3 this proposal because different from the previous ones.
4 They have a legion of people. It's just me. So I really
5 appreciate this kind of attention.

6 But the Medicare three-year value-based payment
7 plan is a highly innovative alternative payment model. I
8 respectfully request the Committee give the proposal a
9 thorough evaluation for demonstration. So I respectfully
10 disagree with this is a wrong fundamental with some of
11 your, you know, comments -- status, as a fundamental
12 overhaul of the Medicare program. And I myself, size 2
13 right here, don't have that power.

14 So this model is a small-scale demonstration
15 instead of a broad overhaul of the entire Medicare system.
16 It targets a small group of physician and Medicare
17 beneficiaries based on a voluntary participation under
18 close supervision of Centers for Medicare & Medicaid
19 Services.

20 Therefore, Medicare 3VBPP fits well within the
21 advanced alternative payment model, the advanced APM
22 category as defined by the regulation of "Medicare Access
23 and CHIP Reauthorization Act of 2015, quote/unquote,"
24 MACRA, for eligible physicians or patient groups.

25 It is also well within the administrative power

1 of the Secretary of Health and Human Services, as regulated
2 by MACRA, and the Patient Protection and Affordable Care
3 Act.

4 The purpose of this proposal is to test an
5 innovative payment model that incentivizes physicians and
6 patients to engage in better communication and cooperation
7 on preventive care and chronic disease management and to
8 better align the financial incentives of the patients and
9 physicians. Therefore, it is necessary to launch a
10 demonstration of such financing model that gives the
11 patients more choices than Medicare Advantage, of the
12 Medicare Advantage capitation model for a further evidence-
13 based discussion about Medicare Reaffirm.

14 My response to the four points raised by the PRT
15 as talked by Bruce are below. First, this model is,
16 indeed, an innovative advanced alternative payment model to
17 target a small group of clinicians and patients for a pilot
18 and demonstration. Its purpose is to test here -- and I'm
19 saying it again. It's to test. You can say the
20 jurisdiction is at CMMI, but I want to hear what you guys
21 are thinking. You're running -- you're CEOs and whatever,
22 and you're running the organization, but I want to hear
23 what you are thinking because I have never run any
24 organization. I'm just a health economist, but I'm doing
25 my best, okay?

1 So it's an innovative model, and then you
2 evaluate the results in the field. Its participation is
3 voluntary, and I said it before, and I'll say it many, many
4 times. And I'm going to say it again. It's voluntary. If
5 tested successful, it will lead to further discussion about
6 more general policy modification. So going beyond this
7 Committee in this room, ultimately I think all the people
8 in this room want to make Medicare better and more
9 efficient and more financially sustainable.

10 So besides guaranteed benefit of their services
11 currently covered by Medicare A/B and D, there are added
12 elements in the package of Medicare benefits available to
13 the beneficiaries in Medicare 3VBPP. These changes are for
14 more choices, better value services, and more patients'
15 empowerment. The proposed changes, such as fully covered
16 preventive services and wellness care and financial reward
17 for participation and wellness care, will enhance the
18 benefit and value of the services provided by traditional
19 Medicare.

20 And third, the combination of expanded threshold
21 in catastrophic coverage provides the financial protection
22 to guarantee that the proposed copayment and coinsurance
23 will be lower than the traditional Medicare fee-for-service
24 on average. Therefore, if tested successful, the proposed
25 payment model will not only strengthen the status of

1 Medicare as the cornerstone of social insurance for the
2 seniors, but also, more importantly, provide stronger and
3 more sustainable financial protection for the seniors by
4 liberating them from the unpredictable out-of-pocket
5 expenditures on supplemental insurances.

6 And finally, I strongly disagree with Bruce. So,
7 you think I made a strong point of the Medicare eligibility
8 age. I would argue that there is no change, no change of
9 Medicare eligibility rules. The proposed voluntary
10 postponement of Medicare initiation can only be triggered
11 by the beneficiaries instead of the physicians or the
12 federal government or, you know, CMS or whatever.

13 The choice of initiation age after 65 gives the
14 incentives for the seniors who have other sources of the
15 insurance to tap into Medicare on their own pace. If
16 tested effective, such mechanism will inspire more
17 discussion about more responsible and financially savvy
18 retirement planning policy.

19 And last, I welcome constructive ideas regarding
20 the technical element of this proposal from the Committee
21 members, and based on the discussion I learned before -- I
22 never thought about this, you know, the terminology of
23 beneficiary design or benefit design. I still believe this
24 is a payment model, and I disagree with the payment -- the
25 definition of payment model as a cult. I heard cult a lot,

1 like this is how we pay the physicians and you fall into
2 this cult and we define this and this is how we pay the
3 physicians. I think the physician payment model is just
4 how you pay the physicians, how this money flows from the
5 federal government to the physicians through the
6 transaction of services.

7 So my argument is this feels within the
8 alternative payment model, and again, this is not a
9 fundamental operate of the entire Medicare system. I don't
10 have that power, and nobody does in this room; in
11 particular, me.

12 So I think, you know, based on whatever, the law,
13 the MACRA or PPACA or whatever new laws will come through
14 the pipeline, I think there must be some route that such
15 idea could be given a chance of a demonstration in the
16 field and see if it will work for the benefit of the
17 Medicare patients.

18 Thank you.

19 CHAIR BAILET: Thank you, Dr. Yang.

20 So questions from the Committee, starting with
21 Harold, Bruce, and then Grace.

22 MR. MILLER: Two questions. First of all, could
23 you say a word about what led you to develop this and
24 whether you have some physician groups that you've talked
25 to that want to implement this if it were approved?

1 DR. YANG: How did I develop this idea? Because
2 I started thinking about this during the grand -- the great
3 bargaining. Is it 2012 when the federal government was
4 talking about an overhaul of the tax system, while
5 uplifting of the entitlement program? I was thinking about
6 a financial system ability and the value-based payment at
7 the same time. But I don't want to use the word "defined
8 contribution" because this is not a defined contribution
9 program, indeed. You can call it defined contribution, but
10 I don't think this proposal or this idea deserves that hat.

11 For the physician groups, I talked to a bunch of
12 private practitioners within my community. I never talked
13 to any CEOs, but I talked to real practicing physicians
14 like oncologists, my family physician, my kids'
15 pediatricians, and policy experts and health economists.
16 They welcome this idea because, basically, this is ordinary
17 people's reaction. They would like to -- the physicians'
18 response is like the medical care decision and the payment
19 and the transaction should eventually be between the
20 patients and the physicians. It's not -- it shouldn't be
21 through the federal government.

22 And again, I don't want to go into the political
23 discussion like Congress because this is technical, but
24 like some of my family physicians, they started to reject
25 Medicare patients. Like I go to see my doctor in the North

1 Atlanta family practice, and since maybe two years ago,
2 they refused to see Medicare payments -- Medicare patients
3 anymore, but I had -- because I am still working, I have
4 private insurance, and they like to see me. But my family
5 physician told me that, "We don't want to see Medicare
6 patients anymore because it's not worth it."

7 So I started thinking about something that will
8 align -- here, I like to use the word "align" -- the
9 benefits and the expectations and the value, whatever you
10 call it, of the patients and the physicians and the federal
11 government together because if we want to achieve more
12 sustainable Medicare benefit, Medicare system, whatever,
13 everybody has to give up something.

14 MR. MILLER: So a second question is in the
15 proposal, you had -- there were several ways the
16 beneficiaries could use the money, and the fourth one,
17 which seemed to be the one that was closest to an actual
18 physician payment model, you described as a low-premium
19 fee-for-service plan with negotiated rate of reimbursement
20 between the providers and the patients.

21 Could you say a little bit more about that? I
22 mean, are you envisioning direct contracting between
23 patients and providers? Are you imagining that they would
24 have to actually pay sort of a whole capitation-type
25 premium to a group of providers, or they would simply

1 contract directly for individual services that they might
2 contract with somebody for primary care and then contract
3 with somebody else for management of a hip problem or
4 whatever? What exactly are you envisioning happening
5 there?

6 DR. YANG: I think that's a very good question.

7 So I am envisioning because I -- you probably --
8 you know, I mentioned somewhere in the -- later, you know,
9 later in the proposal. I think the most ideal situation
10 for this kind of contracting is through a more
11 comprehensive physician group, like they have both general,
12 like some physician groups with multi-specialty, with both
13 general practitioners and specialists, so that patients can
14 obtain comprehensive service within the physician system.
15 But their transaction fee, like how the physicians are
16 getting paid, will be based on the contract between the
17 patients and the physician.

18 MR. MILLER: Yeah. Well, so technically, today,
19 I mean, a physician group could organize a Medicare
20 Advantage plan and have the patient sign up for that, and
21 then the physicians could pay themselves. However, they
22 wanted to through the Medicare Advantage plan. So I wasn't
23 quite sure what you were seeing as different here and
24 whether it was really the notion of direct contracting for
25 an individual patient with individual physicians or whether

1 you're simply seeing this as a version of a provider-
2 sponsored Medicare Advantage plan.

3 DR. YANG: I would not use the word "Medicare
4 Advantage" because the Medicare Advantage is capitation,
5 but this one is a low premium. It's like, based on the
6 premium, is like lock in the patients with the physician
7 group, but the rest of the payment will be fee-for-service.

8 And, you know, the cost control is through the
9 patient self-control of the Medicare are capped instead of
10 the Medicare, the Medicare MA (Medicare Advantage)
11 capitation, which is imposed by the federal government.

12 And on top of that, the Medicare MA, I think is
13 well-known knowledge. It's common sense. Medicare MA
14 doesn't save money because on average, the Medicare MA
15 capitation rate is higher than the average fee-for-service
16 reimbursement, and the fee-for-service expenditures at PMPY
17 (per member per year) level, I think before it's 1.06, and
18 the patient per -- you know, the PPACA reduced the rate to
19 1.3?

20 MR. MILLER: So let me just ask one final
21 question. So you had a statement in here that says,
22 "However, there is no annual limitation on Medicare
23 contribution." What did that mean?

24 DR. YANG: Oh, yeah. Because this is -- what's
25 the difference between the Medicare MA and the model I am

1 proposing, because imposing an annual limitation, saying --
2 that is defined contribution. When you're saying this is
3 the amount, the Medicare will contribute to you within a
4 year, and there is an annual limitation on how much you can
5 use Medicare money. That is defined contribution.

6 But what I am proposing is not defined
7 contribution. It's this is your money, and this is still
8 your benefit, but we're going to pay the service provided
9 by you through physicians in a different way and give you
10 more power to control the benefit, the whatever, the
11 benefit money you're entitled to.

12 MR. MILLER: Okay. Thank you.

13 CHAIR BAILET: Grace.

14 DR. TERRELL: This is just a question, and I
15 don't know if you read all the public comments on this
16 particular proposal. But there was a specific, fairly
17 lengthy one from the --

18 DR. YANG: BIO (Biotechnology Innovation
19 Organization).

20 DR. TERRELL: -- Biotechnology Innovation
21 Organization that came out pretty strongly about concerns
22 that the way that this is structured would lead to
23 potential lack of access or judgments on the part of the
24 patient that would allow them to really have access to
25 innovations, biotechnology, as the field progresses.

1 So I just wondered if you had specific thoughts
2 on their concerns about that, that you would like to share
3 with the Committee.

4 DR. YANG: I think this proposal will not only --
5 not only will not -- you know, this proposal -- first of
6 all, I don't think this proposal will limit patient choices
7 at all because, first of all, this is voluntary
8 participation, and second of all, this will enhance the
9 patient choices because in one of the elements I suggest to
10 combine, the Medicare Part B services with Part A and Part
11 D together, and that way, I will get rid of the Medicare
12 donut hole for Medicare Part D, because to give the
13 patients more choices and higher budget from the federal
14 government to protect, you know, for the -- to reimburse
15 prescription drugs.

16 And through the mechanism, the patients not only
17 have a higher budget from the federal government, but also
18 have more choices both in the inpatient settings and from
19 the outpatient settings as they're through Medicare Part D.
20 So the B program and D program will be more mingled
21 together and give the patients more flexibility and
22 choices.

23 So I respectfully disagree with points from BIO.

24 DR. MEDOWS: Dr. Yang?

25 DR. YANG: Yeah.

1 DR. MEDOWS: Would you help me, please? I want
2 to make sure I'm understanding this. The Medicare account
3 would be front-loaded with three years' worth of Medicare
4 payments based on risk-adjusted?

5 DR. YANG: Yeah.

6 DR. MEDOWS: And then the patient would have to
7 manage that account, pick from the choices, but manage it
8 over that three-year period?

9 DR. YANG: Yeah.

10 DR. MEDOWS: If they don't manage it correctly
11 and they run out of funds or something catastrophic
12 happens, how will they get their care paid for? I mean,
13 are they pretty much kind of out of it at that point?

14 DR. YANG: No. The cap is not. The cap is not
15 to -- if you read it through the lines, above cap, they not
16 fall into the cliff. It's just the copayment, and the
17 copayment is means-tested. So the copayment is means-
18 tested.

19 So for the lowest-income people, even if they go
20 over the cap -- probably before they don't pay anything,
21 but now probably they pay two percent. But the higher-
22 income people will pay a higher percent, maybe 10 percent,
23 15 percent, or up to 30 percent.

24 And then I also explained -- and based on field
25 experience with Medicare Part A, a lot of the enrollees and

1 a large percentage of the Medicare MA enrollees are low-
2 income populations; in particular, like Latinos or African
3 American community, because the capitation system get rid
4 of the out-of-pocket payment. And it's highly popular
5 among the low-income population.

6 And technically, for implementation, here's my
7 recommendation. I think the same as Medicare Part D. For
8 the low-income people, there should be. I'm saying if this
9 is going large scale, okay -- so I don't want to lose
10 track. Like first of all, I'm talking about demonstration,
11 and then suddenly, we're talking about large
12 implementation. And that's the reason I recommended
13 demonstration is, for example, we can test this within a
14 small community, like low income or, for example, minority
15 communities, like to see how people react to this plan,
16 because it's not very easy to manage the same as Medicare
17 Part B.

18 So for Medicare Part D, there are a lot of
19 supplemental measures. Like there is additional government
20 support for people who fall into Medicare -- fall into the
21 -- and there's a community-outreaching activities to help
22 people, to help the low-income or low-informed or low-
23 educated people facing a lot of problems with access to
24 pick the plan that really helps them with social workers or
25 NGOs (non-governmental organization) and those kind of

1 things.

2 But I appreciate it. That's a very good
3 questions.

4 CHAIR BAILET: All right. So, Bob, final
5 comments? Yeah, please.

6 DR. BERENSON: I mean, I think there's some
7 revisionist stuff going on here. I appreciate the proposal
8 but -- let me just read to you from your proposal and you
9 explain to me why this is not defined contribution. "Each
10 participant is given the choices to spend their Medicare
11 account to enroll in one of the plans below: a capitated
12 HMO plan, that the Medicare account contributes to the
13 capitation, a PPO plan, that the Medicare account
14 contributes to the premium; a high-deductible PPO plan," et
15 cetera, and then, finally, "low-premium fee for service
16 model." Why isn't that a defined contribution? What
17 happens -- don't -- yeah, that's the question. Why isn't
18 that a defined contribution?

19 DR. YANG: So first off, can you define what is a
20 defined contribution?

21 DR. BERENSON: It's given a fixed amount of money
22 to go purchase health insurance, rather than the current
23 Medicare program, which is a defined benefit program, where
24 you're guaranteed benefits no matter how much you spend.
25 It's a contribution to go purchase health insurance.

1 DR. YANG: Well, I disagree with you, because,
2 first of all, my program -- the proposal I have proposed,
3 is to give the Medicare beneficiaries to -- the choices to
4 enroll into a Medicare program -- the carrier to contract
5 with the Medicare benefit carriers who can do a better job
6 of prevention and care coordination.

7 And second of all, I come back here again. There
8 is no definite amount of money defined in this proposal,
9 and saying I'm going giving you \$10,000, where I'm only
10 giving you \$13,000. There is no set element. There is a
11 quote/unquote "financial cliff" that requires copayment,
12 but there is no limitation, either at annual base or
13 lifetime base, that's saying this is a definite defined,
14 precise -- precisely defined amount of money that the
15 government will come to give to you.

16 And on top of that, based on my proposal, all the
17 beneficiaries, all the voluntary Medicare beneficiaries
18 have access to all the traditional Medicare benefits that
19 have been offered through Medicare Part A, Part B, and Part
20 D, and they are getting better value off the federal
21 investment.

22 DR. BERENSON: You're giving them money to find a
23 better choice, right, so that's defined contribution.

24 In any case, there's no point in arguing.

25 * **Comments from the Public**

This document is 508 Compliant according to the U.S. Department of
Health & Human Services Section 508 Accessibility guidelines.

1 CHAIR BAILET: So, Dr. Yang, thank you for
2 submitting your proposal and the discussion today. And
3 while you are taking your seat, I understand, actually, you
4 may have to leave for another meeting. But I want to make
5 sure that if there's someone on the phone or in the
6 audience that has a comment, as Dr. Yang steps away, this
7 would be a good time for anybody to make a comment at this
8 point.

9 [No response.]

10 CHAIR BAILET: It looks like there aren't any.
11 Okay. Thank you.

12 DR. YANG: Thank you. Thank you very much, and
13 you have my email. If you want to talk to me, just, you
14 know -- thank you.

15 CHAIR BAILET: Good. Alrighty.

16 * **Committee Deliberation**

17 CHAIR BAILET: So we now move forward with
18 deliberation and voting. I'm sensing that we are ready to
19 -- Len.

20 DR. NICHOLS: So, Mr. Chairman, I got this little
21 voting toy and I don't see asterisk on here. Is that like
22 the question mark?

23 MS. STAHLMAN: Press zero.

24 MS. PAGE: Yeah, if you want to vote not
25 applicable you hit zero.

1 * **Voting**

2 CHAIR BAILET: Okay. So why don't we set up the
3 voting parameters here. We're going to start with
4 Criterion 1, and let me just review the scores here.
5 Number 1 and 2, do not meet; 3 and 4, meets; 5 and 6, meets
6 and deserves priority consideration; and then for you, Len,
7 the asterisk means it's not applicable, and because there's
8 not an asterisk key on this, we are going to actually -- we
9 have designated the 0 to reference the asterisk. Alrighty,
10 then? All right.

11 So we're going to go with Criterion 1, Scope,
12 which is a high priority item for the Committee, aimed to
13 either directly address an issue in payment policy that
14 broadens and expands the CMS portfolio, APM portfolio, or
15 including APM Entities whose opportunities to participate
16 in APMs have been limited.

17 So let's go ahead vote on this first criteria,
18 please.

19 [Electronic voting.]

20 CHAIR BAILET: Ann.

21 * **Criterion 1**

22 MS. PAGE: Zero Committee members voted 5 or 6,
23 meets and deserves priority consideration; zero Committee
24 members voted 3 or 4, meets the criterion; zero members
25 voted 2, does not meet; one member voted 1, does not meet,

1 and nine members voted not applicable. So the majority has
2 determined that Criterion 1 is not applicable to this
3 proposal.

4 CHAIR BAILET: Thank you, Ann. We're going to go
5 with the second criterion, which is Quality and Cost, also
6 high priority. Anticipated to improve health care quality
7 at no additional cost, maintain quality while decreasing
8 cost, or both, improve quality and decrease cost.

9 High priority item. Let's vote, please.

10 [Electronic voting.]

11 CHAIR BAILET: Ann.

12 * **Criterion 2**

13 MS. PAGE: Zero Committee members voted 5 or 6,
14 meets and deserves priority consideration; zero members
15 voted 3 or 4, meets; zero members voted 2, does not meet;
16 three members voted 1, does not meet, and seven members
17 voted not applicable. So the Committee has determined that
18 Criterion 2 is not applicable to this proposal.

19 CHAIR BAILET: Thank you, Ann. Criterion number
20 3, which is Payment Methodology, a high priority. Pay the
21 APM Entities with a payment methodology designed to achieve
22 the goals of the PFPM criteria, addresses in detail through
23 this methodology how Medicare and other payers, if
24 applicable, pay APM Entities and how the payment
25 methodology differs from current payment methodologies, and

1 finally, and why the physician-focused payment model cannot
2 be tested under current payment methodologies.

3 A high priority item. Let's go ahead and vote,
4 please.

5 [Electronic voting.]

6 CHAIR BAILET: Ann.

7 * **Criterion 3**

8 MS. PAGE: Zero committee members voted 5 or 6,
9 meets and deserves priority consideration; zero members
10 voted 3 or 4, meets; zero members voted 2, does not meet;
11 three members voted 1, does not meet, and seven members
12 voted not applicable. The Committee has determined that
13 Criterion 3 is not applicable to this proposal.

14 CHAIR BAILET: Thank you, Ann. Criterion 4,
15 Value over Volume. Provides incentives to practitioners to
16 deliver high quality health care.

17 Vote, please.

18 [Electronic voting.]

19 CHAIR BAILET: Ann.

20 * **Criterion 4**

21 MS. PAGE: Zero Committee members voted 5 or 6,
22 meets and deserves priority consideration; zero members
23 voted 3 or 4, meets; zero members voted 2, does not meet;
24 three members voted 1, does not meet, and seven members
25 voted not applicable. The Committee has determined that

1 Criterion 4 is not applicable to this proposal.

2 CHAIR BAILET: Thank you, Ann. Criterion 5,
3 which is Flexibility. Provide the flexibility needed for
4 practitioners to deliver high quality health care.

5 Please vote.

6 [Electronic voting.]

7 * **Criterion 5**

8 CHAIR BAILET: Ann.

9 MS. PAGE: Zero members voted 5 or 6, meets and
10 deserves priority consideration; zero members voted 3 or 4,
11 meets; zero members voted 2, does not meet; one member
12 voted 1, does not meet, and nine members voted not
13 applicable. The Committee has determined that Criterion 5
14 is not applicable to this proposal.

15 CHAIR BAILET: Thank you, Ann. Criterion number
16 6, Ability to Be Evaluated. Have the evaluable goals of
17 quality of care cost and other goals of the PFPM.

18 Please vote.

19 [Electronic voting.]

20 CHAIR BAILET: Ann.

21 * **Criterion 6**

22 MS. PAGE: Zero members voted 5 or 6, meets and
23 deserves priority consideration; zero members voted 3 or 4,
24 meets; zero members voted 2, does not meet; two members
25 voted 1, does not meet, and eight members voted not

1 applicable. The Committee has determined that Criterion 6
2 is not applicable to this proposal.

3 CHAIR BAILET: Thank you, Ann. Criterion 7 is
4 Integration and Care Coordination. Encourage greater
5 integration and care coordination among practitioners and
6 across settings where multiple practitioners or settings
7 are relevant to delivering care to populations treated
8 under the PFPM.

9 Please vote.

10 [Electronic voting.]

11 CHAIR BAILET: Ann.

12 * **Criterion 7**

13 MS. PAGE: Zero members voted 5 or 6, meets and
14 deserves priority consideration; zero members voted 3 or 4,
15 meets; zero members voted 2, does not meet; three members
16 voted 1, does not meet, and seven members voted not
17 applicable. The majority has determined that Criterion 7
18 is not applicable to this proposal.

19 CHAIR BAILET: Thank you, Ann. Criterion number
20 8, Patient Choice. Encourage greater attention to the
21 health of the population served while also supporting the
22 unique needs and preferences of individual patients.

23 Please vote.

24 [Electronic voting.]

25 * **Criterion 8**

1 MS. PAGE: Zero members voted 5 or 6, meets and
2 deserves priority consideration; zero members voted 3 or 4,
3 meets; two members voted 2, does not meet; zero members
4 voted 1, does not meet, and eight members voted not
5 applicable. The majority has determined that Criterion 8
6 is not applicable to this proposal.

7 CHAIR BAILET: All right. Thank you, Ann. Nine
8 is Patient Safety. To maintain and improve standards of
9 patient safety.

10 Please vote.

11 [Electronic voting.]

12 * **Criterion 9**

13 MS. PAGE: Zero members voted 5 or 6, meets and
14 deserves priority consideration; zero members voted 3 or 4,
15 meets; zero members voted 2, does not meet; three members
16 voted 1, does not meet, and seven members voted not
17 applicable. The majority has determined that Criterion 9
18 is not applicable to this proposal.

19 CHAIR BAILET: Thank you, Ann, and the last
20 Criterion is number 10, which is Health Information
21 Technology. Encourage the use of health information
22 technology to inform care.

23 [Electronic voting.]

24 * **Criterion 10**

25 MS. PAGE: Zero members voted 5 or 6, meets and

1 deserves priority consideration; zero members voted 3 or 4,
2 meets; zero members voted 2, does not meet; three members
3 voted 1, does not meet, and seven members voted not
4 applicable. The PTAC has determined that Criterion 10 is
5 not applicable to this proposal.

6 CHAIR BAILET: Thank you, Ann. Ann, if you could
7 just give us a quick summary. Thank you.

8 MS. PAGE: The Committee determined on all 10 of
9 the criterion did not apply to this proposal.

10 CHAIR BAILET: All right. Thank you, Ann.

11 We are now actually going to vote for the
12 recommendation to the Secretary. We are going to start
13 voting electronically and then move to an individual report
14 out. Again, the four numbers here are 1 is do not
15 recommend to the Secretary; 2 is recommend payment model to
16 the Secretary for limited-scale testing; number 3 is
17 recommend the proposed payment model to the Secretary for
18 implementation; and then 4 is recommend proposed model to
19 the Secretary for implementation as a high priority item.
20 And then the asterisk is not applicable.

21 So please vote.

22 DR. BERENSON: And could I just --

23 CHAIR BAILET: Yes, please, Bob.

24 DR. BERENSON: So not applicable with this
25 overall recommendation would be that we would tell the

1 Secretary that we did not evaluate this proposal because it
2 was not --

3 CHAIR BAILET: Well, I would just -- again, I
4 think we did evaluate the proposal and that we found --

5 DR. BERENSON: No, we didn't.

6 CHAIR BAILET: Well, and we found it wasn't --

7 DR. BERENSON: We found that we are not
8 recommending the proposed payment model, but we also did
9 not do -- we did not make a judgment on the merits of the
10 proposal.

11 CHAIR BAILET: No, we did not.

12 DR. BERENSON: So which way do we go, in terms of
13 --

14 DR. NICHOLS: Asterisk is very different than 1.

15 MR. STEINWALD: We will, I hope, highlight --
16 well, we haven't voted yet, but looking ahead, that we have
17 -- we rendered no judgment about the merits of the
18 proposal. It's not applicable because it's not a
19 physician-focused payment model, and our language needs to
20 capture both of those elements so that there is no
21 ambiguity.

22 VICE CHAIR MITCHELL: And I just --

23 DR. BERENSON: So how are you going to vote?

24 MR. STEINWALD: I am going to vote not
25 applicable.

1 DR. BERENSON: Okay.

2 VICE CHAIR MITCHELL: So I intend to vote do not
3 recommend, because even though I don't think the criteria
4 applied, what I did read I thought was ill-advised. So I
5 would not have recommended it.

6 MR. MILLER: I am also going to vote do not
7 recommend, because of that. The applicant thinks it's a
8 payment model. I don't think that it is defined well
9 enough to describe a payment model, and I think we should
10 not recommend it.

11 DR. TERRELL: Ditto.

12 CHAIR BAILET: Len.

13 DR. NICHOLS: I'm stunned. It seems to -- I
14 thought we were precluded from evaluating it in a serious
15 way, precisely because we determined it was not applicable.
16 I'm happy to tell him it's a bad idea, but I don't think we
17 want to -- I thought the whole point of the neutral
18 language was to avoid judgment about the nature of this
19 kind of proposal -- forget the specifics -- this kind of
20 proposal. And, therefore, I see a real distinction between
21 asterisk and 1, and I thought we had all been headed toward
22 asterisk.

23 MR. STEINWALD: I agree.

24 CHAIR BAILET: Bob.

25 DR. BERENSON: Except for, I mean, on all of

1 those votes we had one or two people who wanted to
2 positively turn it down. They gave it 1s or 2s, and a
3 whole bunch of us gave it asterisks. So I think we want to
4 maintain that same distinction. There are some people who
5 are confident about turning it down. Some of us will want
6 to say not applicable because we didn't evaluate it. But I
7 think that's the distinction we're maintaining.

8 CHAIR BAILET: Harold.

9 MR. MILLER: So my opinion is even if we -- I
10 didn't -- I felt that the criteria were applicable, too, if
11 it was a payment model, but even if we didn't feel the
12 criteria were applicable, I don't think that that precludes
13 us individually from saying whether or not we think that
14 this should go forward in any fashion. You know, and I
15 think the Committee as a whole can conclude that it didn't
16 have the expertise or whatever to be able to evaluate that.
17 I didn't -- I think we could have determined whether there
18 was some merit to it. I read it carefully, tried to assess
19 whether there was merit to it. Could not find any
20 description of merit, and, therefore, to me, simply saying
21 it's not applicable and that we don't know is different
22 than what I felt. I looked at it and didn't see merit or
23 didn't see enough detail to be able to determine merit.

24 So that's why I'm voting. I'm not suggesting
25 everybody else has to vote that way, but that's my

1 conclusion.

2 CHAIR BAILET: Bruce.

3 MR. STEINWALD: Materially, not applicable and do
4 not recommend amount to the same thing. I mean, we are
5 certainly not recommending it. So I'm thinking it's kind
6 of a distinction without a difference.

7 But I will say this. We may have had the
8 expertise to evaluate it. I don't know that we didn't. I
9 mean, all of us, in some way or another, have been -- have
10 seen models like -- models -- have seen proposals like this
11 in the past and have seen the various debates that get very
12 political very quickly. And that's what I think we should
13 avoid getting anywhere close to.

14 And so I don't think it was lack of expertise. I
15 think it was really, fundamentally, it's not the kind of
16 thing that this Committee should be reviewing.

17 CHAIR BAILET: Tim and then Bob.

18 DR. FERRIS: I think I -- I think there -- I'm
19 concerned that there is a difference between the two,
20 although I understand they end up in the same place. One
21 is an assessment of the proposal and one is a statement
22 that proposal could not be assessed because it didn't meet
23 our criteria.

24 Now you can handle that in the comments or
25 whatever, but I've seen proposals for changes in benefit

1 structures and contribution plans. I know that I am -- it
2 is -- it would be incorrect of me, because I do not have
3 nearly the background required to make an assessment of
4 that, and I would be so -- I am concerned for myself, just
5 myself, that I could not vote number 1, because that is a
6 -- that reflects an assessment that this should not -- at
7 least how I understand it -- that this should not be
8 recommended, because of some value judgment placed on the
9 proposal. And I am certainly not prepared to place a value
10 judgment on this proposal.

11 DR. BERENSON: Yeah, I mean, I think Tim said
12 what I wanted to say. I don't -- but I agree with Bruce.
13 We're not constituted to review this. If the Congress
14 wanted us to be reviewing restructuring proposals, I think
15 they -- if they wanted a body to advise CMMI, they would
16 not have had our makeup. And so whereas some of us may
17 feel confident in reviewing what is, in fact, not a very
18 strong proposal, there could be a very good proposal coming
19 through, and I don't think we want to set the precedent
20 that we are reviewing on the merits of proposals that have
21 to do with fundamental restructuring of the program.

22 CHAIR BAILET: Len.

23 DR. NICHOLS: I think, picking up on Tim and Bob,
24 I think it would be a mistake for us to signal that we were
25 open to consideration of these kinds of broader

1 restructuring things. I actually think, Timmy, you could
2 figure it out, but I also think it's a bad idea for us to
3 try, because it's just too big for what MACRA set us up to
4 do.

5 CHAIR BAILET: Harold.

6 MR. MILLER: So I think we have made a
7 distinction all along that do not recommend doesn't
8 necessarily mean bad idea, in general. It means that we do
9 not -- are not prepared to recommend that. And we've made
10 that distinction with others, sort of -- lots of good ideas
11 there but needs work, and therefore we're not recommending
12 it, but without prejudice.

13 In this particular case, I'm just saying, we
14 asked the applicant what she thought this was. She said
15 this is a payment model. If she had said this is a
16 fundamental benefit design, then I would have said not
17 applicable because that's not what this is. But she said
18 it's a payment model, so I looked at it and I said is there
19 a payment model here and I saw no payment model. So,
20 therefore, I'm saying -- again, it's just me -- I'm not
21 recommending because I don't -- I think, from her
22 perspective, she doesn't think it's a benefit design. She
23 thinks it's a payment model, and I don't think that we -- I
24 can recommend that as a payment model. So that's why I'm
25 making that distinction.

1 DR. TERRELL: It's so weird when I agree with
2 him, but I do.

3 CHAIR BAILET: I think this is the first time.
4 Right. I think I'm going to go buy a Powerball ticket.

5 MR. MILLER: No, there was one other time. I
6 marked it on my wall.

7 CHAIR BAILET: Did you? Okay, very good.

8 [Laughter.]

9 CHAIR BAILET: With all seriousness, we're going
10 to go ahead and --

11 DR. CASALE: I'm so sorry. I just --

12 CHAIR BAILET: No, no. Please, Paul.

13 DR. CASALE: I'll just add on. I'm attaching my
14 comments to Tim and Len. I mean, I think -- and Bob, too.
15 Just because she said it's a payment model doesn't mean
16 it's a payment model, at least the way I'm thinking about
17 it. So even when I looked at it, I don't see it that way,
18 so I don't feel comfortable to even consider one.

19 CHAIR BAILET: Okay. Thank you, Paul.

20 So I think we are in the process of voting on
21 this. I think we should complete the --

22 MR. MILLER: Do you want to restart it?

23 CHAIR BAILET: Yeah, yeah. Why don't we -- can
24 we reset it, Matt? Please.

25 That's just a test. Nothing to see here. Move

1 along. Okay. Now we're going to vote.

2 [Electronic voting.]

3 * **Final Vote**

4 MS. PAGE: Zero members recommend -- zero members
5 recommend the proposed payment models to the Secretary for
6 implementation as a high priority. Zero members recommend
7 proposing it to the Secretary for implementation. Zero
8 members recommend proposing it to the Secretary for
9 limited-scale testing. Three members do not recommend --
10 affirmatively do not recommend the proposed payment model
11 to the Secretary, and seven members voted that this is not
12 applicable.

13 CHAIR BAILET: Thank you, Ann.

14 And we're going to now just go around and see how
15 we voted. Oh, what?

16 DR. NICHOLS: [Speaking off microphone.]

17 MS. PAGE: Two-thirds is seven when 10 members
18 are voting, so --

19 CHAIR BAILET: It's okay, Len. I know you're an
20 actuary, and yeah, yeah. It's okay. We'll get you a
21 bigger calculator. Okay.

22 [Laughter.]

23 * **Instructions on Report to the Secretary**

24 CHAIR BAILET: So we're going to start with you,
25 Rhonda, please.

1 DR. MEDOWS: Okay. I voted that it was not
2 applicable because I believe that it extends well beyond a
3 payment model. That's pretty much it.

4 CHAIR BAILET: Bob?

5 DR. BERENSON: I support the PRT's views.

6 CHAIR BAILET: Len?

7 DR. NICHOLS: I voted that it was not applicable
8 because I think it's dangerous to imply it is.

9 VICE CHAIR MITCHELL: I was on the PRT, and I
10 voted do not recommend. I do think that the large majority
11 of the criteria were not applicable, and I voted as such,
12 but there were elements of the model that I would actually
13 affirmatively vote against. And I did so.

14 CHAIR BAILET: I think it's not applicable for
15 reasons already stated.

16 Bruce?

17 MR. STEINWALD: I agree with the PRT, too.

18 One thing I decided not to argue with the
19 proposer, but she said a couple of times it's not a
20 restructuring of the Medicare program; it's just a small-
21 scale demonstration. Do you remember? And I was going to
22 say, "Yeah, but it's a small-scale demonstration about
23 restructuring the Medicare program." So you wouldn't do a
24 demonstration unless you thought maybe that's where you
25 were headed.

1 So I'm not sure that that needs to be captured in
2 the report. I don't know how others feel. Maybe just
3 keeping it clean, cleaner, and simpler would be best.

4 CHAIR BAILET: Paul.

5 DR. CASALE: Yeah. I voted not applicable, and
6 as I stated, although she declared that it was a payment
7 model, I didn't see that.

8 CHAIR BAILET: Thank you.

9 Harold?

10 MR. MILLER: I voted do not recommend.

11 CHAIR BAILET: Grace?

12 DR. TERRELL: I voted do not recommend. My logic
13 was very similar to Elizabeth's.

14 Interestingly, when I was going through the
15 individual things, I was bobbling back and forth between
16 some, which I thought you absolutely could evaluate within
17 the context of our criteria that we're to go by and others
18 that were absolutely not applicable.

19 But ultimately, I don't necessarily agree with
20 the majority opinion, but that we shouldn't make a judgment
21 one way or the other on these things. I think that this
22 particular situation, we could. I don't think there has to
23 be a strong minority opinion in the report back.

24 CHAIR BAILET: Thank you.

25 Tim.

1 DR. FERRIS: I don't think what I'm going to say
2 is a surprise, but I voted not applicable for the reasons
3 already stated.

4 CHAIR BAILET: Thank you, Tim.

5 Ann.

6 MS. PAGE: Staff just has a question. So the
7 Committee's vote is not applicable in the report to the
8 Secretary. Do those of you who voted do not recommend, do
9 you want that recorded as sort of a minority view and/or if
10 you do, do you want to elaborate? So it's just a question
11 how much is that --

12 DR. TERRELL: Whatever makes you happy.

13 CHAIR BAILET: I thought it was that you guys
14 said no, that you didn't --

15 MR. MILLER: I would say -- I mean, I don't
16 disagree with the Committee determining not applicable. I
17 would just -- I personally would just note that in fact
18 some Committee members felt that the applicant asserted
19 that it in fact was a payment model, and therefore, some
20 people -- some people's votes were based on the fact that
21 -- because that's why it's based on that assertion in my
22 opinion. I was not trying to evaluate its merits
23 otherwise. It was asserted as a payment model, and that's
24 why, but I'm happy to support the not applicable since most
25 of the criteria came out that way.

1 CHAIR BAILET: Rhonda?

2 DR. MEDOWS: I actually think it's important that
3 your vote and the rationale behind it be included in the
4 report.

5 MS. PAGE: Okay.

6 CHAIR BAILET: So, Ann, given that, do you have
7 what you need to be able to represent that opinion?

8 MS. PAGE: Right. The only -- I've heard that
9 there were a few people who voted do not recommend based on
10 the assertion that it was a payment model, even though
11 there was some potential disagreement on that. And I don't
12 -- if you want to say any more -- okay. I'm going to leave
13 it that way.

14 DR. NICHOLS: I don't think anybody thought it
15 was a payment model except the applicant.

16 MR. MILLER: Correct. I agree with that, but the
17 point was it was represented after even a question. It was
18 represented as a payment model, and so, therefore, that was
19 -- that was the basis of my vote. What I was trying to
20 make clear earlier is I don't see it as a minority opinion
21 that needs to be reflected in the report, per se, in terms
22 of I didn't -- I don't disagree with what the Committee
23 came up with.

24 CHAIR BAILET: All right. We are now going to
25 move on to the final proposal for today, which is the Mercy

1 Accountable Care Organization annual wellness visit billing
2 at rural health clinics. Bob Berenson was the lead
3 proposal review team.

4 UNIDENTIFIED SPEAKER: [Speaking off microphone.]

5 **Mercy Accountable Care Organization: Annual**
6 **Wellness Visit Billing at Rural Health Clinics**

7 * **Committee Member Disclosures**

8 CHAIR BAILET: And we're going to do the
9 disclosures, starting with me since most of my Committee is
10 just stepping away. So, Jeff Bailet, Executive Vice
11 President, Health Care Quality and Affordability of Blue
12 Shield of California. I have nothing to declare.

13 Elizabeth?

14 VICE CHAIR MITCHELL: Elizabeth Mitchell, CEO,
15 Network for Regional Healthcare Improvement. Nothing to
16 disclose.

17 CHAIR BAILET: Len?

18 DR. NICHOLS: Len Nichols. I direct the Center
19 for Health Policy Research and Ethics at George Mason
20 University, and I have nothing to declare.

21 DR. BERENSON: I'm Bob Berenson. I am an
22 Institute Fellow at the Urban Institute, and I have nothing
23 to disclose.

24 DR. MEDOWS: I'm Rhonda Medows, EVP, Population
25 Health, Providence St. Joseph Health. I have no

1 disclosures.

2 DR. TERRELL: Grace Terrell, an internist at Wake
3 Forest Baptist Health Integrated System and CEO of Envision
4 Genomics. Nothing to disclose.

5 MR. MILLER: Harold Miller, CEO of the Center for
6 Healthcare Quality and Payment Reform. No disclosures.

7 DR. CASALE: Paul Casale, cardiologist, Executive
8 Director of New York Quality Care. Nothing to disclose.

9 MR. STEINWALD: Bruce Steinwald, health economist
10 in Northwest Washington. I have nothing to disclose, but I
11 would like Tim to turn his card right side up.

12 CHAIR BAILET: And Tim Ferris, Dr. Ferris,
13 stepped out, but we have his disclosure. Nothing to
14 disclose. He's one of the members of the PRT -- and I'm
15 just speaking for you, Tim, which is a pretty weighty
16 obligation on my part. So you might want to do it
17 yourself. Thank you.

18 DR. FERRIS: Tim Ferris. Nothing to disclose.

19 CHAIR BAILET: Thank you.

20 Okay. I'm going to turn it over to Bob. Bob,
21 you got the wheel.

22 * **PRT Report to the Full PTAC**

23 DR. BERENSON: So, we have another proposal in
24 which we're going to recommend not applicable. It's the
25 other end of the spectrum. This has to do with what we

1 considered de minimis changes to an existing payment model
2 rather than an alternative payment model. Our Committee is
3 me and Tim and Len.

4 So let me go through the [unintelligible] now, do
5 we have the proposers on the phone?

6 MS. STAHLMAN: They are.

7 DR. BERENSON: Do we know they are there?

8 MS. STAHLMAN: We know that they are there.

9 DR. BERENSON: Okay. So very good. They're not
10 here in person. So the presentation overview is the
11 standard, the team composition. Has the proposers, do they
12 know all this stuff, or do I need to go through it? The
13 slides like this.

14 [Off-microphone discussion.]

15 DR. BERENSON: All right. Let me go through this
16 real fast. The Chair and the Vice Chair assign two to
17 three PTAC members, including at least one physician, to
18 each complete proposal to serve as the PRT. One PRT member
19 is tapped to serve as the lead reviewer. In this case I am
20 that person.

21 The PRT identifies additional information needed
22 from the submitter and determines to what extent any
23 additional resources and/or analyses are needed for the
24 review. ASPE staff and contractors support the PRT in
25 obtaining these additional materials.

1 After reviewing the proposal, additional
2 materials are gathered and public comments received, and
3 the PRT prepares a report of its findings to the full PTAC.
4 The report is posted to the PTAC website at least three
5 weeks prior to the public deliberation by the full
6 Committee, which is taking place right now.

7 The PRT report is not binding on the PTAC. PTAC
8 may reach different conclusions from those contained in the
9 PRT report.

10 I'm not going to go through the details of this
11 slide. The point of this slide, which I thank Tim for
12 preparing for us, is to make the point that this is a well
13 -- there is a well-defined payment model for rural health
14 clinics. They are defined in statute. The basic payment
15 model, which is on the right side, is called an "all-
16 inclusive rate." Each beneficiary encounter, regardless of
17 the number or intensity of the services provided, is paid a
18 single rate. The AIR (all-inclusive rate) is calculated
19 for each rural health clinic annually by the Medicare
20 administrator contractor based upon each RHC's (rural
21 health clinic's) cost report. The RHC's AIR is subject to
22 a national payment limit, which is updated annually.

23 There are a few exceptions to the AIR such as the
24 Welcome to Medicare exam, which prompts a second AIR
25 payment if performed on the same day as another covered

1 service. This is a specific exception. There are a couple
2 of other exceptions. Currently, the annual wellness visit
3 is not such an exception to the all-inclusive rate.

4 So the proposal overview is that Mercy Medical
5 Center's Round 2 HCIA project related to rural critical
6 access hospitals, Mercy proposes that annual -- and these
7 are quotes from the actual proposal -- that "annual
8 wellness visits be eligible for an additional encounter
9 payment at the all-inclusive rate similar to the initial
10 preventative physical exam for patients that are new to
11 Medicare, and that the annual wellness visits be
12 categorized as an incident-to-carveout so that RNs
13 (registered nurses) are able to provide the AWV (annual
14 wellness visit) under direct supervision of a physician at
15 the clinic. This is the precise request that Mercy came to
16 the PTAC with.

17 Through these changes, they hypothesized and
18 provided some data that more AWVs would be conducted and
19 eventually cost savings would be realized by identifying
20 health risks that can be mitigated.

21 In summary, the proposal summary is to make an
22 additional payment for providing the annual wellness visit,
23 and, again, I've been through that. So, basically one
24 change is to include the annual visit just like they do the
25 Welcome to Medicare exam as an exception; and number two

1 would be to allow non-practitioners to provide an annual
2 wellness visit, mostly RNs, rather than higher-level
3 physician substitutes.

4 So, we summarized this and came to the
5 conclusion, which I'll now get to after you'll see lots of
6 "not applicables," that the payment method -- well, here
7 are the issues identified by the PRT and why we came to the
8 conclusion that we didn't really want to review the merits
9 of the proposal. The PRT unanimously and unequivocally --
10 that was my word -- did not consider the proposal to
11 represent an alternative physician payment model that PTAC
12 should be reviewing but, rather, rules changes within a
13 well-established payment methodology, and then say the
14 Secretary may wish to consider the merits of the proposal
15 as part of CMS' ongoing supervision of rural health
16 clinics.

17 This, by the way, is within the authority or the
18 jurisdiction of CM (Center for Medicare), not CMMI. They
19 are the ones who administer the rural health clinic program
20 and the AIR.

21 The PRT had a lengthy discussion before arriving
22 at its recommendation, concluding that it lacked the
23 expertise or standing to consider technical modifications
24 of an existing payment methodology, such that any
25 recommendations it would make regarding this proposal could

1 have unforeseen and unintended consequences. At the same
2 time, so that the public and future submitters more clearly
3 understand the scope of PTAC's work, the PRT suggests that
4 the PTAC develop criteria that distinguish proposals that
5 meet tests of meriting review as alternative physician
6 payment models and those that seek modifications and
7 establish payment methodologies such as the all-inclusive
8 rate approach for rural health clinics.

9 And then we have -- we would have -- for each of
10 these, we have not applicable except for Criterion 3, which
11 is the payment methodology, which pretty much repeats what
12 I just went through.

13 The third bullet there, two of the PRT members
14 point out that the proposed modifications do not include
15 accountability for either quality or spending associated
16 with the rule changes, and as such, the proposal does not
17 meet what they consider hallmark expectations for
18 physician-focused payment models.

19 And the third member, who was me, didn't
20 necessarily disagree, but thought that this -- we needed a
21 broader discussion of what the criteria would be and didn't
22 want to just establish one at this point. So that's why
23 the language here says "they point out" rather than
24 "recommend" this as a criterion. But this could be one of
25 the criterion that could be considered as meaningful in

1 distinguishing between an APM and just an established
2 payment model.

3 And I think that is it. We go through the rest
4 of this, and we all say "not applicable" because we
5 basically made a judgment that these were minor changes --
6 perhaps important changes but minor changes -- to a well-
7 established payment model. They were not requesting a new
8 payment methodology. They were establishing, they were
9 requesting some rule interpretation modifications, and as
10 such, we didn't think we wanted to review it.

11 That's it. That's my report.

12 CHAIR BAILET: Thank you, Bob.

13 Comments from the remaining PRT members? Harold?

14 Oh, well, maybe questions for the PRT.

15 DR. BERENSON: The other two [off microphone].

16 DR. FERRIS: I think Bob did a great job
17 representing us, so --

18 DR. NICHOLS: So, wait. I'm on this Committee,
19 too.

20 CHAIR BAILET: Like I said, Len, I --

21 DR. NICHOLS: And I have something to say, and it
22 is that Tim had this really cool two-part test he proposed,
23 and I was enamored of it, but Robert was not. And what he
24 thought actually was it made sense, but he thought the full
25 Committee should discuss it, and I agreed with that. And

1 that's why we didn't push harder to get it in the PRT
2 report.

3 So I would just point out, Mr. Chairman, it might
4 be useful, after we finish this proposal discussion, to
5 come back to that two-part test as a starting point for how
6 to start drawing these lines.

7 CHAIR BAILET: And I agree, Len, not even knowing
8 what the two-part is. I think we need --

9 DR. NICHOLS: I can't remember it, but it was
10 really cool.

11 CHAIR BAILET: I think we need to have a
12 discussion after this -- we're done with this proposal,
13 before we adjourn.

14 DR. NICHOLS: Just sometime [off microphone].

15 CHAIR BAILET: Okay. Very good. So we've got
16 Bruce and Harold.

17 * **Clarifying Questions from PTAC to PRT**

18 MR. STEINWALD: Just to clarify, under current
19 law the Secretary would have the authority to make these
20 changes and it would be subject to a rulemaking process.
21 Is that how you --

22 DR. BERENSON: Tim, that is correct, right? This
23 is regulatory, right? The decision about the AWV is a
24 regulatory decision and could be modified by -- through
25 rulemaking, correct?

1 MR. DUBE: That's our understanding reading the
2 regulations.

3 DR. BERENSON: Yeah, we looked into that some,
4 and that's what would have to happen. So as I understand
5 it -- and maybe this, I shouldn't be saying this, but I'm
6 going to say it anyway. They got to us because CMMI
7 referred Mercy to the PTAC for their proposal instead of
8 referring them to CM, which would have been the, I think,
9 the logical first place to go. We referred them to CM, and
10 those conversations are happening or have happened. So
11 that's how this proposal came to us, as I understand it.

12 CHAIR BAILET: Harold and then Grace.

13 MR. MILLER: I want to disagree in the strongest
14 terms with my colleagues on the PRT about this. If the
15 payment model proposal is problematic, then we should say
16 that we don't think that it's a good payment model. But I
17 think the notion of saying that this whole thing is not
18 applicable is really inappropriate.

19 This is how health care is delivered in many
20 rural communities around the country. This is how
21 physicians are paid in many parts of the country. And so
22 to somehow categorically suggest that anything that is
23 involved with rural health clinics is off the table I think
24 is inappropriate, or to suggest that somehow this is a
25 well-established payment model, I think that the physician

1 fee schedule is a well-established payment model. Anything
2 that people come in and want to do differently could be
3 done regulatorily by the Secretary if he or she wanted to,
4 depending on which gender is in office at that particular
5 point. And so for us to somehow say that there is
6 something different about coming in and proposing a change
7 to the way rural health clinics are paid, from saying that
8 there should be something different about the way physician
9 practices under the physician fee schedule are paid is
10 just, I think, wrong.

11 The most predominant alternative payment model
12 that exists out there is called an ACO, which changes
13 absolutely nothing about the way physicians are paid other
14 than giving them a bonus or a penalty, depending on the
15 structure. So the notion that somehow changing the way a
16 rural health clinic is paid is somehow off the table I
17 think is completely and totally inappropriate.

18 I think that this proposal could be evaluated in
19 all these respects. We may conclude that we don't think
20 that it meets the criteria, but I think it absolutely can
21 be evaluated against all the criteria. We can say, does
22 this, in fact, enable practitioners -- i.e., people who
23 practice in rural health clinics -- an opportunity to
24 participate in something that they don't otherwise have an
25 opportunity to participate in? Will it improve quality and

1 cost? Will it encourage value over volume? Will it give
2 more patients choices? All of those things could be
3 evaluated against a rural health clinic payment change,
4 which this is.

5 Now, again, I'm not saying that I think that this
6 is the best model, and we'll talk about that. But the
7 notion that somehow it's not applicable I think is just
8 wrong.

9 CHAIR BAILET: I think Bob has a comment on that.

10 DR. BERENSON: Yeah, now, I don't think we have
11 ever said that because it's dealing with the rural health
12 clinics and there's an established payment methodology that
13 we wouldn't consider proposals. We've considered this one
14 a de minimis modification in the established payment model.
15 I could imagine any number of proposals for changing how
16 fees are calculated in the Medicare fee schedule, which I
17 would consider real and substantive, as opposed to coming
18 in and saying we want to get paid a little more for doing
19 an appendectomy, which is a change in the payment model but
20 -- so it does -- so I don't think we are in any way arguing
21 that rural health clinic payment is off limits. I think we
22 are arguing -- and I'll look to my two colleagues -- that
23 this particular proposal was nominal -- would have a
24 nominal effect on behavior, on incentives. It might be a
25 good one, but it would -- it's not a payment model. It is

1 just a tinkering with an established payment model.

2 DR. NICHOLS: I think the key phrase is "de
3 minimis," and I would take exception, Harold, to saying
4 that we're saying don't touch rural. That's not what we're
5 saying. We're saying that this proposal is a de minimis
6 change in the existing structure and not worthy of what
7 PTAC is intended to do.

8 MR. MILLER: It may be, but that's -- my point is
9 to say that all of the criteria are not applicable because
10 you think it's a de minimis change I don't think is the
11 right -- I think we should go through and say whether or
12 not we think it meets the criteria or not. I don't think
13 -- and I think the impression that this will create is that
14 somehow because there is a statement in the PRT report --
15 I'm challenging two things here. One is the notion that
16 saying that all these things are not applicable and then
17 this statement that says this is an established payment
18 model, the rural health clinic payment model, that implies
19 -- in this statement in the PRT report -- that implies that
20 somehow we view rural health clinic payment as something
21 different than what this Committee addresses. And my point
22 is that is, in fact, how physicians in many parts of
23 America are paid. Whether this model itself is a good
24 model is a different question. But we deal with that with
25 everything else.

1 CHAIR BAILET: Okay. I think this is an
2 important point. Grace?

3 DR. TERRELL: Mine are a couple of questions,
4 actually, for the Committee, and one of it was with respect
5 to the things that they were asking for, how many of them
6 were absolutely related to it being a rural -- or did you
7 not even evaluate their -- because I don't believe an RN
8 can do this in other settings either. So there are certain
9 aspects of it that were just a policy change that was above
10 and beyond that, which is relevant only in the sense of
11 where Harold was going in the conversation that I disagree
12 with, that this was specifically about that particular
13 proposal.

14 Relevant to that is the issue that we talked
15 about earlier in the day, and it's sort of the extremes and
16 in the middle, where there are probably physician-focused
17 payment models for which certain changes in the way things
18 are paid for, whether there's a code or not a code, whether
19 we need to -- you know, someone needs a co-pay, would be
20 relevant to the physician payment model.

21 So it would be nice to understand, since we've
22 had the extremes today, what the middle might be. I will
23 agree that this is not applicable relative to what I
24 understand about it, but I do think a conversation that we
25 ultimately have around what makes those distinctions, maybe

1 it's going to be, you know, Dr. Ferris' two-part solution
2 or something, but are we saying that certain aspects of
3 payment of the fee schedule will never, you know, be part
4 of something that's a physician-focused payment model or
5 not? I think we probably are going to come across that
6 there are criteria that's going to let us be that.

7 So two questions. Was this only about the rural,
8 you didn't even have a chance to evaluate that? And the
9 second one is: Did you talk about what might or might not
10 be criteria that would be inclusive?

11 DR. BERENSON: Well, in the latter one, you know,
12 Tim proposed a criterion, a two-part test. Part of my
13 reaction was that that would handle this proposal, but it
14 wouldn't handle any number of other proposals that we might
15 want to also not consider to be APMs. We can remove
16 offensive language that may imply that we somehow think
17 that rural health clinic payment is off limits to the PTAC.
18 That's not what we meant at all.

19 I guess the point I would make here is we have to
20 be able to distinguish between a model and just a small
21 change in a model. I think we are -- it is incumbent on us
22 to do that. And if ever there's an example of a de minimis
23 change in a model, this is it. They haven't asked for a
24 restructuring of the AIR to promote -- permit physicians
25 and staff to transform how they practice and help patients.

1 They've asked for, "We want to get paid for an AWV." And
2 so I think we came to the judgment that that was -- didn't
3 qualify as a model, but we do not want to imply that for
4 some reason rural health clinic payment is off limits or
5 that even the Medicare fee schedule is off limits for a
6 real structure -- restructuring that would change
7 incentives in a substantial way. If that -- I don't know
8 if that's responsive.

9 CHAIR BAILET: Tim and then Len.

10 DR. NICHOLS: I need to answer --

11 CHAIR BAILET: Go ahead.

12 DR. NICHOLS: Tim's on the -- he may answer, too.

13 I was just going to say there were two dimensions of
14 ruralness that were relevant here. One is people have to
15 travel a long way to get to the clinic, and they would
16 prefer to do all the stuff when they're there, and having
17 them go back and come back for the second visit was
18 problematic from the patient's point of view. So it was
19 convenience and, therefore, access and, therefore,
20 ultimately probably good patient care.

21 Second, staffing issues and having the RN perform
22 the wellness visit under the supervision of a physician in
23 the clinic was a scope of practice kind of issue that is
24 often met in rural America. So to me, those dimensions
25 were why this proposal made sense to them and, in fact,

1 they do make sense, but it's just not a --

2 CHAIR BAILET: Tim and then Harold.

3 DR. FERRIS: So, I'm interested in learning more
4 about the basis of Harold's objection, but I want to make
5 what might be a bridging point, which is in response to my
6 proposed criteria, Bob's main objection to endorsement of
7 that was establishing case law that would prevent some
8 things that we do want to see.

9 I wonder if that isn't part of Harold's
10 objection, and I would say I share that concern. And we
11 had a conversation specifically about this proposal in the
12 context of not wanting to -- because we are establishing
13 case law here, and I hear that we may be setting a
14 threshold and that that's a scary prospect.

15 What I would say is that's a scary prospect in
16 both directions, which is we may be dissuading potentially
17 useful proposals and good proposals that we want to see.
18 We may be simultaneously -- if we go the other way, we may
19 be simultaneously encouraging everyone who wants to change
20 a V code or a, you know, the dollar value on an ICD-9 code
21 or whatever it is, to come with their thing as a new
22 payment model. And so I think this is -- to me it's a
23 legitimate argument to have, or legitimate -- "argument" is
24 not the right word -- a legitimate discussion to set the
25 framework. I think we agreed that this proposal for us,

1 for the PRT -- reminding us and everyone else that the PRT
2 does not determine the PTAC's decision -- was helpful
3 because we all agreed this was on the other side of what we
4 want to see, that it was too small a change for -- and I
5 think it would be -- that was the main.

6 CHAIR BAILET: Bob.

7 DR. BERENSON: I'm just wondering for process,
8 should we hear from Mercy --

9 CHAIR BAILET: Well, they're on the phone.

10 DR. BERENSON: -- and then come back to this
11 discussion?

12 CHAIR BAILET: Right, but I just -- Harold, you
13 have a closing comment or --

14 MR. MILLER: I was -- well, Tim said he wanted to
15 hear more. I mean, I agree with that. I think we need to
16 have a policy about what we're going to do. We have in the
17 -- whatever we call it now, the RFP -- a statement about
18 things that -- submitter instructions, a statement that we
19 developed way back about things we were more likely to
20 recommend, but that's how we framed it. We said more
21 likely to recommend, which says, in fact, that there needs
22 to be some accountability built into the thing. We didn't
23 say, though, that we were not going to consider something
24 else. We just simply said we're not going to recommend it.

25 So my point is here I think that if we want to

1 say it doesn't meet the payment methodology criterion, we
2 should say that. But we shouldn't say everything else is
3 inapplicable. And if we want to change our rules and say
4 you have to pass the payment methodology test first before
5 we'll consider any of the other things, which I wouldn't
6 necessarily disagree with, but that would be a prospective
7 change to people before they -- before they come in on our
8 process.

9 I was going to answer the question about the
10 nurses, and we can ask them, but my impression is the issue
11 is you can have a nurse do it in other places under --
12 anywhere under the supervision of a physician. The concern
13 here is that if the patient just comes in and sees a nurse,
14 they will not have -- it's not a billable encounter because
15 you have to have seen the practitioner, a billing
16 practitioner who is not a nurse, on that visit. So you
17 can't just come in for an annual wellness visit --

18 DR. TERRELL: That's not a rural health issue.
19 That was my point. That's not specific to rural health.

20 MR. MILLER: It is in this particular case
21 because this -- yes, this -- they can't bill that as an
22 encounter; whereas, you could bill the visit to the
23 physician practice -- maybe. I don't know. But, anyway,
24 that's what we need to resolve, but that's the thing you're
25 trying to solve. But we can ask them.

1 DR. NICHOLS: It's not a technical billing
2 difference for rural, but it's a practical issue because of
3 the staffing reality of their world.

4 CHAIR BAILET: All right.

5 DR. TERRELL: RNs do it in my office, okay? But
6 I go in and see the patient as the provider. Are you
7 saying that an RN can't ask the questions and then they go
8 in and do that with the provider seeing them?

9 DR. NICHOLS: We should ask Mercy [off
10 microphone].

11 DR. TERRELL: Okay.

12 * **Submitter's Statement, Questions and Answers, and**
13 **Discussion with PTAC**

14 CHAIR BAILET: Right, and I think that's a
15 perfect segue to actually inviting our submitters, Anne
16 Wright and Sandra Christensen, who are on the phone, to
17 address the Committee. Can you guys hear us?

18 MS. WRIGHT: Yes, we can. Thank you for the
19 opportunity. This is Anne Wright, and I am the Director of
20 Rural Operations at our Mercy Accountable Care
21 Organization, and as somebody on the Committee had
22 indicated earlier, we were the recipient of a Round 2 HCIA
23 award. So, as you'd alluded to, we had indicated in our
24 payment model, in developing our project, that we were
25 going to have our rural participants join our ACO, and they

1 would join a Medicare shared savings contract. And this is
2 one of the challenges that we uncovered as we got into our
3 project a little bit more, that right now all of our
4 participants are kind of living in two worlds -- in a fee-
5 for-service world and in a shared savings world. And with
6 our rural health clinics getting reimbursed under their
7 cost-based methodology, essentially if you work to decrease
8 utilization, all you do is -- your costs stay the same, so
9 you increase the cost per visit; thus, we don't have any
10 opportunity with our rural sites for achieving shared
11 savings, or we have minimal opportunity.

12 So that encourages the rural sites to live more
13 in the fee-for-service world, and obviously our ACO, along
14 with others, a huge strategy of ours is to get preventative
15 services completed, and one of those big ones being annual
16 wellness visits. And so when we are doing that, we've
17 encountered that -- I think it sounds like the Committee
18 understands correctly that with the all-inclusive rate
19 method of reimbursement, a patient comes in for a medical
20 service of some kind; they're not able to get the annual
21 wellness visit completed that same day or at least able to
22 bill for that service the same day. And that is -- it's a
23 challenge for us because, as the group inferred, the
24 patient would need to come back and transportation is a
25 huge issue in a lot of our rural communities. They would

1 need to leave and come back a separate day for that
2 separate service. So this was a challenge that we've
3 uncovered. Sandra -- I'm going to introduce my colleague
4 here who's also joined us. She has more expertise than I
5 do related to rural health clinic billing. Sandra
6 Christensen, can you introduce yourself since you're on the
7 line as well?

8 MS. CHRISTENSEN: Thank you, Anne, and thank you
9 to the Committee. I am Sandra Christensen, and I am the
10 finance exec for our rural network. So I work closely with
11 -- across the State of Iowa with all of our critical access
12 hospitals who many own and operate rural health clinics, as
13 well as provider-based clinics.

14 Many of your points -- and Anne alluded to --
15 this topic does become access issue, and, you know, how do
16 we -- and that issue as well as one of the Committee
17 members pointed out, you know, the rural health clinic
18 model of payment, which is cost reimbursed, and really what
19 I'm going to call a "safety net reimbursement." And it's
20 so important to continue to -- that we maintain that in our
21 world so that we retain that access to care for patients
22 across rural Iowa and in other states.

23 But I think our proposal talked about we have
24 done a lot of work with the CMMI grant and our Health Coach
25 Program, that we're looking to how do we create the

1 sustainability of that position? You know, our rural
2 health clinics have not mentioned it, but we have a concern
3 that once the grant dollars go away to support that
4 position, how do we have a billing mechanism or something
5 that supports that health coach's role? And I think this
6 proposal starts to address that, that if we can create a
7 billable visit, one that the patient doesn't have to come
8 back to, is -- supports the health coaches, which is an RN
9 today, the role that he or she does, and also being mindful
10 about in our rural communities access to physicians, mid-
11 levels, just physician shortage, this helps expand those
12 services and be able to meet the patient's needs.

13 And, you know, through wellness and prevention
14 models, we are trying to move that patient care out of the
15 ED into our clinics. But if we don't have access to more
16 providers, we've got to create capacity somehow. And I
17 think that was also one of the drivers behind this
18 proposal.

19 MS. WRIGHT: Thank you.

20 Just one additional point of clarification that
21 the group seemed to have in your discussions, the RN
22 billing for the service, and in our clinics that are in our
23 urban locations that are under the physician fee schedule,
24 we do have RNs that their specific role is to actually do
25 annual wellness visits. So they do it from start to finish

1 in our urban clinics and are able to bill for that service
2 as an incident. So it is a difference. My understanding
3 of the rural health clinic legislative statute is that if a
4 physician -- in order to bill for the service, a physician
5 needs to see the patient, and because of the scheduling
6 challenge in doing so with our -- with the physician
7 shortages that we experience in our rural communities, that
8 makes it challenging to get these annual wellness visits,
9 which are huge drivers of quality, to be completed.

10 So I hope that helps to answer some of your
11 questions. If there's any more, we're happy to address
12 those as well.

13 CHAIR BAILET: Thank you.

14 We're now going to open it up for questions from
15 the Committee members, and Harold Miller is first.

16 MR. MILLER: Hi, this is Harold Miller. Three
17 questions for you.

18 First of all, I was a little perplexed. It
19 sounded to me as though most of your rural health clinics
20 are part of critical access hospitals. Is that right?

21 MS. WRIGHT: That's correct.

22 MR. MILLER: So you could, in fact, pay for the
23 nurse simply as a cost to the rural health clinic because
24 there's no limit on the per visit amount for a critical
25 access hospital-located rural health clinic? Right?

1 MS. WRIGHT: Correct.

2 MR. MILLER: So this really shouldn't be a
3 problem for the rural health clinics at the critical access
4 hospitals. I mean, in other words, you can't bill
5 separately for an annual wellness visit, but you could hire
6 a nurse; you could have the nurse doing those visits and
7 simply count the cost of that towards the cost of the rural
8 health clinic. You couldn't do that in an independent
9 rural health clinic, but you can do it at a critical access
10 hospital-based clinic because there's no limit on the per
11 visit payment for a critical access hospital clinic.

12 Correct?

13 MS. CHRISTENSEN: Correct.

14 MR. MILLER: Second question -- So this would be
15 an issue for an independent rural health clinic, but it
16 wouldn't necessarily be an issue for the critical access
17 hospital-based clinics.

18 The second question was: It sounded like your
19 ACO felt it to be valuable to do -- have the annual
20 wellness visits done. I'm curious as to why the ACO then
21 didn't pay for them itself in order to be able to achieve
22 the savings that would be -- that you showed. You showed
23 that the clinics that had the higher number of AWVs had
24 lower spending, so I would think that if the ACO was trying
25 to reduce spending, it would have decided to invest in

1 those visits itself.

2 MS. CHRISTENSEN: And I think on that one -- this
3 is Sandra Christensen -- they were running up against the
4 whole methodology of cost reimbursement and, as Anne
5 mentioned, decreasing the cost per visit, because as you --
6 and when you're looking at rural health clinics and they're
7 aligned with critical access hospitals, as you're
8 decreasing those number of visits, you're driving up the
9 cost per visit. So in a rural health clinic, one of your
10 points was that, yes, the cost of that health coach should
11 be covered in the rural health clinic, cost reimbursement,
12 and, yes, it is. But it's also spread across all of the
13 payer mix in that clinic. So you're not getting 100
14 percent of that health coach's cost --

15 MR. MILLER: Well, it would be -- I mean, if you
16 had -- if only Medicare was paying for it, then you would
17 have the health coach or the nurse doing it just for
18 Medicare patients. Maybe there's not enough volume to
19 support that, but, in fact, because it's cost-based, if you
20 restricted it that way, it would still be covered because
21 there's no productivity requirement associated with that.

22 And I guess the third question was: Did you
23 think at all about in terms of putting a proposal together
24 to us or to anyone having some kind of a performance
25 measure tied to paying for the annual wellness visits? For

1 example, actually achieving a percentage of the population,
2 actually having the annual wellness visit; as opposed to
3 just saying we want to be paid for the annual wellness
4 visits, actually having a percentage of the population
5 screened or any other kinds of results associated with
6 that? Because I think that's one of the things we're
7 struggling with, is simply adding a payment for a service
8 without any kind of quality or cost measure attached to it.
9 Have you thought about whether there could be a measure of
10 some kind you could attach to the payment?

11 MS. CHRISTENSEN: You know, I'm going to answer
12 from my perspective -- this is Sandra -- and then maybe
13 Anne, because, you know, that's a very good thought because
14 that might be some of the answer on -- you know, we have
15 challenges with the cost reimbursement methodology and what
16 are the incentives to drive quality and compliance from the
17 patient. And, you know, I'm not aware that we did put that
18 in, but that might be something to consider in this model,
19 that that is the benefit or an incentive payment for a
20 rural health clinic provider that, yes, X number of
21 patients meet these annual wellness visits, and that might
22 be a model to consider.

23 MS. WRIGHT: And some of our sites do - they're
24 all of the providers are employed by their own critical
25 access hospitals. So several of them have included in the

1 provider compensation model as an incentive to complete
2 annual wellness visits, that -- but those are the ones, you
3 know, we're struggling, too, with a lot of our sites pay
4 their providers based on RVUs (relative value units), and
5 so they see this as a big time sucker to do annual wellness
6 visits, which decrease their productivity.

7 So it's hard for us to mandate that they -- that
8 they do employ a productivity model for their -- or that
9 they do employ a compensation model change for the
10 physicians that they employ. But it has been done, I
11 guess, in several --

12 MR. MILLER: Every provider organization has to
13 face the issue that if they're going to be paid differently
14 on the outside, they have to pay differently on the inside.
15 But I would just be thinking about whether there was some
16 way that you could ensure that, in fact, the patients, the
17 highest-risk patients were being reached, et cetera,
18 through that model, because I think you actually could do
19 something different like that given the kind of cost-based
20 payment you have.

21 CHAIR BAILET: Thank you, Harold.

22 MR. MILLER: Thank you.

23 CHAIR BAILET: Paul.

24 MS. WRIGHT: Thank you.

25 DR. CASALE: Yeah, hi. Just a clarification, and

1 I may have this wrong. It was my understanding that
2 wellness visits in rural areas could be completed through a
3 telehealth visit. Is that true? Or do I have that wrong?

4 MS. WRIGHT: I think -- no, I do think that that
5 is -- I agree, that's a proposal in 2018 with the -- it's a
6 proposal change effective in 2018.

7 DR. CASALE: Yeah, okay.

8 MS. WRIGHT: So that actually has kind of come
9 about. Since we've submitted this application, we saw that
10 that was in the proposed regulations, and it may be an
11 opportunity. Some of the things that we need, we'd need to
12 just work through operationally. For an annual wellness
13 visit, you do have to take some just preliminary vitals
14 that would -- you know, it's challenging to do that via
15 telemedicine. But certainly portions of the annual
16 wellness visit could be completed via telemedicine.

17 DR. CASALE: Yeah, that might help with the
18 revisit and the travel.

19 MS. WRIGHT: Yes.

20 CHAIR BAILET: Thank you.

21 Any other questions for the submitters from the
22 Committee?

23 [No response.]

24 CHAIR BAILET: Great. So, Anne and Sandra, we
25 thank you for the time and effort to put this proposal

1 together and answering our questions.

2 * **Comments from the Public**

3 CHAIR BAILET: I do not see that there are people
4 who are in the queue to make a public statement, so I would
5 open it up first for the phone. Anybody on the phone
6 making a public comment?

7 [No response.]

8 CHAIR BAILET: And then anybody in the room
9 wanting to make a public comment on this proposal before we
10 move to the next phase?

11 [No response.]

12 * **Committee Deliberation**

13 CHAIR BAILET: Okay. So are we ready to go
14 through the criteria? It looks like we are. Matt has
15 queued it up.

16 So, again, just to reiterate, there's 10
17 criteria. We're going to go through them one at a time.
18 The numbers 1 and 2 do not meet, 3 and 4 meets, 5 and 6
19 meets and deserves priority consideration, and then for
20 criteria that the Committee member feels it not applicable,
21 pushing the zero key will illuminate the asterisk column.

22 * **Voting**

23 CHAIR BAILET: So we're going to go ahead and
24 start to vote on Criterion 1, which is Scope, which is a
25 high-priority item, aimed at either directly address an

1 issue in payment policy that broadens and expands the CMS
2 APM portfolio or include APM Entities who has opportunities
3 to participate, and APMS have been limited.

4 Please vote.

5 [Electronic voting.]

6 CHAIR BAILET: Ann.

7 * **Criterion 1**

8 MS. PAGE: Zero members voted 5 or 6, meets and
9 deserves priority consideration. Zero members voted 4,
10 meets. One member voted 3, meets. Zero members voted 2,
11 does not meet. One member voted 1, does not meet; and nine
12 members voted not applicable.

13 So the majority has determined that Criterion 1
14 is not applicable to this proposal.

15 CHAIR BAILET: Thank you, Ann.

16 Criterion Number 2 is Quality and Cost, high-
17 priority item, anticipated to improve health care quality
18 at no additional cost, maintain quality while decreasing
19 cost, or improve health quality and decrease in cost.

20 Please vote.

21 [Electronic voting.]

22 * **Criterion 2**

23 MS. PAGE: Zero members voted 5 or 6, meets and
24 deserves priority consideration. Zero members voted 4,
25 meets. One member voted 3, meets. Zero members voted 2,

1 does not meet. One member voted 1, does not meet. Nine
2 members voted not applicable.

3 The majority has determined that Criterion 2 is
4 not applicable to this proposal.

5 CHAIR BAILET: Thank you, Ann.

6 Criterion Number 3 is Payment Methodology, high-
7 priority item, pay the APM Entities with a payment
8 methodology designed to achieve the goals of the PFPM
9 criteria, addresses in detail through this methodology how
10 Medicare and other payers, if applicable, pay APM Entities
11 and how the payment methodology differs from current
12 payment methodologies, and finally, why the physician-
13 focused payment model cannot be tested under current
14 payment methodologies.

15 Please vote.

16 [Electronic voting.]

17 * **Criterion 3**

18 MS. PAGE: Zero members voted 5 or 6, meets and
19 deserves priority consideration. Zero members voted 3 or
20 4, meets. Zero members voted 2, does not meet. Five
21 members voted 1, does not meet; and six members voted not
22 applicable.

23 The majority has found that six -- that the
24 proposed -- that Criterion 3 is not applicable to this
25 proposal.

1 CHAIR BAILET: Thank you, Ann.

2 And Criterion Number 4 is Value over Volume,
3 providing incentives to practitioners to deliver high-
4 quality health care. Please vote.

5 [Electronic voting.]

6 * **Criterion 4**

7 MS. PAGE: Zero members have voted 5 or 6, meets
8 and deserves priority consideration. Zero members voted 4,
9 meets. One member voted 3, meets. Zero members voted 2,
10 does not meet. One member voted 1, does not meet. Nine
11 members voted not applicable.

12 The majority has determined that Criterion 4 is
13 not applicable to this proposal.

14 CHAIR BAILET: Thank you, Ann.

15 And number 5, Flexibility, provides the
16 flexibility needed for practitioners to deliver high-
17 quality health care.

18 Please vote.

19 [Electronic voting.]

20 * **Criterion 5**

21 MS. PAGE: Zero members voted 5 or 6, meets and
22 deserves priority consideration. Zero members voted 4,
23 meets. One member voted 3, meets. One member voted 2,
24 does not meet. Zero members voted 1, does not meet; and
25 nine members voted not applicable.

1 The majority has determined that Criterion 5 is
2 not applicable to this proposal.

3 CHAIR BAILET: Thanks.

4 And number 6 is Ability to Be Evaluated,
5 evaluable goals for quality of care, cost, and other goals
6 of the PFPM.

7 Please vote.

8 [Electronic voting.]

9 * **Criterion 6**

10 MS. PAGE: Zero members have voted 5 or 6, meets
11 and deserves priority consideration. Zero members have
12 voted 4, meets. One member voted 3, meets. Zero members
13 voted 1 or 2, does not meet; and 10 members voted not
14 applicable.

15 The majority has determined that Criterion 6 is
16 not applicable to this proposal.

17 CHAIR BAILET: Number 7 is Integration in Care
18 Coordination, encourage greater integration and care
19 coordination among practitioners and across settings where
20 multiple practitioners or settings are relevant to
21 delivering care to the population treated under the PFPM.

22 Please vote.

23 [Electronic voting.]

24 CHAIR BAILET: There we go.

25 * **Criterion 7**

1 MS. PAGE: Zero members voted 5 or 6, meets and
2 deserves priority consideration. Zero members voted 4,
3 meets. One member voted 3, meets. Zero members voted 2,
4 does not meet. One member voted 1, does not meet; and nine
5 members voted not applicable.

6 The majority has determined that Criterion 7 is
7 not applicable to this proposal.

8 CHAIR BAILET: Thank you, Ann.

9 Patient choice, encourage greater attention to
10 health of the population served while also supporting the
11 unique needs and preferences of individual patients.

12 Please vote.

13 [Electronic voting.]

14 * **Criterion 8**

15 MS. PAGE: Zero members voted 5 or 6, meets and
16 deserves priority consideration. One member voted 4,
17 meets. Zero members voted 3, meets. Zero members voted 1
18 or 2, does not meet. Ten members voted not applicable.

19 The majority has determined that Criterion 8 is
20 not applicable to this proposal.

21 CHAIR BAILET: Thank you, Ann.

22 Patient Safety is number 9, Aim to Maintain and
23 Improve Standards of Patient Safety. Please vote.

24 [Electronic voting.]

25 * **Criterion 9**

1 MS. PAGE: Zero members voted 5 or 6, meets and
2 deserves priority consideration. One member voted 4,
3 meets. Zero members voted 3, meets. Zero members voted 1
4 or 2, does not meet; and 10 members voted not applicable.

5 The majority has found that Criterion 9 is not
6 applicable to this proposal.

7 CHAIR BAILET: Thank you, Ann.

8 The last criterion, Number 10, is Health
9 Information Technology, encourage the use of HIT to inform
10 care.

11 Please vote.

12 [Electronic voting.]

13 * **Criterion 10**

14 MS. PAGE: Zero members voted 5 or 6, meets and
15 deserves priority consideration. Zero members voted 4,
16 meets. One member voted 3, meets. Zero members voted 1 or
17 2, does not meet; and 10 members voted not applicable.

18 The majority has determined that Criterion 10 is
19 not applicable to this proposal.

20 CHAIR BAILET: And, Ann, just to summarize the
21 voting, please?

22 MS. PAGE: The Committee determined that all 10
23 criteria are not applicable to this proposal.

24 CHAIR BAILET: Okay. So now the next and final
25 phase is actually voting on the recommendation to the

1 Secretary. So if we could get that up, Matt?

2 Thank you.

3 So we have four numbers, 1 through 4: 1, do not
4 recommend the model to the Secretary; number 2 is recommend
5 the model for limited-scale testing; 3 is recommend the
6 proposed model to the Secretary for implementation; and 4
7 is recommend the proposed payment model to the Secretary
8 for implementation as a high priority. Again, we the fifth
9 category, which is not applicable, and that is by pressing
10 the key zero will get you the asterisk here.

11 So we're going to vote electronically first, and
12 then we're going to go around the room. So please vote.

13 Ann?

14 [Electronic voting.]

15 * **Final Vote**

16 MS. PAGE: Zero members voted 4, recommend
17 proposed payment model to the Secretary for implementation
18 as a high priority. Zero members voted recommend proposed
19 payment model to the Secretary for implementation, and zero
20 members voted recommend the proposed payment model to the
21 Secretary for limited-scale testing. One member voted to
22 not recommend the proposed payment model to the Secretary,
23 and 10 Committee members voted that that proposal is not
24 applicable. And that would be the recommendation to the
25 Secretary.

1 * **Instructions on Report to the Secretary**

2 CHAIR BAILET: All right. So we're going to
3 start with Tim, and we'll just go around the room.

4 DR. FERRIS: I voted not applicable, and it was
5 for the reasons that we had discussed. Maybe if I try to
6 articulate them briefly, it was because we considered this
7 proposal to be a technical change in regulations that did
8 not represent a new model but represented a change in
9 technical regulations related to an existing model, and
10 with concerns about the difficulty of drawing a clear line
11 between those things, I felt that this fell clearly on the
12 side of that, of that line, where this was not a new
13 payment model.

14 CHAIR BAILET: Grace?

15 DR. TERRELL: I voted not applicable, and with --
16 I agreed with the PRT's logic. And with respect to the
17 fact that we established -- we're calling it case law, but
18 we need to make sure that our public understands it is not
19 case law. It's a metaphor that we're using, but we
20 established a logic at the Committee level with the last
21 one around this issue of applicability and how we vote.

22 I, therefore, flipped from my opinion last time
23 and voted not applicable because I believe now that that
24 would be where the Committee's consensus was, so I will do
25 that in the future if something is deemed not applicable.

1 CHAIR BAILET: Thank you, Grace.

2 Harold?

3 MR. MILLER: I voted do not recommend. I would
4 like to be recorded as a very strong minority opinion. I
5 do not believe it was appropriate to say that these were
6 not appropriate. I think all of the criteria were
7 appropriate for this model. I did not feel that the
8 payment methodology was something that we should recommend,
9 but I think that all of the criteria are applicable. And I
10 would like to have that recorded.

11 I do think that we should be defining more
12 clearly what kinds of things we want to see and what
13 characteristics we want to have, but I think that
14 ultimately, if someone -- unless we are going to say, which
15 we have not said so far, we will not accept applications,
16 then I think if someone sends us an application, even if we
17 have said clearly what we are not inclined to recommend,
18 then we should review it and review it and recommend
19 against it or don't recommend it, but not simply punt on
20 the evaluation of it against all the criteria because I
21 think it is helpful to the applicants. I think it is
22 ultimately helpful to the Secretary to CM, to CMMI or
23 anyone else to know that we said we felt that something, in
24 fact, might improve quality and reduce cost, et cetera, but
25 that we didn't even think the payment methodology was

1 adequate versus something that we didn't even think was a
2 payment at all.

3 And I think this was a -- is a payment model. It
4 just does not meet the kind of criteria that we should
5 approve.

6 CHAIR BAILET: Paul?

7 DR. CASALE: Yeah. I voted for not applicable,
8 and I respectfully disagree, Harold. I just didn't see
9 this as a model to -- that I could evaluate each criteria.

10 I think some of your suggestions to the
11 submitters about, well, if you're going to be paid
12 differently on the annual wellness, you're going to tie it
13 to some cost or outcome or other measures. And I just
14 didn't see enough to see that this was, indeed, an actual
15 model other than just a change in payment.

16 CHAIR BAILET: Bruce.

17 MR. STEINWALD: I voted not applicable. I think
18 since there is an established rulemaking process for a
19 change like this that it's not necessary or desirable for
20 us to evaluate it.

21 And furthermore, given the volume of proposals
22 we're getting and the volume of materials we have to review
23 for meetings like this, I certainly wouldn't want to
24 encourage more proposals of the kind that are -- let's call
25 them "de minimis changes" in payment methodology.

1 CHAIR BAILET: I also voted not applicable and
2 for the reasons already stated.

3 VICE CHAIR MITCHELL: I voted not applicable for
4 every criteria and for the overall model.

5 DR. NICHOLS: I voted not applicable because I
6 think it's important not to prejudice the Secretary against
7 the idea that he might want to -- or she might want to
8 consider this coding business they're asking for because,
9 in fact, it probably does make sense in their context, but
10 it's not a model that rises to the level I think we should
11 be -- we should be concerned with.

12 DR. PATEL: I also voted not applicable for
13 reasons already mentioned.

14 DR. BERENSON: I largely -- I voted not
15 applicable, and Bruce stated my view pretty exactly. I
16 don't think our job is to administer -- tell CM how they
17 administer established payment models that they have
18 authority to do. We're supposed to be identifying
19 important new alternative payment models that fundamentally
20 change incentives, change behavior, and if we spend all of
21 our time deciding on the merits of a code change, we will
22 not have any energy to do what we're supposed to be doing.

23 DR. MEDOWS: I voted non-applicable because I
24 believe it is a rural health clinic reimbursement issue for
25 annual wellness visits. I also believe that it is

1 something that needs to be addressed with respect to
2 expanded scope of practice for RNs in rural communities
3 where there is a real need to actually have providers
4 available.

5 Thanks.

6 CHAIR BAILET: Thank you, and thank Anne and
7 Sandra for submitting the proposal and staying with us,
8 even though it's on the phone, while we ask clarifying
9 questions and finished our process.

10 Any final comments because --

11 MS. WRIGHT: Thank you for the --

12 CHAIR BAILET: Go ahead, please.

13 MS. WRIGHT: No, I just -- I just wanted to say
14 thank you for the opportunity.

15 CHAIR BAILET: You're welcome.

16 I think it's important, Tim, if you could just
17 summarize where we are as it relates to the Secretary's
18 report specifically in the comments, please.

19 MR. DUBE: Certainly.

20 So, at this point, 10 of the PTAC members voted
21 that it was not applicable. One PTAC member voted that it
22 -- that all 10 criteria should be evaluated, and I did want
23 to just probe the PTAC members to see if there was a direct
24 response to Dr. Miller's assertion that all 10 criteria be
25 [unintelligible]

1 DR. TERRELL: Mr. Miller.

2 MR. DUBE: Oh, Mr. Miller. Sorry.

3 MR. MILLER: Harold.

4 CHAIR BAILET: He plays one on TV.

5 [Laughter.]

6 MR. DUBE: I didn't hear any direct responses to
7 his assertions, and I wanted to make sure that if there
8 were any, that we recorded those.

9 DR. CASALE: Well, I responded. I said I
10 respectfully disagreed that it could be evaluated on all
11 the criteria because I didn't feel there was enough in
12 there, particularly around --

13 MR. MILLER: I think it's a minority opinion. I
14 think everybody does disagree with what I said. That's why
15 I said I think it -- I want to be recorded as a minority
16 opinion.

17 DR. BERENSON: But I would want to put in the
18 record that the PRT did not review those 10 criteria on the
19 merits, so that I would have no basis for voting one way or
20 another for those 10 criteria because we didn't establish
21 -- we didn't discuss them at all. We took the position
22 that since the proposal wasn't applicable, we had no
23 judgment. And I think that needs to be repeated. I think
24 it represents the majority view as to why they voted --
25 that we voted non-applicable.

1 CHAIR BAILET: Harold.

2 MR. MILLER: I guess one thing I would propose is
3 I -- for the language into the final report, I guess I
4 would suggest wholly independent of my point, I would
5 suggest that we not include the statement that is at the
6 beginning of the last paragraph, where it says concluding
7 that it lacked the expertise or standing to consider
8 modifications to an existing payment methodology because I
9 think everything we are doing is modifications to existing
10 payment methodologies, and that's to me an odd thing to
11 say.

12 It's a completely different thing to say, I
13 think, in terms of some technical changes to something, but
14 that statement as it's written, it seems to me to be overly
15 broadly sweeping.

16 DR. BERENSON: I am more than happy to take that
17 statement out.

18 * **Discussion on Atypical Proposals**

19 CHAIR BAILET: Any other comments, Tim, at this
20 point?

21 [No response.]

22 CHAIR BAILET: No?

23 So that concludes our fourth proposal, and I just
24 wondered, given the fact that this was the second, what we
25 were classifying as atypical, whether we could spend a

1 minute as a Committee and actually deliberate to some
2 degree or discuss amongst ourselves with the public
3 listening in on what do we do futuristically, what's our --
4 do we have a methodology, whether it's Tim's, you know,
5 bifurcation, two-part model? I don't know. But I think if
6 we could spend a minute, it would be helpful.

7 So I don't know if you want to open it up, Tim,
8 or, you know, you've got a point of view on it.

9 DR. FERRIS: Well, I think to me, framing this
10 conversation in the context of maybe -- maybe the term for
11 this is the "Goldilocks Dilemma" for the PTAC, which is we
12 reviewed -- or we're asked to review a proposal that seemed
13 in some ways too large for PTAC.

14 We also reviewed a proposal, which we -- some of
15 us felt was too small for PTAC, and I have to say I have
16 some degree of discomfort establishing -- and I think this
17 reflects what I have learned from Bob -- establishing what
18 -- where the cutoffs are based on criteria because I worry
19 that any criteria we come up with -- we haven't seen enough
20 proposals to know whether or not if we establish criteria.

21 On the other hand, it might be beneficial to us
22 to put some strawman, straw-person criteria out, not as a
23 rule, but as a test of our own process to see whether or
24 not proposals that we think are too large or too small, if
25 the criteria work.

1 I worry that if we don't propose something that
2 our process for figuring out what guidance to give the
3 public will be delayed even further.

4 So in that spirit, in the spirit of that context
5 of the Goldilocks Dilemma for the PTAC, the criteria was
6 actually -- it's not a mystery. It was actually in the
7 language of the PRT report under the payment methodology,
8 which is there has to be some accountability for quality,
9 very general, just some accountability for quality, and
10 some accountability for cost.

11 I believe that the last proposal that we reviewed
12 would not -- there was -- I didn't see it; maybe it was
13 there -- either accountability. There was a -- there was a
14 statement that they believed quality would get better, but
15 there was no measurement of quality, and there was no
16 proposed accountability for quality.

17 There was also a statement that they believed
18 cost would get better, but there was no -- in the
19 methodology itself, there was no accountability for that.
20 They didn't pay any penalty if they didn't -- if it didn't
21 get better.

22 So that was the framework that it seemed to
23 apply, that didn't seem particularly limiting, although it
24 might be. I worry that it might be -- and seemed to apply
25 to at least this proposal. So that was the -- that's all I

1 have to say.

2 CHAIR BAILET: All right. So I have Harold,
3 Bruce, Bob, and Grace.

4 MR. MILLER: So I agree with everything Tim just
5 said, and in fact, we have that already in the document for
6 the submitter instructions where we said that we were more
7 likely to recommend. That's how we phrased it.

8 I recall that we ended up with that language
9 because we concluded through the counsel process, et
10 cetera, that we were not able to refuse to accept
11 proposals. Now, we could revisit that, but that's my
12 recollection, was that we were -- we talked about saying we
13 don't want to review proposals of the following character,
14 and I believe we concluded at that point -- and that -- or
15 at least the concern was that we didn't have -- this is
16 another one of those under-the-statute things. We didn't
17 have the ability to somehow say we were precluding certain
18 proposals from coming in.

19 My concern is that saying, sort of using the
20 round-about way of saying that we don't think that the
21 criteria are applicable, it seems to me that what it's
22 leading us to is some sort of a statement about an order of
23 the criteria that we will -- that we will review in, that
24 we will not review the other criteria if we think that it
25 doesn't meet the payment methodology criteria.

1 It seems to me, as I reflect on a lot of the
2 things that we've been looking at, is that some of those
3 other criteria reviews end up being somewhat -- I don't
4 know -- perfunctory, anyway, if we think that the payment
5 methodology really is fundamentally flawed, and again, my
6 concern is I guess the semantics of somehow saying the
7 criteria isn't applicable.

8 So it seems to me that the solution would be to
9 say we're going to review the payment methodology first and
10 if the payment methodology doesn't count -- now, we had --
11 at least in my mind, we had put some of the other things
12 sort of first in order because we fundamentally didn't want
13 to just be changing payments. We wanted to be improving
14 quality, and we wanted to be improving cost. And that was
15 kind of the threshold first.

16 But as a practical matter, what has turned around
17 is that somebody might have really great goals for quality
18 and really great goals for cost, but if they don't have a
19 payment methodology that works, then we say, fundamentally,
20 no, we're not going to recommend it.

21 So it just seems to me that a practical
22 reflection of what we are is that we are saying that the
23 payment methodology is kind of the first criterion, and if
24 it doesn't pass on that, we're not going to recommend the
25 model. And we might recommend changes to it or whatever,

1 but that to me might be the way to sort of split the
2 Gordian knot, in my opinion.

3 CHAIR BAILET: Bruce is -- So it's Bruce, Bob,
4 and Grace.

5 MR. STEINWALD: Yeah. I'm not sure we've learned
6 enough from these two proposals to establish criteria. I'm
7 a slow learner, so take that into account.

8 There's another proposal. There was three
9 atypical proposals, and the PRT decided to actually go
10 through the criteria on the proposal we were looking at
11 tomorrow. And we may learn something from that discussion,
12 but fundamentally, even though I agree with the points
13 about accountability, I think we need more case law, Grace.

14 CHAIR BAILET: Bob.

15 DR. BERENSON: Yeah, I agree with Bruce there. I
16 can think of at least two other circumstances in which I
17 would say it doesn't qualify as an APM. One is if it's a
18 payment model that isn't physician-focused. Somebody has a
19 new payment model for home health care, and physicians are
20 peripheral or not involved at all, I would say it's not
21 something we should be reviewing. Even though it is a
22 payment model, it's not a physician-focused payment model,
23 and we would need to establish what we think is physician-
24 focused.

25 And then the one that's going to come up tomorrow

1 has to do with Medicare. It's a Medicare payment model,
2 and my hunch is we will come up with their criteria as they
3 present. So that would be, number one, I don't think we're
4 ready, but I agree with Harold that we should send a signal
5 out that maybe we want to be a little more -- maybe we want
6 to be stronger, that we will not consider some models that
7 are -- and fill in the blank -- that are just mere -- I
8 don't know what we would say, but I do think we have to
9 figure out how to communicate this.

10 And then the second point I want to make is I
11 happen -- and while I went along reluctantly with it months
12 ago -- to not agree that accountability for cost and
13 quality is the hallmark of an APM. I think one can make
14 dramatic improvements in value in a physician fee schedule
15 through coding and payment, and I don't hold to that
16 criterion. I do understand that the PTAC did establish
17 that, but I would want to reconsider it.

18 It was the CMS formulation. It was Patrick
19 Conway's formulation. I don't think it's right, and I can
20 imagine substantial changes to fee-for-service that
21 improves value. And I would not want to say, "Oh, no,
22 those are not value-based payment models because it doesn't
23 have explicit process measures for measuring quality."

24 CHAIR BAILET: Len. Like I said, Grace.

25 DR. TERRELL: There was discussion of a strawman,

1 so I wanted to just put out the things that I think we have
2 learned so far today as we broaden the discussion tomorrow
3 with respect to how we might actually find Baby Bear.

4 [Laughter.]

5 DR. TERRELL: What I believe we've learned is
6 that it -- and maybe this would be partly out of tomorrow
7 -- it's got to be relevant to the Medicare population as
8 opposed to other populations. So that would be something
9 that, you know, could be an a priori criteria.

10 The second one is -- it was just alluded to,
11 which is it has to be relevant to the way physicians and
12 the other qualified providers in the regulations are paid.

13 The third one that we talked about today was an
14 overall change to the Medicare benefits at the MACRA level
15 is not what our job is, and we could probably get language
16 around that, that we could be clear about.

17 And then what we just learned, I believe, is that
18 it's got to be more than just a change to policy with
19 respect to how certain fees are paid or not paid today,
20 with the scope issues -- so it's got to be more than just a
21 fee schedule change.

22 The next one is that it -- and Bob has brought
23 this up in several cases before, is there -- and we talked
24 about it today briefly to. It ought not to be -- if
25 there's some other way it can be done in the current

1 situation, for example, the chronic care codes, then we can
2 -- then that needs to be fleshed out. I mean, if somebody
3 comes with a new way, but there's already a way it can be
4 done, there's got to be something more than just it's a
5 different way of getting to the same results. It's got to
6 be something better. And maybe that's the place where the
7 cost, quality could be articulated in a way that we could
8 get to consensus.

9 And then my final concept, which is not that,
10 which is Harold's proposal that if it doesn't meet the
11 payment methodology in these criteria or any others that we
12 come up with, we just don't go forward and review, the
13 problem is that's a PRT that's making that distinction as
14 opposed to the full PTAC, which may not agree with it. And
15 so we would have to come up with a way of addressing that.

16 If there was a consensus at the PRT level that
17 three out of three said isn't applicable, could there be
18 some process there that got directly to the full PTAC or
19 not, it would slow things down potentially up front, but it
20 may actually decrease the amount of work downstream. So
21 that component of this proposal, if we went in that
22 direction, would have to go PTAC first and then PRT.

23 But it could be appropriateness that came out of
24 the PRT, so those are the things that I learned, I think we
25 learned today.

1 CHAIR BAILET: All right. So go ahead, Len.
2 Sorry.

3 DR. NICHOLS: So I think of life as a Google doc,
4 and I don't know why we can't put stuff up there now, even
5 though it's not going to be final, because we have learned
6 a lot in the last couple of days. And what I'm most
7 concerned about is that we send signals to the community
8 about where our rank order and what our priorities and what
9 our -- so forth -- really is.

10 I personally would be quite happy if the payment
11 model criterion did get elevated up to an uber level
12 because my suggestion of triggering Grace's mechanism here
13 is if the PRT thinks this thing they're reviewing doesn't
14 rise to the level, in my view, the payment model is the
15 right thing to shop around.

16 I agree the whole PTAC has to judge that. We
17 can't depend on a three-person PRT to do it for us, but I
18 don't know why we couldn't do that in expeditious manner,
19 and then we have an agreement.

20 I understand why we can't do it legally.

21 MS. PAGE: It has to be in public.

22 DR. NICHOLS: But I'm just saying -- well, I'm
23 happy to do that. Let's do it on the phone in public, but
24 I'm just saying the notion of we've got to wait and go
25 through and yadda yadda, bing, bang, bong, we've got to do

1 every -- that's silly. We can do better.

2 CHAIR BAILET: So, Harold, do you want to -- I'll
3 let you go in front of me.

4 MR. MILLER: Well, I was -- I guess two points.
5 One is to Grace's list. When I look at -- the regulations
6 have two parts to them. At the beginning, they say
7 Secretary has said payment model is Medicare, and its
8 physicians, you know, and/or other providers. So that's
9 kind of like the first thing, and then the criteria follow
10 that. So, in my mind, there's a distinction between saying
11 -- I mean, it's almost like to me it's backwards if it
12 doesn't meet the Medicare criteria, then the criteria
13 aren't applicable. But on the other hand, if it does meet
14 those two things, the criteria are applicable, whether we
15 think it's good or not.

16 So, anyway, I would just -- I would -- I think
17 there's a distinction there between that list of things
18 that we've been talking about that we have to relate back
19 to what our charge is.

20 I don't agree -- I don't see any problem with us
21 saying if a model comes in and the PRT looks at it and
22 says, "Boy, we think the payment methodology is so bad here
23 that we really don't think it's" --

24 DR. TERRELL: Not applicable.

25 MR. MILLER: No. Bad. I'm saying if we think

1 the payment methodology is sufficiently bad, that we don't
2 think it's worth the time to look at all the other things,
3 then take that to the PTAC, have a discussion about that,
4 and if, in fact, the PTAC disagrees that it really ought to
5 be reviewed, then go back and do that.

6 But what we're talking about is people struggling
7 to try to figure out what to do when we know that the
8 groups are overloaded, and, you know, it depends on the
9 volume.

10 Anyway, that's just, again, my opinion.

11 CHAIR BAILET: Okay. So here's my -- My caution
12 is I don't think that the payment model in a vacuum can
13 impugn our ability to review a proposal, and what I mean
14 specifically about that is that there are some very elegant
15 proposals that address seven or eight of the criteria
16 potentially.

17 I can reflect on one or two that we've already
18 reviewed, and there are some in the queue. So I think that
19 if we have specific points of view relative to it, it could
20 be -- it might not be the payment methodology. It may be
21 something else that deems it not applicable, but to stay
22 the course on payment methodology, since that's the theme
23 of the day --

24 DR. TERRELL: It's also the name of our
25 Committee.

1 CHAIR BAILET: Pardon me?

2 DR. TERRELL: It's also the name of our
3 Committee.

4 CHAIR BAILET: Right.

5 [Laughter.]

6 CHAIR BAILET: But I think we could telegraph
7 that if it's a small change to existing payment, we're
8 going to have a particular point of view and maybe activate
9 a review on whether it should go forward or not, or the
10 opposite, to Tim's analogy, that it's so transformative
11 that it's really out of the realm of our Committee's
12 purview. That's another opportunity.

13 And we may find, as we do more of these reviews,
14 there may be other trip wires that will force us to maybe
15 aggregate, come together, and come up with a determination
16 on whether we should push it forward or not.

17 But I guess I just want to make sure that we're
18 not walking out of this meeting that you could have an
19 elegant, very elegant clinical model that is meritorious
20 that has some flaws in the payment methodology that we
21 would not support, right?

22 MR. MILLER: I wasn't suggesting that it always
23 be a two-step process. I was more saying that if the PRT
24 looks at it and basically doesn't think that it meets the
25 payment methodology and has no other reason to bring it

1 forward, but rather than having to go and evaluate every
2 criterion completely, that it would make that judgment.
3 But that's --

4 CHAIR BAILET: I completely agree with you,
5 Harold, but it's that last qualifying comment that you
6 made, that had you made that, I probably wouldn't have
7 raised my placard.

8 So, Elizabeth, bring us home.

9 VICE CHAIR MITCHELL: I don't know about that,
10 but I want to own any contribution made to our inconsistent
11 case law. And I am not prepared to go with the payment
12 model criteria at this point because that was where I
13 really parted company on the big Medicare proposal.

14 But I like this sort of Baby Bear idea, and I'm
15 not sure we're there yet. We don't fully recognize what it
16 would look like, but --

17 DR. TERRELL: Just right.

18 [Laughter.]

19 VICE CHAIR MITCHELL: Just right.

20 But the two things that I think were entirely
21 consistent on the two proposals that we -- on two of the
22 proposals we didn't support was that it could have been
23 done elsewhere. There was another way to do it. Whether
24 it was the CCM or whether it was, you know, the last
25 proposal, there was an alternative approach, and so we

1 weren't needed for that. So maybe that's sort of a
2 threshold that we can start to apply as we identify the
3 others.

4 CHAIR BAILET: I think you finished it off.

5 Oh, Harold.

6 MR. MILLER: We haven't finished it because we
7 haven't talked about what we're going to do with this.

8 I mean, it seems to me that we -- I'll just make
9 a proposition. We need to -- well, we'll have -- but I
10 think we should think about either having a discussion --
11 we could do it by phone and have kind of an open -- invite
12 people in to comment or put out a document. We did that
13 before. We haven't done that in a while, but to basically,
14 back to the earlier point, is not just to have a document
15 out that says we have a non-applicable category, but to say
16 we are considering the following things or we're
17 considering the following options.

18 We're thinking about we might do this, we might
19 do that, and see what people say to -- has input to all of
20 us. That would be a concrete next step that would kind of
21 move us forward on that, get some feedback, find out
22 whether other people see there's a problem with that before
23 we try to make any decision.

24 CHAIR BAILET: So, Harold, that's a slightly
25 different direction than where we were going because I

1 thought what we were going to do is what we just did,
2 meaning we -- As a Committee, we're going to develop a
3 point of view. We weren't necessarily opening it up to the
4 public for them to comment. I thought it was an
5 opportunity -- well, I thought it was an opportunity for us
6 to determine whether we move forward with a full evaluation
7 or not.

8 MR. MILLER: Well, but we're -- if we're --
9 that's a change in process, we would have to -- that's all
10 I'm saying, is I think we --

11 CHAIR BAILET: Understood.

12 MR. MILLER: -- we need to say here's what we're
13 thinking about --

14 CHAIR BAILET: I got it.

15 MR. MILLER: -- and get feedback on it, and I was
16 just suggesting that maybe we could also have some options
17 in there if there are certain things that we're not all
18 fully in agreement on.

19 CHAIR BAILET: Len?

20 DR. NICHOLS: I would support getting comments
21 from the Secretary, from CMMI, from everybody we know,
22 including the public, but I think we need to know what the
23 rest of HHS thinks about us deciding these are beyond the
24 pale because people may say no, no, no, you have to -- and
25 I would like to hear -- I mean, first of all, I'm not

1 qualified to interpret statutory language, in my opinion.
2 I don't always like what general counsel does when they
3 take that hat on, but they're better at it than I am or at
4 least they're more experienced. So I'd like to know what
5 they think about us deciding this and we're looking for
6 Baby Bear here, and she said, "Oh, no, no. You're looking
7 for all bears." I want to know if Baby Bear is okay.

8 DR. CASALE: I think that's a good point, and I
9 wanted to ask the submitter, but I didn't. What Bob said,
10 apparently the submitter was sent by CMMI to us, not to CM,
11 right? So how did --

12 MR. MILLER: They must think it's applicable.

13 DR. CASALE: So to Len's point about having some
14 discussion with them, CM -- CMMI.

15 CHAIR BAILET: So, in summary, do we -- no, I
16 don't think we're done. I think we need to circle back.

17 So, Harold, your proposal, is that --

18 MR. MILLER: My proposal would be I think we need
19 to write something up, circulate it amongst ourselves, with
20 the idea being that it's going to be posted as a
21 modification or proposed modifications to our process --

22 CHAIR BAILET: For comment.

23 MR. MILLER: -- for comments. That's what we did
24 before.

25 CHAIR BAILET: All right. So that's the next

1 step.

2 MR. MILLER: That would be the next step.

3 CHAIR BAILET: All right.

4 Do we need motion on that, or are we good to go?

5 MR. MILLER: I'd like to make a motion that we do
6 that.

7 DR. MEDOWS: Second.

8 CHAIR BAILET: All in favor?

9 [Chorus of ayes.]

10 CHAIR BAILET: Alrighty, then. So, we've got
11 that captured. We've lost --

12 MS. STAHLMAN: No, we lost the DFO.

13 CHAIR BAILET: We lost the DFO.

14 So I'm going to go ahead. I want to thank
15 everybody for hanging with us this entire day, and we'll
16 see you back again tomorrow.

17 * **The meeting is adjourned.**

18 [Whereupon, at 6:34 p.m., the PTAC meeting was
19 recessed, to reconvene at 9:00 a.m. on Tuesday, December
20 19, 2017.]

21